|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2017/5/13 ¤U¤È 05:23:24
|
·PÁÂOBI¤j¦b «¼C¤j¡¨2015¦~4Q¤¤¸Î¡A ¦¬¦¨ !¡§ªºªO¤W´£¨ÑªºThera ^¤å³ø§i, ¨ä¤¤¤S¥HCIBC 2017/4/19 ¨º¥÷µ¹¤F§Ú³Ì¦h±Òµo, ¥ß°¨¤WThera ºô¯¸«Å¥¨ä3/1ªº investor webcast (www.theratech.com/en/content/theratechnologies-host-investment-community-webcast-march-1-2017), webcast ªº¸ê®ÆÀÉ ¡]½Ð¦Û¦æ¤U¸ü¡^¤¤¦³¸Ô²Óªº355 ¤W¥««e¥«³õ¤ÀªR (¨ü³X¹ï¶HÀ³¬OHIV±MªùÂå¥Í, À³¸Ó«Ü¦³°Ñ¦Ò©Ê), ¦A¥[¤W¹L¥h¥b¦~2«×°Ñ¥[°õ¦æªø¥D«ùªº·|ijµ§°O, ¤U±¦³´XÓ«ÂI¤À¨É¤@¤U, ³Ñ¤U¤£¨¬ªº´N½Ð¦U¦ì¦Û¦æ¥h«õÄ_¤F¡K 1. ÃÄ»ù¡GThera ±q¤½¨p¬ÛÃö³¡ªù ( ³ø§i¤¤¥ÎPayer, À³«ü«OÀIÅé¨t)Àò±oªº¦^õXÅã¥Ü¥X¨C¦~7~10¸U¬üª÷ªºÃÄ»ù¬O¥i¥H±µ¨üªº. 2. ¥«³õº¯³zA¡G¦b¦ôpªº20-25k MDR¯f¤H¤¤ 50-56% ªº¯f¤H¤w±Á{»Ýn´«ÃĪº¶¥¬q¥BÂå¥Í¤wªí©úÄ@·N¨Ï¥Î355. 3. ¥«³õº¯³zB: 355¤@¥¹¤W¥«·|³Q¯Ç¤JMDR ªvÀøguidline ¤¤¥B¤]·|³Qµø¬° Medicae PartB (¤£¬O¤Óª¾¹D¨ä·N¸q, ¦ý¬O¤å¤¤«ü¥X«OÀI³æ¦ì±NÃø¥H©Úµ´¤ä¥I¦¹ÃÄ) 4. ÃÄÃÒ¼f¬d¡G¤j¦h¹w´ÁHIVÃĹL¥h´XÓªº¼f¬d®É¶¡¤£¶W¹L6Ó¤ë, 355¥H¨ä¬ð¯}©ÊªvÀø¡Ï©t¨àÃĪºª¬ªpThera. webcast ¤¤Áô¬ù´£¨ì¦³¾÷·|´£¦¼Æ¶g¨úÃÒ 5. ¬d¼t¡GCIBC´£¨ì Thera guide ¤ÀªR®v6/7¤ë·|¬d¼t, ¦ý¬OFDA§Æ±æ´£«e¤@ÂI, ©Ò¥H5/6¤ë¤]¦³¥i¯à. ¦A¤ñ¹ïªáºX»P·ç¤h«H¶Uªº³ø§i¡K..§Ú·Q2018¤¤¸Î¶}©lÁÈ¿úªº¾÷·|À³¸Ó·¥¤j. ¥[¤Wwebcast ¸ê®Æ²Ä40¶¤¤Åã¥Ü¾ú¥v¤W¦¨¥\ªºHIV¥ÎÃÄ¥§¡²Ä4¦~¹Fpeak sales. ¬Ý¨Ó¤¤¸Î±N¬O¬~¨ê·sÃĤ½¥q³£¬OÁ«·l³fªº¦Ã¦Wªº»âÀY¦Ï. ¦]¥»ºôºûרt²Î¡A¸ê®Æ«ì´_¨ìµy¦®Éªº°O¿ý¡A¬G³y¦¨Ó¤H¯d¨¥³Q®ø°£¡A³y¦¨¤£«KÁٽШ£½Ì¡C BY¥²´Iºôª©¥D
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/23 ¤U¤È 07:34:44²Ä 742 ½g¦^À³
|
·PÁÂÂyªÌ¤j~ §Aªº´£¿ô¬Oµ½·N¦bĵ§i¨º¨Ç°µµu½uªº¤H§a!? ¥H²{¦b¤¤¸Îªº¨«¶Õ¤£·|¤@¤U¤l½Ä¤W¥h,¦ý¤¤ªø´Á«ù¦³! ±N¨Ó¦^ÀY¤@¬Ý........¤]³\¤~µo²{¤T¦Ê¦h¤¸ªº¤¤¸Î¬O§C°ò´Á! |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/4/23 ¤U¤È 06:13:11²Ä 741 ½g¦^À³
|
åF¥J¡ã ¤µ¤Ñ¨ì©³¬O«ö«ç¡A ì¨Ó¤µ¤Ñ¥h©Ô¤ÉªÑ»ùªº³ºµM¬O§ë«H°òª÷ ¡]²b¶R¤J970±i¡^⋯,³o¤G¦~ªº¤¤¸Î¤Ï«ü¼Ð §Ô¤£¦í¶i³õ¡A¯uªº´À§ë¸ê¤H¾á¤ß¡A¤Q¦¸¶R¶i ¦³¤E¦¸³Q°±·lKO¡A ¾i¾i¤p¹q¤lÁÙ¥i¥H¡A¤¤¸Î¥«È¶W¹L700¦h»õ¤¸¡A ¥L̶ȯàµu¶i¯Ê¥X¡Anªø´Á¤U¤j¥»¾i¤¤¸Î¡A ¤j®a¤£¥Î¤Ó´Á«Ýªº¡A ¤×¨ä®³»¸òµÛ¥~¸ê«ô¡A¯uªºn´£¨¾¥~¸ê¼¾÷˵¹ ¥LÌ¡]¹³¤µ¤Ñ¥~¸ê´N²b½æ¥X388±i¡^¡A n°l°ªªº¡A©yÂÔ·Vµû¦ô¡I |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/23 ¤U¤È 01:31:30²Ä 740 ½g¦^À³
|
¦A¹L´X¤Ñ , ·sÃĶ}©l½æ! À禬¼Æ¦r¥X¨Ó,¶]±¼ªº§ë«H¦ÛÀç°Ó·|ºCºC¦^¨Ó! ¯uªº¦³Àò§Q,ªø½u§ë¸êªº°òª÷¤]·|¶i¨Ó! ¬Û«H¤@Áû±Ï¥@ªºÃÄ,¤]¬O¤@ÁûÁÈ¿úªºÃÄ! |
|
|
·|û¡GPROTSAI10146704 µoªí®É¶¡:2018/4/23 ¤W¤È 10:41:19²Ä 739 ½g¦^À³
|
§Þ³N¤ÀªR¥u¯à°Ñ¦Ò ¤W©P¤@½²¤jÁ¿ ¬K®L¬î¥V ¦³¤Hª¾¹D¬Æ»ò·N«ä¶Ü |
|
|
·|û¡G¶³²H·»´10146472 µoªí®É¶¡:2018/4/23 ¤W¤È 10:20:30²Ä 738 ½g¦^À³
|
¦bªk»¡·|ÁÙ¨S¤½§i«e, §Ú¤]¬O¦bªÑª¯ºôªºAPP¦³¬Ý¨ì4/25, 5/4¦³ªk»¡. (·í®É¤ß¸ÌÁÙ·Q, ·|¤£·|¼g¿ù¤F, ÁÙ¨S¤½§i°Ú) ¬Q¤Ñ¤SÅ¥¤F¤@¹M201603 CFO¥DÁ¿ªºªk»¡: ¦bÁ¿¨ìIM®É, ¦³¤@¬q¸Üı±o¤¤ªÖ: §Ṳ́]¨S¹w´ú¤j·§Market ¦h¤j, ¦]¬°«ÜÃø¹w¦ô, ·sÃÄ´N¬O³o¼Ë, §A·íµM¥i¥H°äÄêÁ¿¦h¤j¦h¤j, ³£¤£¤Á¹ê»Ú. ©Z¥ÕÁ¿¤]¨S¤Hª¾¹D, ½æ¤F¤~ª¾¹D. |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2018/4/23 ¤W¤È 09:27:14²Ä 737 ½g¦^À³
|
¤Ñ©R¤j¤j§A¦n, ·PÁ§A ÁÂÁ |
|
|
·|û¡GPROTSAI10146704 µoªí®É¶¡:2018/4/23 ¤W¤È 09:16:19²Ä 736 ½g¦^À³
|
¤Ñ©R¤j¦b¤½¥q©|¥¼¤½§iªk»¡«e´N¤wª¾ªk»¡·| ¥»¤H±À´ú¤Ñ©R¤j¬O§ë«H·~¤º©ÎªÌ¤½¥q¬£ ¥t¥~¤@¦ì½²¥ý¥Í¦]¬°¤£²nªO¤W¦³®d¤p**enªº´c·N§ðÀ» §â±À¤å¥þ§R¤F ³o¦ì½²¥ý¥Í¤W©P¤@Â_¨¥¶RÂI¨ì¤F ¥i±¤¥L°hª©¤F ³oÓ¦a¤è¬O¥æ¬y·N¨£ªº¦a¤è ¥i¤£¬OÄF¦YÄF³Üªº§ëÅU |
|
|
·|û¡Gbill10135881 µoªí®É¶¡:2018/4/23 ¤W¤È 06:21:35²Ä 735 ½g¦^À³
|
¤¤¸Îª©¦³©¯¯à¦³¤Ñ©R¤jªº¯uª¾¨ô¨£¡A¤À¨É¸Î¤Í¡A¤Þ»â¸Î¤Íªø½u§ë¸ê¡A°J¤ß·PÁ¡C¦Ü©ó´XÓ¤£®É¦b¥Í§Þ¦Uª©¸Ë¯«§Ë°ªº®d¤p¡A¥i§O¦A¨Ó¤¤¸Îª©¤¥|¤T°Õ¡I®ö¶O§Ú̪º®É¶¡¡AÁÂÁ¡C |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/4/22 ¤U¤È 09:09:06²Ä 734 ½g¦^À³
|
«¢«¢¡ã ²×©ó¬Ý¨ì°£¤F¤Ñ©R¤j¥Î¤ß¨}Wªº«õ±¸¤½¥q°ò¥»±¥~¡A ¤S¦³¨Çªø´Á»{¯uªº§ë¸ê¤H,¤]¬Ý¨ì¤Fªñ¥b¦~¨ÓÄw½Xªº ·¦VÂà换⋯, ¤¤¸Îª©ªº§ë¸ê¤H¯uªº«D±`¦¨¼ô¡A¤]¯à°÷±µ¯Ç¤@¨Ç·ÀI ¹w§i¡]¨Æ¹ê¤W¦³¨Ç¹w§i½T¬OÃa¤¤Âæn¡A¬Ý¦ü®t¹ê«h§® ´Nµêµê¹ê¹ê°Õ¡^¡A ³o¯uªº¬O¦n¨Æ¡A¤£ºÞ¹ï¤½¥q©Î§ë¸ê¤H¡A ªø´Á¦Ó¸Ó¨¥¤½¥qªÑ»ù¤@©w¤ñ¸û°·±d¡A§ë¸ê¤H¤£±R«ô µêÀÀªº¯«¤H¡A¤~¤£㑹¤H¤ª¥ç¤ª¡A¤£ª¾¬°¦ó¦Ó¶R¡A «¢¡ã©Ò¥HÅo⋯, ¤¤¸Î¯uªº¡ã¥O¤H¡u¬Ý¤£Ãa¡v¡A¡]§ë«H¡BÃÒ¨é¦ÛÀç°Ó°£¥~¡^ |
|
|
·|û¡Gmetrostar10141472 µoªí®É¶¡:2018/4/22 ¤U¤È 08:37:54²Ä 733 ½g¦^À³
|
¤jªÑªF«ùªÑ¨Ó¨ì·s°ªªº43.44% (¤T¤ë©³¬°40.89%) ¦ÓªÑªFÁ`¤H¼Æ¤U°23227,(¤T¤ë©³¬°23837) ¨C¤H¥§¡±i¼Æ¤W¤É10.78,(¤T¤ë©³¬°10.50) ´²¤á³Q¬~¥X¥h¤£¤Ö, Åã¥Ü³Ìªñ¦³¤j¤á¦b¦¬Äw½X! |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2018/4/22 ¤U¤È 07:21:07²Ä 732 ½g¦^À³
|
¥xÆW¦¤j¦n ¥xÆW¦¤j»¡ªº«Ü¤¤ªÖ~ÆgÆgÆg¡I §Ú¬Û«H¸g¹L¯E¹©¨Æ¥ó«á§ë¸ê¤H²{§ó¯à ¤À¿ë¥X½Ö¬O½Ö«D¤F~¯¬¤j®a¾Þ§@¶¶§Q ³£¯àÁȤj¿úµo¤j°]¡C |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/22 ¤U¤È 06:37:52²Ä 731 ½g¦^À³
|
¤p¶§¤j~¦n¤[¤£¨£ Ây¤j~³o¸Ì·íµM¤£¬O¤@¨¥°ó,¦ý§AY¯uªº¬O¸Û¤ß°Q½×,§ÚÌ·íµM¼Ö¨£! ¤£¹L§A»¡250«Ü¦h¤H¥X²M,²{¦b¬O273,Ãø¹D§A»{¬°´²¤á¦³¯à¤O¦b19¤éÀ£¦¨¤W¼v½u,µM«á¦A20¤é¤j½L¶^190ÂI±¡ªp©Ôº¦12¶ô!? ³o¥i¯à¶Ü? ¤p§Ì»{¬°¦³¤j¤H¶i¨Ó¤F! ¤p§Ì¥H«e¦b¯Eª©¬Ý¹L¤@¨Ç¤H²Õ¦¨¶BÄF¶°¹Î§|±þ´²¤á,²{¦bÁÙ¶}¥t¥~ªºª©¦bÄF! §Æ±æ§A¤£¬O! |
|
|
·|û¡G54310143745 µoªí®É¶¡:2018/4/22 ¤U¤È 04:27:19²Ä 730 ½g¦^À³
|
·PÁ¤ѩR¤j¤À¨É¡A ½Ð°Ý4/25~4/27¤Î5/4¤¤¸Î°Ñ¥[ªk»¡·|®É ¾P°â¤è±ªº¸ê°T·|¤£·|´¦ÅS? |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/4/22 ¤U¤È 03:57:49²Ä 729 ½g¦^À³
|
Ô£¦Ì¡ã ¬ÝÃa¤¤¸Î¡A½Ö»¡ªº¡A ¥u¬O´yz¤@¤U¡u¥«³õ¡vªº¯u¹ê²{ªp¡A ºÙ¤£¤W¬ÝÃaªº¡A ¥u¬O§Æ±æ¥¦¤£nÅܦ¨¡uµVµVª©¡vªº¤@¨¥°ó¡A ¡]¥uã¯B¸ØµV²y±¸°_¡A¤£ãµ½·N´£¿ôªº¨¥½×¡^¡A ¯uªº¡AÅý¤j®a¦b¤¤¸ÎªÑ»ùªº¦¨ªø¹Lµ{¤¤¡A ¥¢±¼§Ù¤ß½}¤F¡I |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2018/4/22 ¤U¤È 03:49:45²Ä 728 ½g¦^À³
|
³o´X¤ä¦Ñª°¯W¤S¦b¦Uª©¶Ã©ñ°²®ø®§¤F¡B«¢«¢¡K¡K ¤°»òµäµä¡Bµõ¾B¡Bµõ¾Bµäµä¡BÄê¤Ñ¡K¡K¡K¡K ³o¸s¤H«ç»òµL©Ò¤£¦b°Ú¡H |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/22 ¤U¤È 03:38:29²Ä 727 ½g¦^À³
|
©Ò¥H þ¤j~ §A¬JµM³o»ò¦³¨£¦a,»°§Ö·Q¿ìªk¦hÉú³! ¤j¤OªºªÅ¤U¥h,©Î³\§A¯à¤jÁÈ! ¦pªG§A¥u¬OÂdzoÓ°Q½×°Ï©ñ°²®ø®§·ÏÃú¼u·Q»~¾É¸Î¤ÍÌ,¨º§A´N¬ÙÂI¤O§a! |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/4/22 ¤U¤È 02:05:58²Ä 726 ½g¦^À³
|
©Ò¥H°Õ¡ã ¡uÁo©úªº¥«³õ§@¤â¡v¡A¤Î±j¯P°l¨Dµu´Á¡]¶g¡B¤ë¡B©u¡^ÁZ®Ä ªº¡u°ê¤º§ë¸ê°ò¥»¸g²z¤H¡v¡A¡uÃÒ¨é¦ÛÀç°Ó¾Þ½L¤â¡v¡A ¤~¨S¿³½ì¡A¬Æ¦Ü¦¦b250¤¸«e¡A²MܤF¡A ¥u³Ñ¤U¡ã¡A³Ñ¤U¤Ö¼Æªº¡u¤£ª¾¤£Ä±¡v¤Î¡u«áª¾«áı¡v¡A ¤£·QÁÈ¿úªº§ë¸ê¤H¡A ¾¼¡ã,¯u´À¥L̾á¤ß¡I |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/22 ¤U¤È 12:58:50²Ä 725 ½g¦^À³
|
¬ü°ê®w¦s9000²~¥u°÷642¤H¤@Ó¤ë¨Ï¥Î¡C Y¤¤¸Î¦b®³¨ìÃÄÃÒ«á¤~¶}©l¤U³æÅý»s³y°Ó¥h¥Í²£¡A³o¼Ëªí¥Ü«e¨âÓ¤ë½æ¤£¤F¦h¤Ö¤H¡A³o¼Ë·Pı¤£¤Ó¦X²z¡AÀ³¸Ó¬O¦´N¦³¦b¥Í²£¨ä¥¦§å¤F¡C |
|
|
·|û¡G¬K©M´º©ú10141799 µoªí®É¶¡:2018/4/22 ¤U¤È 12:05:48²Ä 724 ½g¦^À³
|
¤¤¸Î104¦~¤WÂd«e·~ÁZµoªí·|ªº¸ê®Æ www.corpasia.net/canpanel/taiwan/listco/4147/events/1/CH/20151103_fTa3LbLc2GCj.pdf ²Ä25¶´N¦³¼g¤FIbalizumab¬°®¦·O¨Ï¥Î¤§ÃÄ«~¡A¤£¹L¨S¦³¼g¦h¤Ö¤H¥Ó½Ð¥ÎÃÄ(«Ü¦©O¡A104¦~´N¦³Compassionate Use) ¶}½æ«á³o¨Ç¯f±w´N¬O°ò¥»¥Î¾P°â¤F ·íµMÁÙ¬On¬Ý¤½«O½Íªº¶i«× ¶}½æ«áµLºÃ°Ý¾P°â´N¬OCompassionate Useªº¯f±w©¹¤W¥[ |
|
|
·|û¡G¬K©M´º©ú10141799 µoªí®É¶¡:2018/4/22 ¤W¤È 10:15:12²Ä 723 ½g¦^À³
|
¤£ª¾ÃÄÃÒ®Öã«e¦³¦h¤Ö¯f±w¥Ó½ÐCompassionate Use ªÑªF·|¥i¥H°Ý°Ý ¤£¥Î²q´ú¶}½æ«á²Ä¤@©u¦h¤Ö¯f±w¡B²Ä¤G©u¤S¦³¦h¤Ö¡Bº¯³z²v¦³¦h¤Ö §Q¦h¬OCompassionate Use¡A³o¸s¯f±w§´§´ªº¬O²Ä¤@¦~°ò¥»Àò§Q¨Ó·½ |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/4/21 ¤U¤È 10:17:03²Ä 722 ½g¦^À³
|
ü§r¡B ¨Ç·Lº¦¤@¤U¤U¡A´N§â¼¤±æ´£髙¡A ¡uÃh©ê¡vªø´Á§ë¸ê¥x¿n¹qªº¾÷ºcªk¤H¡A ¶¶§Q²¾±¡¤¤¸Î¡A¥Ø«e¯uªº¦³ÂIÃøªº¡A ¬Ý¬Ý¦¨¥æ¶q¶È4700±i¡A¯uªºÃø¥H¼ÖÆ[¡A ½Ö¥s¤¤¸ÎªºªÑ©Ê¤Ó¡u¤û¡v¥Ö¤F¡A ³s§Ö³t·í¨R¶i¥Xªºµu»L¡u¤¤òÄÒ¡v⋯, ¹Å¸qÀ°¡Bªê§ÀÀ°¡A¤]°Q¤£¨ì¦n³B¡A ¥¢¤â¦ÓÂk¡I ©Ò¥H¡A¨Ìªº¬Ý¾P°â¼Æ¦rÅo |
|
|
·|û¡G¸²µåô10146373 µoªí®É¶¡:2018/4/21 ¤U¤È 06:11:56²Ä 721 ½g¦^À³
|
±q¥x¿n¹qºM¥Xªº¸êª÷¦pªG¦³¦Ê¤À¤§¤@§ï¶R¤¤¸Î¡A ¤¤¸Î´N¼Q¥X¤F¡I |
|
|
·|û¡GPROTSAI10146704 µoªí®É¶¡:2018/4/21 ¤W¤È 10:14:47²Ä 720 ½g¦^À³
|
THera ¤W©u¤´Á«·l ²{¦b»ù¦ì¬Oñ¤F355®Éº¦¤W¨Óªº»ù¦ì §A¬O¸ó°ê§ë¸ê¤H ·|¶RTHera ÁÙ¬O¤¤¸Î ©P¤´«¤â¦¨¥\ |
|
|
·|û¡Gmengs10146592 µoªí®É¶¡:2018/4/21 ¤W¤È 01:23:27²Ä 719 ½g¦^À³
|
½Ñ¦ì«e½ú¹ï©óTHªºªÑ»ù«ç»ò¬Ý©O¡H ¤w¸g°±¦b¥[¹ô9¤¸¦n¬q®É¶¡¤F¡Astockhouse¤Wªººô¤Í¤]¶}©lļ°Ê §Ú̳£ª¾¹D¤À¼íTH ®³48%¡A¥L̪º¤ä¥X¬O¦æ¾P/¤H¨Æ©M¨½µ{ª÷¡C¦ý§K°£©ó¶}µo·sÃĪº·ÀI¡A¬G«Ø¥ß¦bEPS®t¤£¦hªº«e´£¤W¡AªÑ»ùÀ³¸Ó¤]¤£·|®t¤Ó¦h¡C¥B«ö·Ó¦¹¼Ò²Õ¡ATH¥i¯à¯à±µ¨ì§ó¦h¹³¬OTaimed³o¼Ëªº¤½¥q¡AÀ禬Ãzµo¤OÀ³¸Ó§óÅå¤H¡C³o¼Ëªº»¡ªk½Ð°ÝªO¤W«e½ú̦³¨£¸Ñ¶Ü |
|
|
·|û¡G¥Í§Þ·sÂA¤H10146669 µoªí®É¶¡:2018/4/20 ¤U¤È 05:54:31²Ä 718 ½g¦^À³
|
¦¹½g¬°4¤ë16¤é¥Zµn¦b¯Ã®ÉªºªÍÀùªvÀø·sµo®i, ¦A¦¸ÂI¥X§K¬ÌÀøªkªº¦h«À³¥Î ªÍÀù¯f¤H¨Ï¥Î§K¬ÌÀøªk¬¡±o§óªø¤[ ¤@¶µ«¤jªº³Ì·s¬ã¨sÅã¥Ü¡AY¬Oµ¹¤©¿©±w³Ì±`¨£ªÍÀùÃþ«¬¯f±w¤@ºØ¬¡¤Æ§K¬Ì¨t²Îªº·s«¬ÃĪ«¡A¦A·f°t¤ÆÀø¡A¥i¥H¤j¤j¦a´£ª@¯f±wªº¦s¬¡²v¡C ÂåÃıM®aÌ«ü¥X¡A³o¶µÅå¤Hµo²{À³·|§ïÅÜÂå¥ÍªvÀøªÍÀùªº¤è¦¡¡C ¿©±w¦¹ºØÀù¯gªº¯f±wÀ³¸Ón¾¨¦±µ¨ü§K¬ÌÀøªk¡C ¦¹¶µ¬ã¨spµeªºt³d¤H¡A¦P®É¤]¬O¯Ã¬ù¤j¾ÇLangone °·±dÂåÀøPerlmutterÀù¯g¤¤¤ßªº¯ÝµÄ¸~½FÃĪ«pµeªºÁ`ºÊLeena GandhiÂå¥Íªí¥Ü¡A¦¹¶µµo²{·N¨ý³æ¥u°µ¤ÆÀø¦A¤]¤£¬O¼Ð·ÇªvÀø¤èªk¤F¡C §K¬ÌÀøªk¦bªvÀø¦hºØÀù¯g¤è±³£¥\®Ä¨ôµÛ¡C³QºÙ¤§¬°checkpoint §í¨î¾¯ªº¥|´ÚÃĪ«¤w¸g®Öã¤W¥«¡A¦¹ÃþÃĪ«¥i¥H»¤¾É¯f±w¦Û¨ªº§K¬Ì¨t²Î¨Ó±þ¦º´c©Ê²ÓM¡C ³oºØÃĪ«ÃÄ»ù¨C¦~¶W¹L¤Q¸U¬üª÷¡A¦³¥i¯à·|²£¥ÍÄY«ªº°Æ§@¥Î¡A¦Ó¥B¶È¯àÀ°§U¤£¨ì¤@¥bªº¬Y¨Ç¯f±w¡C µM¦Ó¤@¥¹ÃĪ«°_§@¥Î¡A¨ä¤ÏÀ³¬°ªø®Ä«¬¡C ¬ã¨s¾ÇªÌ«E±ý§ä¥Xµ²¦X¨ä¥LªvÀø¤è¦¡¨Ó´£¤ÉÀø®Ä¡A¨Ã¥B¨M©w¦óºØ°t¤è¹ï©óÓ§O¯f±w®ÄªG³ÌÀu¡C ¥ô¾C¾|Àù¯g¤¤¤ßÃĪ«¸~½F¬ìªº¥D¥ôRoy HerbstÂå¥Í»¡¨ì¡G §ÚªvÀøªÍÀù±wªÌ¦Ü¤µ¤w¸g¦³25¦~¤F¡A§Ú±q¥¼¨£ÃѹL¹³§K¬ÌÀøªk©Ò±a¨Óªº¦p¦¹¥¨¤jªº¨å½dÂಾ¡C Roy HerbstÂå¥Í¨Ã¥¼°Ñ»Ppembrolizumabªº¬ã¨spµe¡C ªÍÀù©~¥þ²yÀù¯g¦º¦]ªºº¦ì¡A¤@¦~¹Ü¨«¤@¦Ê¤C¤Q¸U±ø¤H©R¡C ¬ü°ê2018¦~¹wp±N·|³y¦¨15¸U4¤d¤H¦º¤`¡C ¦¹¶µ¬ã¨s¤¤ªº¯f±w¬Ò¬°«DÅ窱¡B«D¤p²ÓMªÍÀùªº¥½´Á±wªÌ¡C ¬¡¤Æ§K¬Ì¤OªºÃĪ«¬O¤@ºØ¥s°µPembroliumabªº checkpoint§í¨î¾¯¡A¤SºÙ¤§¬°Keytruda, ¬°ÃÙ§U¦¹¶µ¬ã¨spµeªº¬ü°êÀq§J¤jÃļt©Ò»s³y¡C ¦Ó¤ÆÀøÃĬO¤@ºØºÙ¬°pemetrexedªºÃĪ«¡A¥t¥~¥[¤Wcarboplatin ©Î cisplatinÃĪ«¤G¾Ü¤@¡C GandhiÂå¥Í»¡¨ì³æ¨Ï¥Î¤ÆÀø©Ò¯à²£¥ÍªºÀø®Ä¦³¡A³»¦h¼W¥[´XӤ몺¹Ø©R¡A¦h¼Æ¯f±w¶È¯à¦h¦s¬¡¤@¦~©Î¤@¦~¥H¤U¡C µM¦ÓY¨âªÌ¡]§K¬ÌÀøªk¥[¤W¤ÆÀø¡^µ²¦X¨Ï¥Î¦¨®Ä¨ôµÛ¡A¦¹ºØµ²¦XÀøªk¤w¸g³Q®Ö¥i¦¨¬°ªÍÀùªvÀøªº¤@½uÀøªk¡A¦]¦¹ÂåÀø«OÀI¤½¥qÀ³¸Ó·|¥þÃBµ¹¥I¡C GandhiÂå¥Í¹w©w·|¦b¬ü°êÀù¯g¬ã¨s¨ó·|©ó¤U©P¤@¦bªÛ¥[ô©ÒÁ|¦æªº·|ij¤¤µoªí¬ã¨sµ²ªG¡A¦Ó¨ä¬ã¨sµ²ªG¤]¤wµoªí¦b·s^®æÄõÂåÀøÂø»x¤¤¡C ¨ä¥L´X¶µ¦b·|ij¤¤µoªíªº¬ã¨s³ø§i¤]«ü¥X¨Ï¥Î§K¬ÌÀøªk¹ï§ÜªÍÀùªº«¤j¬ð¯}¡A µM¦Ó¦h¼Æ³£¤´µM¦b¬ã¨sªì´Á¡A¸ûµL¥i¯à·|¦bÃĪ«¨Ï¥Î¤W±a¨Ó¥ß§Y©ÊªºÅܲ¡C HerbstÂå¥Í»¡¨ì¡A°²¦p§A·Qn¬Ýªº¬Oªø´Á¦s¬¡²v¡A§A¤@©w±o¥ß¨è¶}©l¨Ï¥Î§K¬ÌÀøªk¡C HerbstÂå¥Í»¡¹D¡C ¤ÆÀø¦³¥¦ªº¨î¡A¦Ó§K¬ÌÀøªk¯à°÷ªv¡Àù¯g¡C §Ú±a»âC¾|ªÍÀù¹Î¶¤¡A§Ú̪º¯f±w¨Ï¥Î§K¬ÌÀøªk¦s¬¡¦Ü¤w¸g¶W¹L¤K¦~¡C ªÍÀùªº¨ä¥L¬ã¨s¤¤©Ò¨Ï¥Îªº¥t¤@ºØºÙ¤§¬°nivolumab ©Î¬OOpdivo¡]¥²ªv§´¬I¶QÄ_©Ò»s³y¡^ ªºcheckpoint§í¨î¾¯¡A¨ä¾÷Âà»PpembrolizumabÃþ¦ü ¡C §ÚÌ©Ò¦³ªº«D³Ì²×¼Æ¾Ú¡AHerbstÂå¥Í»¡¹D¡A¦bªÍÀùªvÀø¤W¡A§ÚÃhºÃ³o¨Ç§K¬ÌÃĪ«¾÷Âà¬Û¦ü¡A¦p¦P¥i¤f¥i¼Ö¹ï¦Ê¨Æ¥i¼Ö¡C ¦h¼Æ¯f±w¥ÎÃĪ«¨â¦~ ¨ä¤¤¤@¦W¦s¬¡¦Ü¤µ¤w¸g¦³¤K¦~ªºC¾|¯f±w¡A¨Ï¥Î¸ÓÃĪ«ªø¹F¨â¦~¡A¦Ü¤µ¤´µM¦wµMµL®~¡C ¥t¤@¦W¯f±w¦b¨Ï¥Î¨â¦Ü¤TÓ¤ë«á¦]¬°ÃĪ«°Æ§@¥Î¥²¶·°±ÃÄ¡A¦ý¬O¨â¦~¤§«á±¡ªpÂà¦n¡C HerbstÂå¥Í´£¥X´XӾDzz»¡©ú¬°¦ó¤ÆÀø©M§K¬ÌÀøªk·f°t¨Ï¥Î¤Ñ¦çµLÁ_¡C ¥L»¡¸~½F²ÓM´N¹³¬O¤@³U³U¸Ë¤FÁô°Î°_¨Óªº³J¥Õ½è¡A¤@¥¹¬ªº|Âܸñ¡A§K¬Ì¨t²Î·|±N¨äÂê©wÂÇ¥H§ä¥X¤Î§ðÀ»Àù¯g¡C ¨Ï¥Î¤ÆÀø±þ¦º¸~½F²ÓM±o¥H±È¶}³U¤l¡AÄÀ©ñ¥XÂðΪº³J¥Õ½è¡A¨Ã¨ó§U¨Ï¥ÎcheckpointÃĪ«©Ò»¤µo¥X¨Óªº§K¬Ì²ÓM¿ëÃÑ¥X§@©Çªº¸~½F²ÓM¡C ¥Lªí¥Ü¤]¦³¤@Ó¥i¯à©Ê¬O¡A¤ÆÀø¥i¯à·|±þ¦º¤@¨Ç§K¬Ì²ÓM¡A³o¨Ç§K¬Ì²ÓM·|»P¦ì©ó§K¬Ì¨t²Î¨ä¥L³¡¦ì¸Ì°õ¦æ±þ¦ºÀù¯g¥ô°È¤¬¬Û¤zÂZ¡C GandhiÂå¥Í©Ò°µªº¬ã¨s¹ï¶H¬O¥]¬A¨Ó¦Û16Ó°ê®a¦UÓÂå¾Ç¤¤¤ß¡A¦~ÄÖ¤¶©ó34·³¨ì84·³ªº616¦ìªÍÀù¥½´Á±wªÌ¡C ±wªÌªº¸~½F¥Ñ©ó¯Ê¥F¬Y¨ÇÅܲ§®è¥¼²Å¦X±µ¨ü«UºÙ°w¹ï©ÊªvÀøªº¸ê®æ¡C ¯f±w¸g¥ÑÀH¾÷¿z¿ï±µ¨ü¤£¦PªºÀøµ{¡G¥i¯à¬O¤ÆÀø¥[¤W§K¬ÌÀøµ{¡F¤S©ÎªÌ¬O¤ÆÀø¥[¤W¦w¼¢¾¯placebo¡]µù¸Ñ¤@¡^¡F¤T¤À¤§¤Gªº¨ü¸ÕªÌ©Ò±µ¨üªº¬O¥]§t§K¬ÌÀøªkªº¡]¤ÆÀø¥[§K¬ÌÀøªk¡^¤G¦X¤@ªvÀø¡C ¦b°lÂܨü¸ÕªÌ¥§¡10Ó¥b¤ë¤§«á¡A±µ¨ü§K¬ÌªvÀøªº±Ú¸s¦º¤`¥i¯à©Ê°§C¦Ê¤À¤§¤¤Q¡F¥¼±µ¨ü§K¬ÌÀøªkªº¨ü¸ÕªÌ¥§¡¤j·§¦s¬¡²v¬O11.3Ó¤ë¡F¦Ó±µ¨ü§K¬ÌÀøªkªº±Ú¸s¦s¬¡²v¸ûªø¡A¥§¡È©|¥¼ºâ¥X¡C µM¦Ó±µ¨ü§K¬ÌªvÀøªº¯f±w¸s²Õ¸û®e©ö²£¥ÍµÇŦ¯fÅÜ¡A¤]¸û®e©ö²£¥Í»P§K¬Ì¬ÛÃöªº¤£¨}¤ÏÀ³¡A¤]¸û±`¦]¬°°Æ§@¥Î¦Ó¤¤¤îªvÀø¡C ±µ¨ü§K¬ÌªvÀøªº¯f±w±Ú¸s¹w¦ô¦s¬¡12Ӥ뤧¤[¬ù¥e¦Ê¤À¤§69.2¡A¦Ó¥¼±µ¨ü§K¬ÌÀøªkªºªº¯f±w¦s¬¡12Ó¤ë¬ù¥e¦Ê¤À¤§ 49.4¡C GandhiÂå¥Í»¡¹D¡G §Ú»{¬°§Ú̹ï§K¬ÌÀøªkªº²³¦h¦n³B¤Îªì¨B¤ÀªR©Ò§e²{ªº©úÅã®t²§¡A¦]¦¹§ÚÌ¥i±oª¾¯f±wªº¾ãÅé¦s¬¡²v¤Wªº©úÅã®t²§¡A¹ï¦¹ºØºØ§Ú̦A¦A·P¨ì«D±`³Y²§¡C ¨Ã¸É¥R»¡¨ì»P·|´Á¶¡¡A²³¤H¹ï©ó¦o¥H¤Î¨ä¥L¤H´N§K¬ÌÀøªk©Ò°µªº¬ÛÃö¬ã¨s³ø§i³£·P¨ì¬Û·í¿³¾Ä¡C ¦¹¦¸µoªíªº¬ã¨s³ø§i¥Nªíªº¬OªvÀøªÍÀù¤è¦¡ªº¤@Ó¥þ·sªºÅܲ¡AGandhiÂå¥Í³o¼Ë»¡¡C ©Ò¦³Åã¥Üªº¼Æ¾Ú³£¤ñ§Ú̦椧¤w¤[ªºªvÀø¤è¦¡nÀu¶Vªº |
|
|
·|û¡G¸ô¤H¥Ò10135334 µoªí®É¶¡:2018/4/20 ¤U¤È 05:13:34²Ä 717 ½g¦^À³
|
¥Í§Þ¤j ¤¤¸Î¤]¦³¦b±´¯Áªv¡Àøªk, ¤£¹LÁÙ¦b±´¯Á´Á, Â÷Á{§É«eÁÙ¦³¤@¬q¸ô ¤£¹L¤£ºÞ¬Oþ®a¤½¥q, §Ú³£§Æ±æ¯à¦ÂI¦¨¥\ TMB-ADC ADC (antibody-drug conjugates)¬Oªñ¦~°ê»Ú¤j¼tµo®i§ÜÅéÃĪ«ªº³Ì·sÁͶաAì²z¬O§Q¥Î§ÜÅéÃĪ«ªº¼Ð¹v©Ê¡A³s±µ¤WÃĮıj¬r©Ê°ªªº¤p¤À¤lÃĪ«¡A¨Ï¨ä¨ã¦³¼Ð¹v¶Ç¿éªº¯S©Ê¡A¥Î©óÀù¯gªvÀø¹F¨ì±M¤@©Ê±þ¦º¸~½F²ÓMªº®ÄªG¡A¤]¥i¥H¤j´T°§C¤p¤À¤lÃĪ«ªº¬r©Ê»P°Æ§@¥Î*¡C ²M°£·R´þ¯f¬r-¶}µoªv¡Àøªk ¥Ø«e§Ü·R´þ¯f¬rÃĪ«ªºªvÀø¯à¦³®Ä§í¨î¯f¬r½Æ»s¡A¦ýµLªk§¹¥þ²M°£¼ç¥ñ¦bT²ÓM¤ºªº·R´þ¯f¬r¡C¤@¥¹¥ÎÃĤ¤Â_¡A¼çÂæb±J¥DT²ÓM°ò¦]Å餤ªº¯f¬r°ò¦]¦³¥i¯à¦A«×¬¡¤Æ¡A¦]¦¹¯f¤H¥²¶·²×¨ªAÃÄ¡Cªñ´Á¬ã¨s«ü¥X¹B¥Îshock and killªºµ¦²¤¡A¥ý¬¡¤Æ¯f¬rRNA¦X¦¨ÄÀ¥X¯f¬rÁû²É¡A¨Ï±o³o¨Ç³Q¼ç¥ñªºT²ÓM¶i¤@¨B³Q¯f¬r©Î§K¬Ì¨t²Î±þ¦º¡A¦p¦¹±N¦³¾÷·|§¹¥þ²M°£¼ç¥ñªº·R´þ¯f¬r¡CHDAC§í¨î¾¯¤p¤À¤lÃĪ«¨ã¦³¤Wz¬¡¤Æ¯f¬rªº§@¥Î¡A¦ý¨ä¬r©Ê°ª¡A°Æ§@¥Î¤j¡A¤£¾A¦X°µ¬°ªø´ÁªvÀø¨Ï¥Î¡C¦ý¥þ·sªºTMB-ADC§Þ³N±NHDAC§í¨î¾¯¤p¤À¤lµ²¦XTMB-355 (ibalizumab)¡A¦³±æ§JªA²{¦³ªº¥ÎÃÄ«]¡A¶i¦Ó¹F¨ì²M°£·R´þ¯f¬rªº¥Ø¼Ð¡C §@¥Î¾÷¨î ADC§Þ³N¬O±N¤p¤À¤lÃĪ«³sµ²¦Ü§ÜÅé¤W¡A§Q¥Î§ÜÅ骺¼Ð¹v©Ê±N¤p¤À¤lÃĪ«±a¦Ü¯S©w²ÓM¡C¤@¯ë¦Ó¨¥¡A¤p¤À¤lÃĪ«¬r©Ê°ª¡AÁöµMÃĮıj¦ý¯Ê¥F¼Ð¹v©Ê¡A¦]¦¹·|¶Ë®`¨ì¥¿±`²ÓM¡A¤Þ°_°Æ§@¥Î¡FY°t¦X§ÜÅéÃĪ«ºë·Ç¦a¦b¤HÅ餺¿ëÃÑ¥X¯S©w¨üÅé (receptor)¡A»P¨äµ²¦X¡A¦A»¤¨Ï²ÓM±N³sµ²©ó§ÜÅé¤Wªº¤p¤À¤lÃĪ«¡u§]¾½¡v¦Ü²ÓM¤º¡A«hÃĪ«±o¥H±q²ÓM¤º³¡ÄÀ©ñ¡A¹F¨ìÃĮħ@¥Î¡C |
|
|
·|û¡G¶³²H·»´10146472 µoªí®É¶¡:2018/4/20 ¤U¤È 05:00:07²Ä 716 ½g¦^À³
|
¤Ñ©R¤j, ½Ð±Ð¤@¤U, ¦ó¿×IV/IM ªº label extension? ¥Lªº¬yµ{¬O¦p¦ó? ¦³§OªºÃĪº¨Ò¤l¥i¥H°Ñ¦Ò¶Ü? ±i°õ¦æªø¦b¤WÂd«e·~ÁZµoªí·|, ¦³¬ù²¤Á¿¤@¤U, ¦ýÁÙ¤£¬O«Ü©ú¥Õ. |
|
|
·|û¡G¥Í§Þ·sÂA¤H10146669 µoªí®É¶¡:2018/4/20 ¤U¤È 04:48:32²Ä 715 ½g¦^À³
|
3¤ë19¤é¤@½g¥Zµn¦b®É¥NÂø»x¤W¦³ÃöHIV¬ã¨sªº³Ì·s¶i®i, ´£¨Ñµ¹¸Î¤ÍÌ°µ°Ñ¦Ò, Y¦³Â½Ä¶¤WÃ㤣¹F·N¤§³B, ÁٽФѩR¤j¤Î¤¤¸Î¦P¦n¦h¦h«ü±Ð. §Æ±æ¤j®a¤@°_°^Äm©Òªø, ¬°§ë¸êºÉ¤@¥÷¤ß¤O. ÁÙ¦³¤@½g4¤ë16¤é¥Z©ó¯Ã®É¦³Ãö©óªÍÀùªº§K¬ÌÀøªk ®eµy«á©^¤W. ²{¤µ¨S¦³ªv¡HIVªºÃĪ« - µM¦Ó¬ì¾Ç®a¥i±æ¦Vªv¡ªº¥Ø¼Ð§óÁÚ«e¤@¨B ¦b½Í½×¨ìAIDS³oÓ¥DÃD®É¡Aªv¡¥¦³q±`¤£¦b¿ï¶µ¤¤¡C ¦Û±qHIVº¦¸³Qµo²{¦Ü¤µ35¦~µ´¤j³¡¤Àªº®ÉÔ¡A Âå¥ÍÁ`¬O±Nªv¡AIDS³o¼Ë¤@Ó·§©Àµø¬°¬O¤@ºØ¤Û·Q¡A¦Ó«D¨Æ¹ê¡C ·|¦³¦p¦¹ªº·Qªk¨º¬O¦]¬°HIV»P¨ä¥L¯f¬r~µM¤£¦P¡C HIV·|¯}Ãa±¼²zÀ³ºR·´HIV¯f¬rªº§K¬Ì²ÓM¡A¨ÃÂðΦb¨Å骺²ÓMùØ¡C ¼Æ¤ë¡A¦³®É¬Æ¦Ü¼Æ¦~¥H«á¡A¨C·í§K¬Ì¨t²Î¨¾¿m¯à¤O¤U°®É¦ø¾÷µo°Ê²×·¥P©Rªº§ðÀ»¡C µM¦Ó¦¹¦¸¬OÀY¤@¾D¡A¦bHIV¬y¦æ¯f±¡©µ¿N¦Ü¤µ¼vÅT¥þ¥@¬Éªñ3¤d7¦Ê¸U¤H®É¡A³\¦h±M®a̦b¨î©w¤U¤@¥NªºHIVªvÀøpµe®É¡A¥H¤p¤ßÂÔ·VªººA«×º«×¥Hªv¡HIV¬°¥Ø¼Ð¡C ²{¤µ¬ì¾Ç®aÁA¸Ñ¨ìHIV¬O¦p¦óÂðΦb²ÓM¤º¶i¦æ°°¸Ë¥H°k¹L§K¬Ì¨t²ÎªºÄY±KºÊ±± ¡V ¦Ó¬ì¾Ç®a°w¹ï¦p¦óÃѯ}¨Ã¶i¦Ó¤@Á|Äè·ÀHIV¯f¬r´£¥X¤@¨Ç·Qªk¡C ¬ü°ê°ê¥ß°·±d¬ã¨s°|(NIH)°w¹ï¦¹¶µ·sµo²{¡A«ùÄò´£¨Ñ¸g¶OÃÙ§U¬°ªv¡HIV©Ò°µ¥Xªº§V¤O¡A¦Ó¤@¨Ç¤ä«ù¹ÎÅé¦pamfAR¡A ¤]¤£Â_´£¨Ñ¬ÛÃö¸ê·½¡A¤£¶Èn¯àªvÀøHIV¡A §ó«nªº¬O¯à°÷§ä´M¥X¨ÏHIV¯f¬r§¹¥þµ´¸ñªº¤èªk¡C amfARªº¬ã¨sÁ`ºÊÝ°ÆÁ`µô Rowena Johnstonªí¥Ü¡AHIVµ´¹ï¥i¥H³Qªv¡¡AµM¦Ó³Ì³Ì«nªº°ÝÃD¬On¦p¦óªv¡HIV¡C Âk¥\©ó¡]ARV¡^§Ü¤ÏÂà¿ý¯f¬rÃĪ«°Ý¥@¡A¦¹ÃĪ«¯à°÷ªýÂ_¯f¬r¶i¤J°·±dªº²ÓM¤º¶i¦æ½Æ»s¡A²{¤µÂå¥Í¯à°÷»´¦Ó©öÁ|¦a¹ï©ó·P¬VHIVªº¯f±wµ¹»P¦³®Ä±±¨î¡C °²¨ÏHIV¯f¬rµLªk¤j¶q½Æ»s¡A HIV´NµLªkÂX´²¶i¦Ó·P¬V·s²ÓM¡C ³o¼Ë·N¿×µÛHIV§e¶§©Ê¤ÏÀ³ªº¯f±w¥i¥H¬¡±o§ó°·±d¡B§óªø¤[¡C µM¦Ó§Y¨Ï²{¤µªºÃĪ«ªvÀø±j¦Ó¦³®Ä¡AÃĪ«¥²¶·¨C¤é¤fªA¥HÀ£§í¯f¬r¶q¡A¦Ó¦¹ºØÃĪ«ªvÀø¨ÃµLªk¹ê»Ú±NÅ餺¨ü·P¬Vªº²ÓM¥h°£¡C ¬°¨D¦Û«O¡A¦³¨ÇHIV ¨Ã¨S¦³¥D°Ê¤j¶q½Æ»s¡A¦Ó¬O¼ç¥ñ¦b¬Y¨Ç§K¬Ì²ÓM¸Ì¦ø¾÷¦Ó°Ê¡C º¦ìµo²{¨ì§e²{ºÎ¯vª¬ºAªº¯f¬r¸s»E¼Ñªº¬ù¿«ÀN´¶ª÷´µÃľǰ|ÃĪ«¾Ç¨t±Ð±ÂRobert Siliciano ¦p¦¹»¡¹D¡A ¦¹ºØ§Ü¤ÏÂà¿ý¯f¬rÃĪ«¹ï©ó¨¾¤î¯f¬r§Ö³t½Æ»s¦¨®Ä¨ôµÛ¡A¦ý¥Ø«e´Æ¤âªº¬O¡A¦³¥t¤@ºØ§ÎºAªºHIV¤]¦P®É¦s¦b©ó¨ÅéùØ¡A¥¦¨Ã¨S¦³¶i¦æ½Æ»s¡A¦Ó¬O¼ç¥ñ¤£°Ê¡A ¬J¤£¨ü¨ì§Ü¤ÏÂà¿ý¯f¬rÃĪ«ªº¼vÅT¡A¤]¨S¦³³Q§K¬Ì¨t²Î»{¥X¡C ´N¬O³o¨ÇHIV¯f¬r¡A¥¦Ì¦b¯f±w°±¤îªAÃĮɶɱ_¦Ó¥X¡A¹ï±J¥D¤j¸v§ðÀ»¡C µM¦Ó¤T¤ë¥÷¦bªi¤h¹y©ÒÁ|¦æªº¤@³õ¥DÃD¬°§Ü¤ÏÂà¿ý¯f¬rÃĪ«º[¾÷·|©Ê·P¬V¡]µù¸Ñ¤@¡^ªº·|ij¤¤©Ò°µ¥Xªº³Ì·s³ø§i¡A¬ã¨s¾ÇªÌ´¦ÅS¥X±j¤OÃÒ¾Ú»¡©ú³o¨Ç¦b°Êª«¨¤WÂðΧe²{ÀR¤îª¬ºAªº¯f¬r¬O¥i¥H³Q¬¡¤Æ¨Ã¥B¶Ð°£ªº¡C µù¸Ñ¤@ ¾÷·|©Ê·P¬V¡G¾÷·|©Ê·P¬V¬O¥Ñ²Óµß ¡B¯f¬r¡B µßºØ©Ò¤Þ°_¡A ¥ĻQ¥Î¥±`¨S¦³ªº¾÷·|¦ø¾÷¦Ó°Ê¡A¤ñ¦p»¡·í±J¥D§K¬Ì¨t²Î´î®z®É¡A³o¨Ç¯fì¹ï©ó§K¬Ì¤O¥¿±`ªº°·±d±J¥D¬O¤£·|¤Þ°_¥ô¦ó¯e¯fªº¡FµM¦Ó¡A·í§K¬Ì¤O¥X²{°ÝÃD¡A©Î¬O¨Å馳¬ï³z©Êªº¶Ë®`¡A¦¹®É´N»s³y¥X¤@Óµ´¨Îªº¾÷·|Åý³o¨Ç¯fì³y¦¨·P¬V¡C ¦b¤@¶µ¨Ï¥ÎHIV¯f¬r¦bµU¤l¨¤W©Ò¶i¦æªº¬ã¨s¤¤¡A Dan Barouch Âå¥Í©M¥L¦bBeth Israel Deaconess Âå¾Ç¤¤¤ß¥H¤Î«¢¦òÂå¾Ç°|ªº¦P¨Æ®i¥Ü¥X¤@ºØÃĪ«¡A¦¹ºØÃĪ«¦P®Éݨã¨ë¿E§K¬Ì¨t²Î¤Î¬¡¤Æ¼ç¥ñ¡BÀR¤î¤£°ÊHIV ªº¥\¥Î¡A¦¹ºØÃĪ«µ²¦X¤@ºØ±j¤jªº§ÜÅé¥i¥H¥Î¨Ó¤¤©M³QHIV©Ò·P¬Vªº²ÓM¡A¦³®Ä¹K¤îHIV¦A¦¸§ðÀ»¡C¦¹ºØÃĪ«¹ï©ó¨ü¸Õªº11ºØ°Êª«¤¤ªº¨ä¤¤¤ºØ¦b°±¤î¨Ï¥Î§Ü¤ÏÂà¿ý¯f¬rÃĪ««á¥b¦~¤§«á¡AÃÒ©ú¦³®Ä¡C ¹ï©ó¨º¨ÇHIV¯f¬r¤S¦A«×¥X²{ªºµU¤l¡A¥L̨¤W©ÒÀËÅç¥Xªº¯f¬r¶q¬Û¸û©ó¨º¨Ç¥¼¸g¥ÎÃĪº°Êª«¡A¯f¬r¶qn§C100¿¡C Barouch »¡¹D¡A §Ú»{¬°§Ú̪º¼Æ¾Ú«ü¥X¤F§Ú̪ºÃĪ«¤¶¤J¹F¦¨¥\¯à©Êªv¡ªº¥i¯à©Ê¡C ¼Æ¾ÚÅã¥Ü¥X¨Ó¥ÎÃĪº¦³®Ä©Ê¡A ¦Ü¤Ö´N°Êª«ªº¹êÅç¤W©ÒÅã¥Ü¥Xªºµ²ªG¡A´N§Ú©Ò»{ª¾ªº¬O«e©Ò¥¼¨£ªº¡C ¨Æ¹ê¤Wªñ¥b¼Æªº°Êª«¦b°±¤î§Ü¤ÏÂà¿ý¯f¬rÃĪ«¥ÎÃĪº¨â¶g¤º¨Ã¥¼¥X²{HIV¯f¬r¶q¼W¥[ªºª¬ªp¡A³oºØ²{¶H·N¿×µÛBarouch©Ò¿×ªº¾_¦í¨Ã±þ¦º ¡]shock and kill¡^ªº¤èªk¤]³\¥i¥H¦³®Ä¦a°w¹ï¸s»EÂðΧeÀR¤îª¬ºAªº¯f¬r¡C ³o¬O¦VªvÀøHIVªº¤U¤@¶ôæ°ì¸ó¤j¨B - ¥h°£¤HÃþ¨¤Wªº¯f¬r¡A¦b¦³´Â¤@¤é¤]³\¥i¯à§K°£¯f±w¶·²×¨¨Ì¿à§Ü¤ÏÂà¿ý¯f¬rÃĪ«¡C ¦¹ºØ¤è¦¡¦Ü¤µ©|¥¼¶i¦æ¤HÅé¹êÅç¡A¦Óªv¡ªº¥Ø¼Ð¦³¥i¯à¤´»Ý¼Æ¦~¤§¤[¡C µM¦Ó§Ú̦s¦³¤@½u§Æ±æ¡C ¦bHIV¦¨¬°¥þ¥@¬É¬y¦æ¯fªº¾ú¥v¤¤¡A¥u¦³¤@¤H³Q¬Û«H¦¨¥\ªv¡¤FHIV¡C ¦¹¤H¬O²{¦~52·³ªº¬ü°ê¤HTimothy Ray Brown¡C 1995¦~¥¿¦b¬fªL°á®Ñ®É³QÅç¥XHIV§e¶§©Ê¤ÏÀ³¡C ¥L¤Q¦~¨ÓÂǥѨϥδXºØ§Ü¤ÏÂà¿ý¯f¬rÃĪ«¹ï¯f¬r°µ¥X¨}¦n±±¨î¡A¤@ª½¨ì¥L¾D¨ü¨ì¥t¤@Ó´¸¤ÑÅRÆE - ¥L³Q¶EÂ_¥X±o¤F¦åÀù¡A¦Ó¦åÀùªº¦¨¦]¾Ú¥LªºÂå¥Íªí¥ÜÀ³¸Ó¸ò¥LªºHIVµLÃö¡C ¬°¤FªvÀøÀù¯g¡ABrown ±µ¨ü¤ÆÀø¤Î¨â¦¸ªº°©Åè²¾´Ó¥H¸m´«¦å²G»P§K¬Ì¨t²Î¸Ìªº´c©Ê²ÓM¡C Brownªº¥DªvÂå¥Í¤F¸ÑBrownªºHIV±a챡ªp¡A¦b´M§ä®½Ãت̮ɦ³¥ý¨£¤§©ú¡A¯S§O§ä¨ì¤@¦ìÅ餺¨ã¦³Åܲ§®è¨Ï±oHIVµLªk·P¬V¨ìBrown·s²¾´Óªº²ÓM¡C Brown¦b±µ¨ü°©Åè²¾´Ó®É´N°±¤îªA¥Î§Ü |
|
|
·|û¡GµLµß®ñ10021927 µoªí®É¶¡:2018/4/20 ¤U¤È 03:43:44²Ä 714 ½g¦^À³
|
pro140¦b¸ÕÅç48¶g¸ÕÅçµ²§ô,·íµM§ï¦^Âû§À°sÀøªk¡C¦]¬°¸ÕÅç48©P´N¸ÕÅçµ²§ô¡C ÃĪ«°µ¤HÅé¸ÕÅç,¸ÕÅç´Áµ²§ôÁÙ¯àÄ~Äò¨Ï¥Î¶Ü? ©Ò¥H²z©Ò·íµM§ï¦^Âû§À°sÀøªk¡C TMB-355¦b°µ¤HÅé¸ÕÅç®É,¸ÕÅç´Áµ²§ô«á¤´¥iÄ~Äò¬I¥´TMB-355¶Ü? |
|
|
·|û¡G¶³²H·»´10146472 µoªí®É¶¡:2018/4/20 ¤W¤È 11:23:10²Ä 713 ½g¦^À³
|
FYI. TMB-355 V.S. Pro 140 investorshub.advfn.com/boards/read_msg.aspx?message_id=140155959 |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/20 ¤W¤È 10:54:03²Ä 712 ½g¦^À³
|
ÁÂÁ¤ѩR¤j¡C |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/20 ¤W¤È 10:49:26²Ä 711 ½g¦^À³
|
ÁÂÁÂDoghead¤j´£¿ô¡C |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/4/20 ¤W¤È 10:42:32²Ä 710 ½g¦^À³
|
¸Î§Q¤j, p35¶¤U¤èªº^¤å(¦³©³½u)ªº³¡¤À, ´N¦³»¡©ú¤H¼Æ½Õ¾ã¨ì20000 ~ 25000 |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/20 ¤W¤È 10:23:58²Ä 709 ½g¦^À³
|
½Ð±Ð¤j¤j¡G P35ªº¥«³õ¤À°t¹Ï¡AMDR¤H¼Æ¬°¦ó©l²×Åã¥Ü³Ìªì¹w¦ôªº8000-9000¤H¡A¦Ó«DTH¤½¥q×¥¿«áªº22000-25000¤H©O¡H |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/4/20 ¤W¤È 10:16:46²Ä 708 ½g¦^À³
|
ÁöµM¥Ø¼Ð¥«³õ¬O5¸U5¤d¤H µL©`ÃÄÅÒÁÙ¬O¥uµ¹MDRªº½d³ò, ¥u³Ñ¤U20000~25000. «ç»ò·|®t³o»ò¤j??? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/4/19 ¤U¤È 11:50:00²Ä 707 ½g¦^À³
|
¸õ¥X¨Ó¼á²M´CÅé³ø¾É¤º®e¡H ¤£¬O¤¤¸Î°õ¦æªø¦Û¤v¤Ó¶¢¡A¦Ó¬O¦]À³ª÷ºÞ·|n¨D¡A³o¬O¤½¶}µo¦æªº¤½¥q»Ýn¿í´`ªº³q«h¡A¤£¬O¯S¨Ò¡C ¡uwww.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&cad=rja&uact=8&ved=0ahUKEwi3sp7R0cbaAhXIoJQKHaKYDH0QFggvMAI&url=http%3A%2F%2Fwww.fsc.gov.tw%2Ffckdowndoc%3Ffile%3D%2F%25E6%25B7%25BA%25E8%25AB%2587%25E8%25BF%2591%25E6%259C%259F%25E5%25BC%25B7%25E5%258C%2596%25E8%25B3%2587%25E8%25A8%258A%25E6%258F%25AD%25E9%259C%25B2%25E4%25B9%258B%25E6%2596%25B0%25E8%25A6%258F%25E7%25AF%2584.pdf%26flag%3Ddoc&usg=AOvVaw2ikhnmhRx9QogGpq3kjyxb ¡v ¡u ²L½Íªñ´Á±j¤Æ¸ê°T´¦ÅS¤§·s³W½d¡v Page 12/15¡G ¡u¡K¸v¡Bªñ´Á¸ê°T´¦ÅS¨î«××q«ÂI ¬°¨Ï§ë¸ê¤j²³¯à¦³®Ä²v¦aÀò±o¥R¤À¥B¤Î®Éªº¸ê°T¡Aª÷ºÞ·|«ùÄò½ÐÃÒ¥æ©Ò¤ÎÂd¶R¤¤¤ß§ïµ½¸ê°T´¦ÅS±¹¬I¡Aªñ´Á¼Wפ§¬ÛÃö±j¤Æ±¹¬Ip¦³´£«e´CÅé³ø¾É¼á²M®É¡B¼È°±¥æ©ö¾÷¨î¤§¤Þ¶i¤ÎÀu¤Æ¦~³ø»P¤½¶}»¡©ú®ÑÀ³´¦ÅS¨Æ¶µµ¥¡A¯÷¤Àz¦p¤U¡G ¤@¡B¼á²M´CÅé³ø¾É ¬°´£¤É¤W¥«¡]Âd¡^¤½¥q«¤j°T®§´¦ÅS¤§§Y®É©Ê¡AÁקK§ë¸ê¤H¨ü´CÅé³ø¾É¤º®e¤§¤£·í¼vÅT©Î¸ê°T¤§¤£¹ïºÙP·l¤ÎªÑªFÅv¯q¡Aª÷ºÞ·|¬¸½ÐÃÒ¥æ©Ò¤ÎÂd¶R¤¤¤ß×q«°T³B²zµ{§Ç¡An¨D¤W¥«¡]Âd¡^¤½¥qµo²{¤j²³¶Ç¼½´CÅé³ø¾É¤½¥q«¤j¨Æ¥ó¡B³ø¾É¤º®e¨¬¥H¼vÅT¦³»ùÃÒ¨é¦æ±¡¡A©Î³ø¾É»P¨Æ¹ê¤£²ÅªÌ®É¡AÀ³´£«e¿é¤J«¤j°T®§»¡©ú¡]ì³W©w»Ý©ó¦¸¤@Àç·~¤é¥æ©ö®É¶¡¶}©l«e¿é¤J«¤j°T®§¡^¡A¨Ã¨Ì¥«³õ¹ê°È¹B§@»Ýn¾ú¸gºu°Ê½Õ¾ã¡A¨ä¾ú¦¸×¥¿ì¦]¤Î«ÂI¦p¦¸¡G ¡]¤@¡^n¨D¤W¥«¡]Âd¡^À³©óµo²{´CÅé³ø¾É·í¤é§Y®É¼á²M¡G ´CÅé«e³ø¾É¬Yª÷±±¤½¥q¨ÖÁʮסA¸Ó¤½¥qÁö¤w©ó¨Æ¹êµo¥Í©Î¶Ç¼½´CÅé³ø¾É¤§¤é°_¦¸¤@Àç·~¤é¥æ©ö®É¶¡¶}©l«e¡A±N¸Ó°T®§¤º®e©Î»¡©ú¿é¤J¤½¶}¸ê°TÆ[´ú¯¸¡A±©¤´¦³§Y®É©Ê¤£¨¬¤§±¡ªp¡C ¬°ºûÅ@§ë¸ê¤HÅv¯q¡Aª÷ºÞ·|©ó¸Ó¨Æ¥óµo¥Í®É§Y©ó102 ¦~9 ¤ë½ÐÃÒ¥æ©Ò¤ÎÂd¶R¤¤¤ß×¥¿«°T³B²zµ{§Ç³W©w¦³Ãö¼á²M´CÅé³ø¾É¤§¥Ó³ø®É¡An¨D¤W¥«¡]Âd¡^¤½¥qµo²{¤j²³¶Ç¼½´CÅé³ø¾É¤½¥q«¤j¨Æ¥ó¡B³ø¾É¤º®e¨¬¥H¼vÅT¦³»ùÃÒ¨é¦æ±¡¡A©Î³ø¾É»P¨Æ¹ê¤£²ÅªÌ®É¡A¶·¥ß§Y¿é¤J«¤j°T®§»¡©ú¡A¦Ü¿ð¤£±o¹O·í¤é¤¤¤È12 ®É¡C¦ý©ó¨Ò°²¤é©ÎÀç·~¤é¤¤¤È12 ®É«á©lµo²{ªÌ¡AÀ³©óµo²{¶Ç¼½´CÅé³ø¾É¤é¤§¦¸¤@Àç·~¤é¥æ©ö®É¶¡¶}©l«e¿é¤J¡C¡v¡K¡K¡]«á²¤¡^ |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/19 ¤U¤È 11:03:28²Ä 706 ½g¦^À³
|
4/12´CÅ黡EPS²Ä¤@¦~¤W¬Ý10¤¸, ¤½¥q¸õ¥X¨Ó¼á²M money.udn.com/money/story/10162/3081780 4/19´CÅ黡EPS²Ä¤@¦~¥u¦³0.65¤¸, ¤½¥q¤]¸õ¥X¨Ó¼á²M www.chinatimes.com/newspapers/20180419000370-260206 (³o½g®Ú¥»¶Ã¼g) ¤£ºÞ¦hªÅ³£¼á²M §Úı±o«ÜOK°Ú ªí¥Ü¤½¥q«Ü¹ê¦b, ¤£·Q³Q¦³¤ß¤H§Q¥Î¦¨¬°ª£§@ªº¹ï¶H |
|
|
·|û¡GÆZ¤û10146692 µoªí®É¶¡:2018/4/19 ¤U¤È 10:37:02²Ä 705 ½g¦^À³
|
¤p§Ì¦b¦¹ª©¼ç¤ô¤w¤[¡A¤@ª½³£«ôŪ¦U¦ì¤j¤jªººëÅP¤ÀªR¡A¯uıªº¨ü¯q¨}¦h¡C¤p§Ì¹B®ð¤]¤£¿ù¡A²Ä¤@¦¸¶RªÑ²¼´N¬D¤W¤¤¸Î¡]¤]¬O¼õ¤F¤@¦~¦h¤~¬Ý¥L¦³°_¦â¡^¡A¤p§Ì¯u¤ß»{¬°¬O¶¡¦n¤½¥q¡C¦ý¤p§Ì¤Q¤À¤£¸Ñªº¬O¡A§O®a¤½¥q¤Ú¤£±o¤Ñ¤Ñ³£¦³®ø®§¥i©ñ¡A¤Ñ¤Ñ³£¦³§Q¦h¥iª£¡C¨º¬°Ô£±i°õ¦æªø¨C¦¸¤@¦³§Q¦h®ø®§´N¸õ¥X¨Ó»¡³o³£¬O´CÅé¦Û¦æ¹w´ú¡A¼â¤j®a§N¤ô©O¡H°µ¨Æï{Ã¥´¬O¦n¨Æ¡A¥i¦³±o®ÉÔ¬O¤£¬O¤]nݵÂI·Åý¤j®aªº§ë¸ê§ó¦³®Ä¯q©O¡C¤p§Ìµoµo¨cÄÌÁٽЦU¦ì¤jô§O¨£©Ç¡A¦b¦¹¹w¯¬¤¤¸Î¶}½æ¶¶§Q¾P°â¬õ½L¡A¤]¯¬¤j®aÁȤj¿ú |
|
|
·|û¡Gmetrostar10141472 µoªí®É¶¡:2018/4/19 ¤U¤È 09:56:44²Ä 704 ½g¦^À³
|
ÁÙ¨S¶}¥XÀ禬«e,À³ÁÙ·|¥´²V¤@°}¤l, ¦ýn¦A¦^¨ì23X ¥i¯à´N¨S¨º»ò®e©ö¤F |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/19 ¤U¤È 07:56:39²Ä 703 ½g¦^À³
|
¤µ¤Ñ¯d¤W¼v½u,À³¸Ó¦³¾÷·|¦^ÀÉ §ÚÁÙ¦³¤W¨®ªº¾÷·|¤~¹ï ¦Ñ¥q¾÷¤W¨®Åo |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/19 ¤U¤È 12:10:56²Ä 702 ½g¦^À³
|
www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/trogarzo-ibalizumab-uiyk.pdf For initial therapy, all of the following: A. Both of the following: 1. Diagnosis of HIV-1 infection 2. Physician attestation that the patient has multi-drug resistant HIV-1 infection and B. Physician confirms that the patient has been prescribed an optimized backround antiretroviral regimen, containing at least one antiretroviral agent that demonstrates full viral sensitivity/susceptibility; ------------------------------------------------------------------------------------------ ¬Ý°_¨Ó¨î¤£¦h. ¥Dn¬Omulti-drug resistant HIV-1 infection ¦ý¤£ª¾MDR¬O§_¦³¸Ô²Óªº©w¸q. ¬d¸ß¨ìªº¬O¹ï¨âºØ, ¥]§t¨âºØ¥H¤WclassªºÃĪ«¦³§ÜÃÄ©Ê, ´N¬Omulti-drug resistant. |
|
|
·|û¡GObi10141963 µoªí®É¶¡:2018/4/19 ¤W¤È 10:18:21²Ä 701 ½g¦^À³
|
United Healthcare coverage criteria www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/trogarzo-ibalizumab-uiyk.pdf ¬Ý°_¨Ó®e©ö¥Ó½Ð¨ìreimbursement |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2018/4/19 ¤W¤È 09:51:48²Ä 700 ½g¦^À³
|
270¹L269 ¦¸°ª ´Á«Ý ¶R«Ü¦n ·~ÁZ»]»]¤é¤W |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/4/18 ¤U¤È 09:36:14²Ä 699 ½g¦^À³
|
§O¤Ó¶Ù¡A ÀHµÛªÑ»ù³v¨B¨«髙¡A§ë¸ê·ÀI¤]¨Ó¤F¡A ¥~¸ê³sÄò¶R¡Aµu´Á¬O¦n²{¶H¡Aªø´Á«h¥¼¥²¡A ¯u¥¿¹ï¤é«áªÑ»ù¦³§U¯qªº⋯, ¨Ì¬O¤U¶g¥H«á¡AÃÄ«~¤W¥««áªº¾P°â¶q¡A ³o¤]´N¬O¥Ø«e¤¤¹ê¤á¡Bª£¤â¡A¬Æ¦Ü§ë«H°òª÷¸g²z¤H¡B ¦ÛÀç¾Þ½L¤H¡A¨ÌªŤ⪺¥D¦]¡I |
|
|
·|û¡G¸ô¤H¥Ò10135334 µoªí®É¶¡:2018/4/18 ¤U¤È 09:10:48²Ä 698 ½g¦^À³
|
¤Ñ©R¤j´£¹L: «nªº¬O¦û2/3 ¥«³õªº¤½«Omedicaid ¡A¦ó®É¯Ç¤J³B¤èÃĪ«¡C¡]TH¹w´Á6~9¤ë¶¡¯Ç¤J). ©Ò¥H¶}½æ«áµu´Á¤º¤]¤£¦³¤Ó¦nªºÀç·~ÃB, ɨ骺¤H·|©ñ°²§QªÅɦ¹¥´À£¶Ü? |
|
|
·|û¡Gpark951210142283 µoªí®É¶¡:2018/4/18 ¤U¤È 05:13:59²Ä 697 ½g¦^À³
|
¤µ¤Ñ³Ì¤j¶R¶W¨é°Ó¬°¥xÆW¶×¥ß¡A¶R¶i566½æ¥X0¡A¬Q¤Ñ¤]¬O¥u¶R¤£½æ¡A³sÄò3¤Ñ¦@¶R¶W1284±i¡C¥~¸ê±q3¤ë6¤é¦Ü¤µ¡A¦@¶R¶W6401±i¡A§ë«H½æ¶W894±i¡A¦ÛÀç°Ó½æ¶W960±i¡C¥~¸ê¥Ø«e«ù¦³46410±i(18.55%)¡A§ë«H279±i(0.11%)¡A¦ÛÀç°Ó1039±i(0.42%)¡Cɨé½æ¥X¾lÃB¦Ü¬Q¤Ñ¬°3150±i¡C¥H¤W¬°¤p§ÌÆ[¹î©Ò±o¡A¦p¦³¿ù»~½Ð«ü¥¿¡C |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/4/18 ¤U¤È 03:43:07²Ä 696 ½g¦^À³
|
³o¬O50¤Hªº©µ¦ùÁ{§É¸ÕÅç¡A§Æ±æ¥L¦¨¥\¡A¤]¯à¨ú±oFDAÃĵý¡C MDR¯f¤H¥i¿ï¾ÜªºÃĪ«¤£¦h¡C ¤£¦P¾÷Âà¹ï¥½缐¯f¤H¦Ó¨¥´N¦³ÁpÃĪº¾÷·|¡C pro 140 ¥Î©ó¥½缐 ´N¦p¦P 2007 ¦~¤W¥«Maraviroc(Selzentry).¤]¬O¥Î©óMDR±wªÌ¡C --------------------------------------------------------------------- ¤Ñ©R¤j, ¦pªG¬O³o¼Ë, ¨º¤¤¸Îªº©t¨àÃÄ·N¸q¬O¤°»ò? ¥Ø¼Ð«È¸s¤@¼ËªºÃij£¥i¥H®³ÃÄÃÒ, ¬O¤£¬O´N¥¢¥h©t¨àÃĪº·N¸q¤F?? |
|
|
·|û¡G¶³²H·»´10146472 µoªí®É¶¡:2018/4/18 ¤U¤È 02:56:11²Ä 695 ½g¦^À³
|
¹wp¤»¶g¤º¤W¥«¶}½æ==>¸õ²¼, Äò¬Ý¥|¤ë©³. |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/18 ¤U¤È 01:52:31²Ä 694 ½g¦^À³
|
¤Ñ©R¤j ¥¦¦ü¥G¬O·Q§ð¨âºØ¥«³õ clinicaltrials.gov/ct2/show/NCT02483078?term=pro+140&rank=2 ³oÓStudy¬O¤£¬O¤ñ¸û²Å¦X¤¤¸Îªº¦¬®×±ø¥ó©O |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/18 ¤U¤È 01:20:16²Ä 693 ½g¦^À³
|
ÁÙ¨S¶R¨¬´N©Ô¤W¥h,¤Ö¶R¤F3±i ©ú¤Ñ¦³¦^ÀɦA¸É,¬Ý¨ÓÀ³¸Ó¨S¬Æ»ò§CÂI¯à¶R«£ |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/18 ¤U¤È 12:21:11²Ä 692 ½g¦^À³
|
¤Ñ©R¤j §Úı±oPRO140¦¹³B©Ò«üªº70000¤H¤@¼Ë¬O¦b«ü¤¤¸Îªº¥«³õ ¦]¬°2/3/4½u«Ü©úÅã»·»·¤£¥u70000¤H ¥B¦bp.13³oÓÃĪ«ªº¥«³õ´N¬O®³TMB-355¬Û¤ñ |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/4/18 ¤W¤È 10:30:38²Ä 691 ½g¦^À³
|
Market Potential for PRO 140 www.cytodyn.com 15 Initial approval Combination Therapy U.S. Market Potential �XHAART failures: ~ 70,000 pts with two or more drug class resistances �X70,000 pts x 70% (R5-HIV strain) = 49,000 HIV pts R5 eligible �X49,000 pts x $24,000 (current market pricing) = ~ $1.2 billion content.equisolve.net/cytodyn/media/a142a8575db88331c0585a336ca2ebfd.pdf ----------------------------------------------------------------------- ¤Ñ©R¤j, ·Q½Ð°Ý§A¤W±POªº¤º®e, ©Ò¿×ªº XHAART failures: ~ 70,000 pts with two or more drug class resistances ³o¤£¬O¤¤¸Îªº¥Ø¼Ð¥«³õ¶Ü? ¬°¤°»òPRO 140¸òTMB355¨âªÌªº¥«³õ¹w¦ô®t³o»ò¦h? ¦pªGTMB-355¨Ï¥Î¦¹¥Ø¼Ð¹w¦ô, EPS´N·|¬O±z¤§«e¦ôªº¤T¿£°...±q50¤¸¸õ¨ì150¤¸...«ç»ò®t¶Z³o»ò¤j? |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/18 ¤W¤È 09:57:53²Ä 690 ½g¦^À³
|
¤Ñ©R¤j PRO 140¦ü¥G¬Oµo®i¦¨¥Ö¤Uª`®g ¦b²Ä¤»²Ä¤C¶¦³´£¨ì |
|
|
·|û¡G¤p©ú10146339 µoªí®É¶¡:2018/4/18 ¤W¤È 09:38:45²Ä 689 ½g¦^À³
|
¥~¸ê³sÄò¤G¤Ñ¤j¶R...´Á«Ý¥~¸ê®ø¤Æ250¥H¤Wªº½æÀ£³á¡A´N³o¼Ë§â250¥H¤U·í§@¤@ӲϹꪺ©³§a! |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/18 ¤W¤È 08:54:49²Ä 688 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j¤j Pro 140²{¦b¦ü¥G¤]¶i®i±o«Ü§Ö ½Ð°Ý¥¦¬O§_¦³¥i¯à·m¨«¤¤¸Î¤@³¡¤Àªº¥«³õ? www.cytodyn.com/media/presentations |
|
|
·|û¡GÂIÂIÂI10142457 µoªí®É¶¡:2018/4/17 ¤U¤È 11:35:33²Ä 687 ½g¦^À³
|
¦³ÃöÁp¥ÍÃĪº°ÝÃD¥i¥H¥hÁp¥ÍÃĪºªO²á®@ ¦b³o²á¥i¯à¦³¤õªá⋯⋯¨þ ¤W¦¸³}ªüÁøÁy®Ñ¦o¦b«e¦~9¤ë¦³po«Ü¦h¤p¬q¼v¤ù ¨ä¤¤¤@Ó¦³Ãö¤¤¸Î¸òÁp¥Íªº°Ó¾÷¤ñ¸û Áp¥ÍÃĤHû¦^µª»¡421ªº»ùȬO¤¤¸Îªº¤Q¿ °Ýªº¤HÁÙ¥H¬°Å¥¿ù¤S°Ý¤@¦¸¦o¤S¦^¤F¤Q¿ ¤Ï¥¿¬Ý¤U¥h£¸Ó¦³ÃÄÃÒ £¸Ó¨S¦³ |
|
|
·|û¡GºCºC¶]10142302 µoªí®É¶¡:2018/4/17 ¤U¤È 07:20:25²Ä 686 ½g¦^À³
|
ã¤F¡IÃÄ©ú±d±o°{¹q¦^ÂkAªÑ IPO¶Ò¸ê¤j´î63% 2018/04/17 17:34 ¹d¦ëºô ¹d¦ëºô·s»D¤¤¤ß ¾ú¸g 3 ¦~¡A³Qµø¬°¡uÂåÃĬɵج°¡vªºµL¿üÃÄ©ú±d¼w²×©ó±N¦^Âk¤¤°ê A ªÑ¥«³õ¡A4 ¤ë 13 ¤éºµo¥Ó½Ð®Öã«á¡A¬Q (16) ¤éº¦¸¤½¶}µo¦æ (IPO)¡Aµo¦æ¼Æ¶q¤£¶W¹L 1.04 »õªÑ¡A¹wp¶Ò¸ê 21.30 »õ¤¸ (¤H¥Á¹ô¡A¤U¦P)¡A¸û¤½¥q¦¹«e©ÜÅSªº 57.40 »õ¤¸¤j´î 63%¡C ¡m®É¥N¶g³ø¡n³ø¾É¡AÃÄ©ú±d¼w¬OÄ~´I¤h±d¤§«á¡A²Ä¤G®a¨«¡uIPO §Ö³t³q¹D¡vªº·s¸gÀÙ¤½¥q¡A±q¦b¤W¥æ©Ò±Æ¶¤¥ø·~¤¤¦W¦C²Ä 73 ¦ì¨ì¶¶§Q¹L·|¡AÃÄ©ú±d¼w¥u¥Î¤F 50 ¤Ñ¥ª¥k¡C ÃÄ©ú±d¼w¦¨¥ß©ó 2000 ¦~¡A¬O¤@®a²[»\·sÃĬãµo¥þ²£·~Ã쪺¥þ²y©ÊÂåÃĬãµoªA°È¥ø·~¡A¾Ö¦³¥]¬A°ê¤º¤W®ü¡BĬ¦{¡B¤Ñ¬z¡BªZº~¡B±`¦{¤Î¬ü°ê¶O«°¡B¼w°ê¼}¥§§Jµ¥¥þ²y 26 Ó¬ãµo°ò¦a / ¤À¤ä¾÷·p¡C2016 ¦~¤½¥q CRO ªA°È¥«¦û²v±Æ¦W¥þ²y²Ä 11 ¦ì¡B¤¤°ê²Ä 1 ¦ì¡C ¥«³õ¤H¤h»{¬°¡AÃÄ©ú±d¼wªº§Ö³t¹L·|¡A±o¯q©óªñ´Á A ªÑ¾Ö©ê¡u¿W¨¤Ã~¡vªº¬Fµ¦¡A¦P®Éµ¹¬ÛÃö¤½¥q«ü¥X¤@±ø§Ö³t¤W¥«ªº¥i¦æ¸ô®|¡A¨ã¦³¤@©wªºÉų·N¸q¡C ¥H¡u°{¹q¡v³t«×³q¹Lµo¼f·|¤§«á¡AÃÄ©ú±d¼w¤@ª½¦bµ¥«Ý¨Ó¦ÛÃҺʷ|ªº¤W¥«§å¤å¡CºµoÀòµo¼f©e³q¹L¡A±±ªÑªÑªF§õ²©Î³\nªøµÎ¤@¤f®ð¡C±q 2015 ¦~ 4 ¤ë±Ò°Ê¨p¦³¤Æ¥H¨Ó¡A§õ²¤Î¨ä¹Î¶¤¤@ª½³£¦b¬°¤W¥«¦£¸LµÛ¡C ÃÄ©ú±d¬Q¦b¤W¥æ©Ò©ÜÅS¡mº¦¸¤½¶}µo¦æªÑ²¼©ÛªÑ·N¦V®Ñ¡n¡A¹wp¶Ò¶°¸êª÷¨Ï¥ÎÃB¬° 21.30 »õ¤¸¡A¸û¤½¥q¦¹«e¹w©ÜÅSªº¼ÆÃB´î¤Ö 63%¡A©Ò¶Ò¶°¸êª÷±N§ë¸ê¤_Ĭ¦{ÃĪ«¦w¥þµû»ù¤¤¤ßÂX«Ø±M®× (7.27 »õ¤¸)¡B ¤Ñ¬z¤Æ¾Ç¬ãµo¹êÅç«ÇÂX«Ø¤É¯Å±M®× (5.64 »õ¤¸)¡B ÃÄ©ú±d¼wÁ`³¡°ò¦a¤Î¤ÀªR¶EÂ_ªA°È¬ãµo¤¤¤ß (91#¡B93#)(2 »õ¤¸) ©M¸É¥R¬y°Ê¸êª÷ (6.39 »õ¤¸)¡C ÃÄ©ú±d¼wªÑ²¼¥N½X¬°¡u603259¡v¡A¸Ó¥N½X¦P®É¥Î©ó¦¹¦¸µo¦æªºªì¨B¸ß»ù¤Îºô¤U¥ÓÁÊ¡A¦¹¦¸µo¦æºô¤W¥ÓÁÊ¥N½X¬°¡u732259¡v¡C |
|
|
·|û¡Gmetrostar10141472 µoªí®É¶¡:2018/4/17 ¤U¤È 06:07:45²Ä 685 ½g¦^À³
|
¥~¸ê«ùªÑ¤w±qÃÄÃÒ«eªº15.4%,¯¸¤W18%¤F ¤µ¤Ñ¨Ó¨ì18.05% |
|
|
·|û¡G¥Í§Þ·sÂA¤H10146669 µoªí®É¶¡:2018/4/17 ¤U¤È 03:42:52²Ä 684 ½g¦^À³
|
¤Ñ©R¤j ±z¦n! «ôŪ±z¦Aª©±¤W©Ò¼gªº¹ï¤¤¸Îªº±M·~¬ã¨s, ¯u¬O¦Û¹Ä¥±¦p, ·PÁ±z´£¨Ñ³\¦h¤¤¸Îªº¬ÛÃöÄ_¶Q¸ê°T, Åý§Ú¯à°÷¨³³t´x´¤¨Ã¥B§ó¥[¤F¸Ñ§Úªº§ë¸ê¼Ðªº, ¤]´Á³\¯à°÷¹³±z¤@¼Ë¹ï©ó§ë¸ê°µº¡, °µ¨¬¥\½Ò. §Ú¦³¥H¤U¨âÓ°ÝÃD·Q½Ð±Ð±z: 1. Áp¥ÍÂ媺·R´þ¯f·sÃľڳø¾É¸ò¤¤¸Î¦ü¥G¬O¬Ûªñªºì²z ¦ý¬O¥i¥H¨Ï¥Î¦b¤@½u¤Î¥|½u¦h«§ÜÃĩʯf±w §Ú·Q¤F¸Ñ¬°¦ó¤¤¸ÎªºTMB355 ¥u¯à°w¹ï¥|½u¦h«§ÜÃĩʪº¯f±w¨Ó¨Ï¥Î©O? ¦pªG¹ï§Ü·R´þ¯fªº¾÷Âà¬O¤@¼Ëªº, ¬°¦ón¨ü©ó¥u¯à°w¹ï¥|½u¯f±w? Ãø¹D¬O¦]¬°·íªìFDA©Òµ¹ªº¬O©t¨àÃĪºì¦]? ·íªì¦]¬°¤¤¸Î¬ãµo¸g¶O¤£¨¬µLªk°µ¤j³W¼ÒÁ{§É¤T´Áªº¸ÕÅç©ÒP¶Ü? 2. ®Ú¾ÚTMB355 ÂåÃijæ±i¤W©Ò±Ôz, ·íªì°µ¤p³W¼ÒÁ{§É¤T´Á®É, ¹ï©ó¦h«§ÜÃĩʨü¸ÕªÌ¦b¨â©P¤@¦¸ªºª`®g¦³ÅãµÛªºÀø®Ä ¦ý¨ì¤F²Ä24©P®É¬ù¬°¦Ê¤À¤§48ªº¯f±w¥i¥H¦³®Ä§í¨î¯f¬r¶q, ¨º»ò¹ï©ó¥t¤@¥bªº±±¨î±¡§Î©O? ¬O§_¹ï©ó¤T´ÁÁ{§É¯f±w¥u¦³¬ù¥b¼Æ¬O¦³®Äªº©O? ¦pªG¥u¦³¥b¼Æ¦³®Ä ¨º»ò¬O§_¥i¥H³o¼Ë»¡ ³Ì²×¦bÂå¥Í«Øij¤U¬I¥´ªº¦h«§ÜÃÄ©m¯f±w ·|¦³¤@¥b¦³¥i¯à·|Âà´«ÃĪ«©O? |
|
|
·|û¡GG94010145720 µoªí®É¶¡:2018/4/17 ¤U¤È 02:02:43²Ä 683 ½g¦^À³
|
·PÁ¤ѩR¤j¸Ô²Ó¸Ñ»¡¡A ¦n¤ß¤@©w¦³¦n³ø ¤£ºÞ¥¼¨ÓªÑ»ù¦p¦óÅÜ°Ê¡A³£¬OÀ°¤j®a¤W¤F¤@ªù³Ì¦nªº»ùȧë¸ê±Ð¨| |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/17 ¤U¤È 01:28:07²Ä 682 ½g¦^À³
|
«D±`ÁÂÁ¤ѩR¤jªº»¡©ú ³o¼Ë§ÚÀ´¤F ¸ÑŪ¦p¤U ·R´þ¯f¦@¦³¤T¸UÓÂå¥Í(¹Ï¥ª¤è¤W±¼g30K) ¨ä¤¤17%(5100¦ì)¤S´x´¤¤F70%ªº¤T¾÷Âà§ÜÃĩʪº³B¤èñ ©Ò¥HTH¸ò¤¤¸Î¥ý¶°¤¤¤õ¤O¦b³o5100ÓÂå¥Í¤W±°µ¦æ¾P |
|
|
·|û¡G¶³²H·»´10146472 µoªí®É¶¡:2018/4/17 ¤U¤È 01:26:00²Ä 681 ½g¦^À³
|
Ó¤H¸ÑŪ: TRx = Total Prescriptions 30K Âå¥Í*17%=5100 Âå¥Í´x´¤ 70% MDR ³B¤è TRx¤W±¨S¼g¥þ³¡¦³¦h¤Ö³B¤è, ¬O30K? |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/17 ¤U¤È 12:22:18²Ä 680 ½g¦^À³
|
¥i§_½Ð±Ð¤Ñ©R¤j ¥h¦~12¤ëªk»¡·|ÀÉ®×p.29ªº¨º±i¹Ïªº·N«ä¬O? ¤p§Ì¬Ý¤£¤ÓÀ´ ·N«ä¬O¦h«§ÜÃĩʪº³B¤è¥u¦³¶}¥X5100±i¶Ü? |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/4/17 ¤W¤È 08:37:37²Ä 679 ½g¦^À³
|
¤Ñ©R¤j⋯, ¹ï¤@ӬݦnÁp¥ÍÃĪºUBÉ@É@É@ªº¤H⋯, »¡¤¤¸Îªº¬ü¦n¥¼¨Ó⋯, ®t¤£¦h¬O¸ò¹ï¤û¼uµ^¤@¼Ë⋯,«D±`¦³¡u¨ë¿E¡v©Ê⋯, ¦]¬°¥LÌÁ`¬OÂû🥚𥚃¬D°©ÀY⋯, ¦ý³o¤]¥i¥H²z¸Ñ⋯,§ë¸ê¤FÁp¥Í⋯,¬Ý¨Ó¥¼¨Ó7¦~¤º¦ü¥G ¤]¨S§Æ±æ⋯,ì½Ì¥Ļa¡I ¥u¬O¤£¸TÃhºÃ⋯,³s¦b¬ü°ê³£¨S¦¬¹L¯f±w⋯, ¥u¦bªF«n¨È¤Î¥xÆWÁ{§É¸ÕÅç⋯, ´N·Qn®³¬ü°êFDA©t¨àÃĤÎBTD¸ê®æ⋯,¬Æ¦Ü¶i¦æ¬ü°êÁ{§É¤G¡B¤T´Á⋯, §A¥H¬°FDA·|§â¬ü°ê¯f¤H⋯,ÀH«KÅý¤H·í½Þ¹êÅç⋯, ¥Ó½Ð¦U¶µ¥Û¨H¤j®ü⋯,è¦n¦Ó¤w⋯¡I ¯uªº·P¿E¤Ñ©R¤jªº§V¤O⋯,¦ý¯uªº¤£¥Î¬°¤¤¸ÎÅG¸Ñ⋯, ³Ì¦h¦A¥b¦~´Nª¾¹Dª¬ªp¤F⋯, |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2018/4/16 ¤U¤È 10:37:07²Ä 678 ½g¦^À³
|
4¤ëÀ禬 5/10¤½§i 5¤ëÀ禬 6/10¤½§i 6¤ëÀ禬 7/10¤½§i ¥b¦~³ø 45¤Ñ ®w¦s¦b¨º? ¦³«K§Q¨ú³fªº¦Ò¶q Åܦ¨¦¬¤J ¨º¬O¨â³y¶¡¬ù©w ¥Î¤F ³o¤ë¤£¬O¦¬¤J ¤U¤ë¥²¬O À³¦³¦s³fºÞ²zªº§a?? ¹q¤l·~¤j¼t ¤£¬O¤£¤Ö¤p¦@À³°Ó©ñ®w¦s¦b¼t¤º |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/4/16 ¤U¤È 09:52:32²Ä 677 ½g¦^À³
|
¤Ñ©R¤j, §ÚÓ¤Hı±o³o½g³ø¾É¬O°äÄꪺ.TH¥»¨´N²{ª÷¤£¨¬¤F. ³oºØ»{¦Cªk¤£¬O¥ú¶R®w¦s¤½¥q´N¯}²£¤F. ¦A»¡¤¤¸Îñªº¬O¦æ¾P¦X¬ù, TH¥u¬OÀ°¦£¦æ¾P¦Ó¤£¬O¥N²z°Ó. ¥N²z°Ó³o¼Ë¶ë³f¬OOKªº. ¦ý¬O©âwªº¦æ¾P§Úı±o¸ò©Ð«Î¥N¾P³æ¦ì¤ñ¸û¹³, «È¤H(«OÀI¤½¥q)±þ»ù»Ýn«Ø°Ó(¤¤¸Îì¼t)¦P·N¤~¯à¥X°â. ¥N¾P½æ¤£¦n¬O¥i¥H³Q«Ø°Ó´«±¼ªº, ¦P¼Ëªº¤¤¸Î¤]¦³³o¼ËªºÅv§Q |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/16 ¤U¤È 09:33:12²Ä 676 ½g¦^À³
|
¨ä¹ê§Ú¤£À´ªº¬O¤½¥q¬°¦ó¥u¤@ª½±j½Õ25000¤HªºMDR¥«³õ ±q¦UºØ¸ê®Æ¬Ý¨Ó¥«³õ³£¤ñ³o25000¤H¤jªº¦h |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/4/16 ¤U¤È 09:22:00²Ä 675 ½g¦^À³
|
§â®w¦s©ñ¦b¸g¾P³æ¦ì, À³¸Ó¤£ºâÀò§Q§a? ³£¤£ª¾¹D°â»ù½æµ¹½Ö, n«ç»ò¤À¼í©O? ¦A»¡ÃÄÃÒ³q¹Lªº®ÉÔ, ´N¦³»¡¥_¬ü¦³9000²~®w¦s, «ç»ò¨S¦b3¤ëªº·~ÁZ¬Ý¨ì? |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/4/16 ¤U¤È 08:41:46²Ä 674 ½g¦^À³
|
·Pı¤Ñ©R¤j ¸ò«¼C©M°õ¦æªø¤@¼Ë. ¦ôÀò§Q³£¶W¯Å«O¦uªº. ©Î³\¤¤¸ÎªºªÑªF»P¤j¤á³£¬O¶W¯Å«O¦uªº. ¦ÛµMªÑ»ù´N¤£·|°_¨Ó¤F. |
|
|
·|û¡Gyu76021610146652 µoªí®É¶¡:2018/4/16 ¤U¤È 05:57:17²Ä 673 ½g¦^À³
|
«¢«¢«¢«¢«¢..»¡¹G´N¨¥«¤F.....¥u§Æ±æ¯à¦³¦U¦ì¥ý¶i±a»âµÛ¤p§Ì..Ä~Äò¿ú¶i...·P®¦ |
|
|
·|û¡Gyu76021610146652 µoªí®É¶¡:2018/4/16 ¤U¤È 05:38:04²Ä 672 ½g¦^À³
|
¶â...·PÁ½²¤j¤À¨É......¥u¦³³o¼Ë..½²¤j¤~¯àµL¨pµ¹¤j®a°Ñ¦Ò·N¨£...¤p§Ì·P®¦¤£ºÉ |
|
|
·|û¡Gmengs10146592 µoªí®É¶¡:2018/4/16 ¤U¤È 02:27:59²Ä 671 ½g¦^À³
|
§Þ³N±¤W«ùÄòºû«ù½L¾ã®æ§½¡A¬õ´Î¶q´¶¹M¤j©óºñ´Î¡A¦n¨Æ¡C¤WÀɽæÀ£Æ[½L¤@Ӥ뤴µM¨S¦³´î¤Öªº¸ñ¶H¡C¼@¥»§Ú¬Ý°£«D¬OÃz¤j¶q«ã¦Y±¼¡A§_«h·|Ä~Äò½L¤U¥h¡C¦]¬°²{¦b°£¤F®M¨c½æÀ£¤§¥~¡AÁÙ¶}©l¦³¤H°µ230-250°Ï¶¡¡A¾ÉP250ªºÀ£¤O§ó¤j¡C ¦Ü©ó¶}½æ·|±Y±¼ªº..§Ú¯º¤F¡C¨Sº¦¦h¤Ö¬On±Y¤°»ò°ÕxDDD ¥ý¬Ý¬Ý¨ä¥L¥»¹Ú¥Í§Þ«ç»òº¦ªº¦n¶Ü?±Y¬On±Y¥hþ?200? |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2018/4/16 ¤U¤È 02:22:56²Ä 670 ½g¦^À³
|
{¥~¸êɨ÷===¹j¤Ñ¤é³ø©ñ®ø®§==== °²°²½æ´X±i=====¤H®a¬O·Ç³Æ¼´¤F -------------------------- ¯u¯u°²°² ¤£¹LˬO³zÅS¤@¥¹¶}½æ.......... ================================================================== ½Ð°Ý§A,¤°»ò¥s°²°²½æ´X±i?¤°»ò¥s¼´¤F? ¦Ó§A¨ì©³³zÅS¤F¤°»ò? Á¿¸Ü³£Á¿¤£²M·¡,Å޿觹¥þ¤£³qªº¤H,Ãø©Ç¦hªÅ³£·d¤£²M,¦³¤HÀ´§A¦b¼g¤°»ò¶Ü? °²°°²©Ç ÁÙ¥H¬°¦Û¤v²{¦b¬O§ëÅU¦Ñ®v,¶}©l¾BµP¤F,¤jº¦´N»¡¸ò§A»¡·|º¦¡A¤j¶^´N»¡§Ú´N¸ò§A»¡·|¶^ ¤£°Ê´N»¡¸ò§A»¡°Ï¶¡¾Þ§@ |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/16 ¤U¤È 01:42:13²Ä 669 ½g¦^À³
|
²{¦bÁÙ¦bÆ[±æªº¤H´N°µ¤@¤U¼ÒÀÀ¦n¤F? °²¦p·sÃĶ}½æ´N§Q¦h¥XºÉ¦Ó¤U¶^!? ¨º¤¤¸Î¤]ºâ¬O¥þ¥@¬É¥Í§ÞªÑªº©_¸´¤F! |
|
|
·|û¡Gyu76021610146652 µoªí®É¶¡:2018/4/16 ¤U¤È 12:37:06²Ä 668 ½g¦^À³
|
½²¤j....±z³o°²¥~¸ê¬ÝªÅ......±z¤£©È¹L«e°ª«á¥Ã¤£¦^ÀY¶Ü¡H |
|
|
·|û¡Gyu76021610146652 µoªí®É¶¡:2018/4/16 ¤U¤È 12:02:33²Ä 667 ½g¦^À³
|
½²¤j..©Ò¥H§A»{¬°¥~¸ê¬Ý¦h¡H¬ÝªÅ¡H¡H |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/16 ¤W¤È 10:59:59²Ä 666 ½g¦^À³
|
¹wp¤U¬P´Á´N·|¶}½æ,³o´X¤Ñ¥i¥H¦A¶R´X±i¤F! À禬·|ºCºC¤W¥h! ¤½¥q¤]±N¤j´TÀò§Q,¥¿¦¡¶i¤J·sªº¨½µ{¸O! |
|
|
·|û¡G¤pªL10146648 µoªí®É¶¡:2018/4/14 ¤U¤È 07:15:49²Ä 665 ½g¦^À³
|
¤Ñ¤j¡Aªø´Á«ù¦³¥Ø¼Ð»ù¦³仠¤¸¥i¯à¶Ü |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/14 ¤U¤È 06:13:58²Ä 664 ½g¦^À³
|
ÁÂÁ¤j¤j´£ÂI¡C |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/14 ¤U¤È 05:27:21²Ä 663 ½g¦^À³
|
¤Ñ©R¤j¡G eps 4.28x26%x79%x29/25x10=10.2¤¸ ³oӺ⦡¤¤ªº79%¦ó¨Ó¡A¥i§_½Ð¤j¤j½ç±Ð¡AÁÂÁ±z¡I |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/14 ¤U¤È 03:14:15²Ä 662 ½g¦^À³
|
«_¬N½Ð±Ð¤Ñ©R¤j¤j¡Gºâ¦¡¤¤ªº79%¥Nªí¤°»ò¡A¤p§Ì·Q¥b¤Ñ¤£©ú¥Õ¡C |
|
|
·|û¡G¤pªL10146648 µoªí®É¶¡:2018/4/14 ¤W¤È 10:45:21²Ä 661 ½g¦^À³
|
¤Ñ¤j¡A²Ä¤T¦~¬O§_¬°30¤¸ |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/13 ¤U¤È 10:12:19²Ä 660 ½g¦^À³
|
ÁÂÁ¤ѩR¤jªº¤À¨É ©Ò¿×ª¾¤vª¾©¼¦Ê¾Ô¦Ê³Ó ¬Ý§¹¤F³sµ²¤¤Áp¥ÍÃĪºÀÉ®×, ¤Ï¦Ó¹ï©ó¤¤¸Î§ó¦³«H¤ß¤F p7. §ÜÅéÃÄ«~¥§¡¾P°âÃB18»õ¬üª÷ p27. ¹w¦ôTMB-355 2019¦~À禬¬°3»õ¬üª÷, ´«ºâ¦¨¤¤¸ÎEPS¤j¬ù¬O10, ²Å¦X³Ìªñ·s»Dªº¹w¦ô Y¬O4¦~¹F¨ì°ª®p, ¨º»òTMB-355°ª®pÀ禬±N¶W¹L10»õ¬üª÷ p27.³Ì¥ªÃä±µ¨üªvÀøªº¤H¼Æ1800¸U¤HÀ³¸Ó¬O«ü¥þ¥@¬É p26. 84%ªº¯f±wÄ@·N¹Á¸Õ¤@Ӥ르°w¤@¦¸, §Y¨Ï¬O¨â¶g¤@¦¸¤]¬O¦³64%ªº¯f±wÄ@·N¨Ï¥Î, ³o¤¤¸Î¤]¦³´£¹L ©Ò¥H¥Î³o¤ñ¨Ò¦A¥h¥´§é¨Óºâ¤@¤UTMB-355º¯³z²vªº¸Ü, ¥«³õ¤]¬O«ÜÅå¤H ¦A¦^¨ìUB-421ªº®Éµ{ °²³]¥¦®³¨ì©t¨àÃÄ¥H¤ÎBTD, FDA¤]¦P·NÁ{§É¶}©l, ·Óclinical trialºô¯¸¤W±ªº®Éµ{¶i®i, ¤@¤Á³£«D±`§¹¬ü ®³¨ìÃÄÃÒ¤W¥«À³¸Ó¤]¬O2022¦~¤§«áªº¨Æ±¡.. ¦¹®É¤¤¸Î¦Ù¦×«¬¤]¤w¤W¥«¤@¬q®É¶¡(¤]¥ý¤£¦Ò¼{TMB-365¦ó®É·|¤W¥«), ¥i¥H¤@Ӥ르¤@¦¸, ¬°Ô£n¨â©P¥´¤@¦¸? §Ú»{¬°¥u¦³¤@ºØ±¡ªp¥²¶·n¿ïUB-421, ´N¬O³Ñ¤U¨º¤Q´XwTMB355µLªkªvÀøªº¯f±w ¤]´N¬O¦Y¤¤¸ÎµLªk¦Yªº¥«³õ ¦³¿ù½Ð«ü¥¿ |
|
|
·|û¡G¤pJ10138989 µoªí®É¶¡:2018/4/13 ¤U¤È 09:32:00²Ä 659 ½g¦^À³
|
Áp¥ÍÃÄ106/5/31¤w¦V¬ü°ê¹«~ÃĪ«ºÞ²z§½(US FDA)´£¥XªvÀø·R´þ¯f§Ü Åé·sÃÄUB-421¤§Á{§ÉIIb/III´Á¸ÕÅç¥Ó½Ð(«°T¤½§i) ¦ý²{¦b¥¼¨£®Öã §Ö¤@¦~¤F ì¦]? |
|
|
·|û¡G¦n¹B10137114 µoªí®É¶¡:2018/4/13 ¤U¤È 07:38:14²Ä 658 ½g¦^À³
|
Doghead¤j ½Ð°Ý±z©Ò»¡ªºÁ{§É¡A¬O¤G´ÁÁÙ¬O¤T´Á¡H ¦b¬ü°ê°µ¶Ü¡H |
|
|
·|û¡Gmengs10146592 µoªí®É¶¡:2018/4/13 ¤U¤È 07:28:30²Ä 657 ½g¦^À³
|
½²¤j§Ú¤]«Ü·Q¼ÖÆ[¬Ý«Ý ¦ý¥H¹L©¹¸gÅç¨Ó»¡¡A³Ìªñ¤@©P¥~¸ê½æ¥X¤@¤d¦h±i¡AÂàªÅ¡C¤Sɨé¶q¤W¤É¡C¨ä¹ê²Õ¦b¤@°_¨Ó¬Ý¡A¬O¾ãÅé¬ÝªÅ¡C ¥Ø«eÁÙ¥i¥H¼y©¯ªº¥u¦³3/6¸¹¥ª¥k©Ô°_¨Óªº¥D¤O¤j¦h¨S¦³¶](¤Ö³¡¤À¥X³f¤F¦p¬üªL)¡C¦Ó¬Q¤Ñªº¤j©Ô©ï¡AÄw½XÅã¥Ü¬O´I¨¹XXµ¥¹j¤é¨R¤j¤áªº³Ç§@¡A¦Ó¤£¬O¥D¤O¶}©Ô¤F¡A¬O¥Õ°ª¿³¤@³õ¡C ¥Ø«e¤p§Ìı±o·|Ä~Äò½L¡A¬Æ¦Ü¦b©¹¤U´ú¤ä¼µ³£¦³¥i¯à¡C¦¨¥»§Cªº·íµM¬O¯º¬Ý¤@¤Á¡C¦¨¥»°ªªº´N...¦Û¦æ·r°u§a! ¤p§Ì³o¨Ç¤é¤l³£¦b¦³ª`·N³o°¦ªº½L¡C25x¥ª¥kªº¤j¶qÀò§Q¥X²M(©Î¬OÀ£½L?!) 23x¥ª¥kªº±j¤O¤ä¼µ(«ç»ò³£½æ¤£¤U¥h)¡C°¾¦h¡A¦ý¤£°l¦h¬O³Ì¨Îªºµ¦²¤! #¥»¤Hªø´Á¬Ý¦h¤¤¸Î¡A¥u´N§Þ³N±°Q½×µu´ÁªºÂøµ®T¼Ö®ø»º¡AYµu´Án¶i¥X½Ð¦Ût¤U¨®¨®¶}¨«ªº·ÀI |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/13 ¤U¤È 04:55:29²Ä 656 ½g¦^À³
|
ibmi.taiwan-healthcare.org/about_detail.php?REFDOCID=0or1skwzqtqjp168&REFDOCTYPID=&PageNO=1 |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/13 ¤U¤È 03:56:07²Ä 655 ½g¦^À³
|
½²¤j~ ³o¼Ë¤]¬Ý±o¥X¥~¸ê¦bÂêÄw½X,¼F®`! |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/13 ¤W¤È 11:05:45²Ä 654 ½g¦^À³
|
ªÑªF·|°Ý¦ó¤j¤@³Õ¤h... ¨â®a·R´þ¯fÃĪº¦P²§©Ê°Ï§O¦bþ,¤£´N³£ª¾¹D¤F¶Ü!? |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/4/13 ¤W¤È 10:36:14²Ä 653 ½g¦^À³
|
Hi §g¤j, §Ú¬Ý¦n¤¤¸Î, Á|Áp¥ÍÃÄ¥u¬OÁ|¨Ò©t¨àÃĦbFDAªºÂ¾ÅvÁÙ¬O¯à³Q¨ú®øªº°²³]»¡©ú Hi ¤Ñ©R¤j, ÁöµM¨S¬Ý¦nÁp¥Í, ¦ý¬OÁÙ¬O´N¤@¨Ç§A´£ªº¼Æ¾Ú§Ô¤£¦í¸ò§A°Q½×°Q½× 1. ÃÄ«~¦¨¥»¥u·|¦û¤@¤p³¡¤À, Á|¨Ò»¡©ú¤¤¸Î¥¼¨Ó¦Û²£¦Û¾P, ¥Í²£¦¨¥»¥i¯à¥u¦û©w»ùªº6%¥ª¥k, Áp¥ÍÃÄÁöµM¥Î¶q¬O¨â¿, ¦ý¬O¤u¼t¤w¸g«Ø¸m§¹¦¨¥BÅu´£, ¨ì®ÉÔ¦¨¥»®£©È¸ò¤¤¸Î®t¤£¦h¦Ó¤w. §Úı±o¥Dn¬Oq»ù»P¥«¦û°ÝÃD, ²¦³º¥Í²£¦¨¥»¦û¤ñ¤£°ª. 2. Áp¥ÍÃĥثeªº½T¬O¤@½u¥ÎÃĸò«á½u¥ÎÃĦP®É¶i¦æ¹êÅç, §A§äªºStudyè¦n¬O¤@½u¥ÎÃĪºcase, ÁÙ¦³¤@Ó«á½u¥ÎÃĪº study Study Type : Interventional (Clinical Trial) Estimated Enrollment : 30 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment Official Title: A Multicenter, Randomized, Parallel-Arm, 24-Week Study of UB-421 in Combination With Optimized Background Therapy (OBT) Regimen in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection Anticipated Study Start Date : September 2018 Estimated Primary Completion Date : May 2020 Estimated Study Completion Date : November 2020 Studies a U.S. FDA-regulated Drug Product: Yes ------------------------ ³oÓ´N¤ñ¸û©úÅã¬O°w¹ï¤¤¸Î¥Ø«eªº¬ü°ê¥«³õªºstudy |
|
|
·|û¡G¶Wô10139528 µoªí®É¶¡:2018/4/13 ¤W¤È 05:43:39²Ä 652 ½g¦^À³
|
¤Ñ©R¤jªGµM±M·~¡IUB421ÅܼÆÁ٫ܦh¡I©Ò¥HªÑ»ù¥u¦³¤¤¸Î1/4¤£¨ì¡Aªp¥B³oºØÃĦpªG¥´¤£¶i¼Ú¬ü¥«³õ¡A´N¥Õ°µ¤F¡A³s¸ò¬ü°êFDA½Í³£ÁÙ¨S½Í¡A¦óªpÃÄÃÒ¡Htmb355®³¨ì¥|¶µ¯S®í¸ê®æ¡Aub421? |
|
|
·|û¡G§g10000178 µoªí®É¶¡:2018/4/12 ¤U¤È 11:34:24²Ä 651 ½g¦^À³
|
Áp¥ÍÃĬÛÃöªº°ÝÃD¡A¥h¦~ªÑªF·|¤W¦³¤H´£¹L¡A³o³¡¥÷´N¨S¤°»ò¦nÁ¿ªº¡A¦pªG§A¬Ý¦nÁp¥ÍÃÄ¡A´N§V¤O¶R¤U¥h¡A¯¬ºÖ§A |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/4/12 ¤U¤È 11:19:24²Ä 650 ½g¦^À³
|
¥t¥~©t¨àÃĪº³¡¤À, FDA«OÅ@´ÁÁöµM¬O¤C¦~, ¦ý¬O¦³´XÓ¨Ò¥~¥i¥HºM¦^©t¨àÃĸê®æ. ´N¬O¸U¤@¦³¨ä¥LªºÄvª§ªÌ¯àÃÒ©úÃĮĤñ355ÁÙ¦n, FDA¬O¦³Åv§Q¥i¥HºM¾P355ªº©t¨àÃĸê®æ. Á|¨Ò¨Ó»¡: ¥Ø«eÁp¥ÍÃĪºUB-421,¦bµoªíªº½×¤å(¥xÆWÁ{§É¼Æ¾Ú)¤W, ®ÄªG¤ñTMB-355¦n¦h¤F UB-421 ¦Ù¦×ª`®g vs TMB-355ÀR¯ßª`®g UB-421 ¥i¥H³æ¿W¥ÎÃÄ16¶g¯f¬r¶q¤£¤Ï¼u vs TMB-355¥²¶··f°tÂû§À°sÀøªk,¦pªG³æ¿W¨Ï¥Î, ¨â©P«á¶}©l¯f¬r¶qÅܦh. UB-421 ¯f¤H100%¦³®Ä vs TMB-355¥u¦³¬ù¤K¦¨±wªÌ¦³®Ä. Áp¥ÍÃÄ¥i¥H¦b´X¦~«á, ¨Ï¥Î¥x¡B¤¤¡B®õ°êÁ{§É3´Áªº¸ê®Æ, ¦V¬ü°êFDA¥Ó½Ð¨ú®øTMB-355ªº©t¨àÃĸê®æ, ¶i¦æ¬ü°ê¤W¥«¥Ó½Ðµ{§Ç. |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/4/12 ¤U¤È 11:06:49²Ä 649 ½g¦^À³
|
§Úªº¦L¶H: ¡u¼Æ¾Ú«OÅ@¡v¬O«ü·s¶i¤½¥q¤£¯à¨Ï¥Î¤¤¸Îªº¼Æ¾Ú¶i¦æ°e¥ó. ¦ý¬OÁÙ¬O¥i¥H¦Û¦æ´ú¸Õ¬ÛÃö¼Æ¾Ú°e¥ó. ¥u¬OªùÂe´£°ª. ¨Ã«D¤£¯à¥Ó½Ð¬Û¦üÃÄÃÒ.¥u¬O12¦~¸Ì±, FDA·|¦b²Ä¤¦~¤~·|¶i¦æ¼f¬d[§Úªº²z¸Ñ¬O¥u¦³«OÅ@«e¥|¦~¤£·|¦³Ävª§ªÌ¥X²{,²Ä¤¦~Ävª§ªÌ´N¦³¥i¯à¦Û¦æ´ú¸Õ¼Æ¾Ú], ¦ý¬O²{¦b¤S¤@Ó©t¨àÃÄ«OÅ@¤C¦~. ½Ð°Ý«OÅ@´Á¬O7+12¶Ü? |
|
|
·|û¡G§g10000178 µoªí®É¶¡:2018/4/12 ¤U¤È 10:54:16²Ä 648 ½g¦^À³
|
¤À¨É¤½¶}»¡©ú®Ñ¤Wªº¤º®e TMB-355 ¥¼¨Ó´¼°]¤§«OÅ@±N±Ä¡u¼Æ¾Ú«OÅ@¡v¤§¤è¦¡¡A¨Ì¾Ú¬ü°ê¤Î¼Ú·ù¹ï©ó¥Íª«»s¾¯·sÃĪºªk³W¡A ¦Û·sÃÄ®Öã¤W¥«¤é°_¬ü°ê¦³ 12 ¦~¤§¼Æ¾Ú«OÅ@¡F¼Ú·ù¦³ 10 ¦~¤§«OÅ@¡C¥t¥~¥»¤½¥q TMB-355 À³ ¥Î©ó¦h«§ÜÃÄ©Ê ¯f¤H¤§»s¾¯Àò±o¬ü°ê FDA ©t¨àÃĸê®æ¡A¦]¦¹¦³ 7 ¦~¦æ¾P«OÅ@´Á¡C ¦]¦¹¥¼¨Ó TMB-355¤W¥««á¦³¬Û·íªøªº®É¶¡¤£·|¦³¥Íª«¬Û¦üÃĪº¥«³õ«Â¯Ù¡A¥i½T«Oªø´Á¤§Àò§Q¨Ó·½¡C ¦¹ ¥~¥»¤½¥q°w¹ï TMB-355 ¶i¦æ§ï¨}¤w¸g¬ãµo¥X²Ä¤G¥N§Þ³N(LM-52 §Y TMB-360/365)¡A ¹wp©ú¦~«×¥i±æ¥Ó½Ð¤HÅéÁ{§É¸ÕÅç¡A¥B¸Ó§Þ³N¤w¸g¶}©l¥Ó½Ð¦U¬É¦U¥Dn°ê®a¤§±M§Q «OÅ@¡A¥¼¨Ó¤W¥««á±N¨ú¥Nì TMB-355 ¤§¥«³õ¡A¦]¦¹Âǵ۫ùÄòªº§ï¨}¬ãµo·s¤@¥N²£ «~¡A°£±M§Q¡Bªk³W¤§«OÅ@¥~¡A±N¥i½T«O¥«³õ¤§»â¥ý»PÄvª§¤O Y¨Ì·Ó¼Æ¾Ú«OÅ@biosimilarn¶i¤J¥«³õ¤]n12¦~¥H«á ¦]¬°©t¨àÃÄÅýÃÄ»ù¥i¥H¦~¦~º¦¡A¥[¤W«á½u¥ÎÃÄÄvª§©Ê¤£±j ´Nºâ©t¨àÃĨì´Á¡A¤]¤£¤@©w·|«K©y 12¦~¥H«á²Ä¤G¥N¤Î²Ä¤T¥N²£«~¤]¤w¸g¤W¥« |
|
|
·|û¡G¶³²H·»´10146472 µoªí®É¶¡:2018/4/12 ¤U¤È 05:03:56²Ä 647 ½g¦^À³
|
¬Q¤Ñ¦³É¨é1430, ÁÙ¨é110, ¤£½T©w¬O¤£¬O¦]¬°¬O³o¼Ë?! |
|
|
·|û¡G54310143745 µoªí®É¶¡:2018/4/12 ¤U¤È 04:30:40²Ä 646 ½g¦^À³
|
·PÁ¤ѩR¤j¤À¨É¡C¡C ½Ð°Ý¡G¥~¸ê4/10«ùªÑ43650±i¡A4/11¥u¶R19±i¡A¬°¦ó«ùªÑ±i¼ÆÅÜ44884±i |
|
|
·|û¡G¸ô¤H¥Ò10135334 µoªí®É¶¡:2018/4/12 ¤U¤È 03:52:27²Ä 645 ½g¦^À³
|
¤Ñ©R¤j ½Ð±Ð¤@¤U, ©xºô¼g TMB-365¬°¦ó¤j¤@³Õ¤hºX¤U¹Î¶¤³Ì·s¶}µoªº²Ä¤G¥NªºTMB-355³æ®è§ÜÅé¡A©ÓŧTMB-360¼s®Äªº§Ü·R´þ¯f¬r¯à¤O¡A§ó¶i¤@¨B´£¤ÉÃĪ«°Ê¤O¾Çªí²{¡A¯àºû«ù§óªø®É¶¡ªº¦³®ÄÃĪ«¦å¤¤¿@«×¡A±N¶}µo¬°¨C¤ë¬I¥´¤@¦¸ªºªø®Ä¥Ö¤U/¦Ù¦×ª`®g¾¯«¬¡A¹wp2018¦~´£¥XIND¥Ó½Ð¡A¶i¤J¤HÅéÁ{§É¸ÕÅç¡C ½Ð°Ý¬O¨C¤ë¬I¥´¤@¦¸ÁÙ¬O¨C3Ӥ르¤@¦¸°w, þÓ¬O³Ì·sªºp¹º? |
|
|
·|û¡Givan10140729 µoªí®É¶¡:2018/4/12 ¤U¤È 03:18:34²Ä 644 ½g¦^À³
|
¤Ñ©R¤j §A¦n, ¥i§_½Ð±Ð¤Ñ©R¤j 4/9¦³´£¨ìTMB365ªº¤À¤l©MTMB355¦³99%¬Û¦ü ³o¸ê®Æ¬O¨Ì¾Ú¤WÂd«e·~ÁZµoªí·| °õ¦æªø©Ò»¡ªº¶Ü? ¥t¥~¦pªGTMB365³o»ò¬Û¦ü ¤WÂd«e·~ÁZµoªí·| °õ¦æªø¦³´£¨ìTMB365¹L¤@´Á¾÷²v¬°¶W¹L50% ³o¾÷²v¦³°¾«O¦u¶Ü? ¥t¥~ ¤WÂd«e·~ÁZµoªí·| °õ¦æªø¦³´£¨ìTMB365¹wp4~5¦~«á·|¤W¥« ²{¦b¬O2018¦~ TMB365©|¦b¤@´Á¶¥¬q ¥i§_¤À¨É§Aªº±M·~¬Ýªk. ÁÂÁ |
|
|
·|û¡GG94010145720 µoªí®É¶¡:2018/4/12 ¤U¤È 01:35:22²Ä 643 ½g¦^À³
|
¨ä¹ê¤@¤äªÑ²¼¥Lªø½u¦p¦ó¨«¡A©³«¬´N¤w¸g¨M©w¤j³¡¤À¡Aµu´Á³£¥u¬OÂø°T ¤§«e§Ì§Ì®³ÃÄÃÒ«e¡A¤]¬O¤@°ï¤H¬ÝÃa¡A¤£Ä@·N«ù¦³¡A¦ý®É¶¡ÃÒ©ú¶V½|¶V°ª¡A¶VÃhºÃ¶V°ª¡AÄ@·N¬Û«Hªº¤H¦³¿}ªG¥i¥H¦Y §ë¸ê¶R½æ´N¬O¦X·N¦¨¥æ¡A¤£¬Ý¦nªº´N¬OºÉ§Ö¤Fµ²¡A¥t´M¼Ðªº¡A¬Ý¦nªº´N¬OÄ~Äò«ù¦³¡A¥Î«H¤ß°í«ù¨Ó¬Ý¤@¤äªÑ²¼ªº¯ß°Ê |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/4/12 ¤U¤È 12:44:18²Ä 642 ½g¦^À³
|
¬Ý¼Ë¤l⋯, ¤µ¤Ñ¤S¬O³ø¯È¸ó±i³ø¾É⋯, ¾ÉP©ó¬Ý³ø¯Èªº§ë¸ê´²¤á¡A ©Î³\¦A¤@¦¸ªº¡A »~§âªF··í±¡¦¡B ¦¬§¹½L«á·t¦Û¶Ë¡B ªº¤é¤lÅo¡I |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/12 ¤U¤È 12:26:29²Ä 641 ½g¦^À³
|
¨ì¤µ¤Ñè¦n½L¾ã¤F¤@Ó¤ë §ðÀ»¶q¦³¥X¨Ó¤F ¤ñ«e¤Ó¥æ©ö¤éªº¥§¡¶q¤j¤W1.5¿ |
|
|
·|û¡GOOXX10022393 µoªí®É¶¡:2018/4/12 ¤W¤È 11:23:23²Ä 640 ½g¦^À³
|
9.¨ä¥LÀ³±Ô©ú¨Æ¶µ:·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à ¨Ï§ë¸ê±Á{·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C ------------------------------------------------------ ¤¤¸Î TMB355 ¤w¦¨¥\®³¤U¬ü°êÃĵý¡A¤W±¤S»¡¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¬O§_¦³¤£¹ê¤½§i¤§¶û¡H |
|
|
·|û¡G¯º¦10143600 µoªí®É¶¡:2018/4/12 ¤W¤È 10:18:37²Ä 639 ½g¦^À³
|
§Ų́Ӭݬݤ¤¸Îªº±ø¥ó 1¡AFDA ¥|¶µ¼úÀyÀu´f : (1) Fast Track (2) Break Through Therapy (3) Accelerated Approval (4) Priority Review ¤¤¸Î¡A¥H¤Wªº4Ó±ø¥ó¥þ¼Æ¶°º¡¡C ¦b¥xÆW¬O°ß¤@ªº ¤@®a¡C ¦b¥þ²y¤]ÄÝ©ó¨u¨£¡C 2¡A¦p¤µ¨ú±oÃÄÃÒ4¤ë¶}©ç¡A¥¼¨Ó16©uyou,qoq¥þ³¡³£¬O¦¨ªø¡Aeps§e²{¸õÄ£¥Üªºª¦¤É 3¡A¸UÂI¦æ±¡¡A¥Í§Þ¨«¤F2¦~ªÅÀY¡A¤~è¿ô¹L¨Ó¡A°ò¨È¯E¹©ªº³±Åµ±N³vº¥´²¥h ©ñ¤UµJ¼{¡A§ä¤@Ó¶R¤F¥i¥HºÎıªºªÑ²¼¡AÀËÅç¦Û¤v§ë¸êªº²´¥ú»P»ùÈ¡I ¬d²z¨~®æ¡]¤Ú¸¯Sªº²×¥Í¦X¥ë¤H¡^Á¿ªº¡G§ë¸êªº°]´I»P¥æ©öªºÀW²v¦¨¤Ï¤ñ |
|
|
·|û¡G¶³²H·»´10146472 µoªí®É¶¡:2018/4/12 ¤W¤È 10:12:33²Ä 638 ½g¦^À³
|
¥|¤ë©³«e¶}½æ, ¤£¬O¦´Nª¾¹Dªº¨Æ. ·s»D¥u¬O¦b°t¦X? ½Ö±µ½Ö½æ? Åý§ÚÌÄ~Äò¬Ý¤U¥h! |
|
|
·|û¡G¯º¦10143600 µoªí®É¶¡:2018/4/12 ¤W¤È 09:57:34²Ä 637 ½g¦^À³
|
¬O¤£¬Oºôx¨è·N±a·¦V¡H¤p¤ß³Q¤H±a¶]!±q¶g½u¤ë½uªº¨¤«×¨Ó¬Ý¡A¤¤¸Î³£¬Oªø¦hªºªÑ²¼¡A¤~讳¨ìÃÄÃÒ¡A·Ç³Æ20¦~§V¤Oªº¦^¦¬¡A¥un§¤µÛµ¥¡A®³´È¤l¦b®ÇÃä¬Ý´N¥i¥H¤F¡A»´ÃPªº¤é¤l¤£¹L¡A¨C¤Ñ·QªF·Q¦è¡A·Q¹j¾ÀªºªÑ²¼º¦ªº¤ñ¸û§Ö¡A³Ì«á¦Û¤vªº¥þ¥á¤F¡A½a¤H´N¬O¨S¦³©w¨£,¦Û¥H爲Áo©ú¡A¥þ¥@¬É³£¬O²Â³Jªº¤H¡A°O±o¸C²´¬Ý¥@¬É! |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/12 ¤W¤È 09:55:42²Ä 636 ½g¦^À³
|
¤j¦¿¤]¬O¤@®a¦ÑÁó«Ü§V¤Oªº¤½¥q,¦b±M§ð«O°·¹«~¤è±! ¤¤¸Î«h¬O·sÃÄ«ü¼Ð...¤@©w·|¦U¦³ªí²{ªº |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/12 ¤W¤È 09:34:44²Ä 635 ½g¦^À³
|
¤ÖÁȦӤw,§O´¨¤ß¨x,¦A±µ¦A¼F...ÁûÁû^^ |
|
|
·|û¡G¦n¹B10137114 µoªí®É¶¡:2018/4/12 ¤W¤È 09:23:10²Ä 634 ½g¦^À³
|
«¢...´¨¤ß¨x¤Ï¬Ù¤¤... |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/12 ¤W¤È 09:12:59²Ä 633 ½g¦^À³
|
¦n¹B¤j~ §A½æ§¹´N¤jº¦,³o¤]¤Ó¥©¦X¤F§a!? |
|
|
·|û¡Gmengs10146592 µoªí®É¶¡:2018/4/11 ¤U¤È 08:10:44²Ä 632 ½g¦^À³
|
¤¤¸ÎªºªÑ¥»ºâ¤pªÑ¤F¡A¤£°Ê´N¬O¤£°Ê¡C¦³¥i¯à·|´`¾Ù°T¼Ò¦¡§a¡AªÑ»ù°l·~ÁZ¡A¦Ó¤£¬OªÑ»ù¥h¹w´ú·~ÁZ¡C¦Ó§Ú¨É¤§©Ò¥H·|¬O³o¼Ë¡A¸ò¯E¹©/°ò¨È¤§«eªºª¬ªp²æ¤£¤FÃö«Y¡C²{¦b¦b³õ¤ºªº§ë¸êªÌ¥i¯à³£¬O¯uªº«Ü¤F¸Ñªº¤Ö³¡¤À¤H¡A¨S¦³¤j¸êª÷¡A¤j³¡¤À¤@ª¾¥b¸Ñªº¶R®a¶i³õÀ°¶R¡A¨º´N·|Ä~Äò°±¦b³o§a¡C ¬Æ¦Ü¥i¯à¤¤ë¤½¥¬¥|¤ë¾P°â¦¨ÁZ¡AÁÙ·|¥ý®£·W¶^¤@ªi¡Aµð~¤£¬O®³¨ìÃÄÃÒ? ªÑ»ù¨â¦Ê¦hÁȳo»ò¤Ö? ¤§Ãþªº¨¥½×³£¬O¥i¥H´Á«Ýªº¡C ÂyªÌ¤jÁ¿±oÀ³¸Ó¨ì«Ü¦h¤H¤ß§¢¸Ì¡A¬ÝµÛ¨ä¥LªÑ¤@ª½öt¡A³o¦ì®³¨ì¬ü°êÃÄÃÒªº¤Ó¤Ó«o¦b¨º¥ð®§¡A¬Oº¡§é¿i¤Hªº! ¤pº¦¤]¦n¡A¬O§a? |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/4/11 ¤U¤È 01:37:35²Ä 631 ½g¦^À³
|
¹ï°Ú¡B¹ï°Ú¡A »°ºò§â¤¤¸Î´«Ä_ÄÖ´IÀA¡A ¥ýÁȪi°Ê¤jªºÄ_ÄÖ¡A ¤¤¸Î³o¤j¤û⋯,´N¥ý©ñ¤û¦Y¯ó¡A ¤Ï¥¿¡Aµu´Á¡u¦ü¥G¡v¨Sn°Êªº²{¶H¡I ¯¬¤j®aÁȤj¿ú |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/11 ¤U¤È 12:01:38²Ä 630 ½g¦^À³
|
¥¦À³¸Ó¬O±µ¨ì¤¤¸Îªº¤j³æ§a |
|
|
·|û¡G¦n¹B10137114 µoªí®É¶¡:2018/4/11 ¤U¤È 12:01:08²Ä 629 ½g¦^À³
|
¹ê¦b¬O¤Ó¿i¤H,§Ô¤£¦í¤F. ¤µ¤Ñ¥ýÀò§Q¥X³õ, µ¥¸I¸I¨ì©u½u¦A¨Ó±µ¤â. |
|
|
·|û¡G¯º¦10143600 µoªí®É¶¡:2018/4/11 ¤W¤È 11:57:01²Ä 628 ½g¦^À³
|
ÃÄ©ú¥Íª«¤S¯¸¤W·s°ªÂI¡I |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/10 ¤W¤È 10:21:44²Ä 627 ½g¦^À³
|
ÁÂÁ¤ѩR¤jªº«ü±Ð¡C |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/10 ¤W¤È 09:48:40²Ä 626 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j¤j¡G2003¦~¬ü°ê¦h«§ÜÃĩʯf±w¦³¦h¤Ö¡HÁÂÁ±z¡I |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/10 ¤W¤È 08:04:04²Ä 625 ½g¦^À³
|
»{¦P§g¤j¬Ýªk~ ¥~¸ê³ø§i°Ñ¦Ò§Y¥i... ¦pªG¦p¥~¸ê©Ò»¡,¨º¤Ñ©³¤U¨S¤@®aÃļt¯à§ë¸ê¤F~ |
|
|
·|û¡G§g10000178 µoªí®É¶¡:2018/4/10 ¤W¤È 07:59:48²Ä 624 ½g¦^À³
|
Ãij£ÁÙ¨S½æ´N¦bºâ 7 ¦~«án¥´§é¡A§Ú¤]¬O¾K¤F¡A§A«ç»ò¤£»¡¹q¤lªÑ5¦~¤ºªÅÀY¡AÀ禬±q EPS10¤¸Åܨìtªº·|¤@°ï? ·d¯º¤]n¦³Ó¦X²zªº¤Ø«×¡A³o¼Ë¸ò¤¤¸Îñ¬ùªº¥[®³¤j°Ó¬O²Â¨ì®a¤F¶Ü? ÁÙ¤£¥uñ 7 ¦~¡AÁÙñ¤F 12 ¦~ªºªø¬ù¡A¥h ¤F¸Ñ¤@¤U¤H®a¬°¤°»ònñ 12 ¦~¡A¤°»ò¬O©t¨àÃħa |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/4/9 ¤U¤È 09:44:20²Ä 623 ½g¦^À³
|
·Q½Ð°Ý¤@¤U¤j®a. §Ú¬Ý¤@¨Ç¥~¸êªº³ø§i, ·|¦b©t¨àÃĤC¦~´Áº¡«á, ±NEPS¥´¤T§é, ½Ð°Ý¬O§_¦]¬°¨S¦³©t¨àÃÄ«OÅ@³y¦¨ÃÄ»ù¥²¶·½Õ¾ã? |
|
|
·|û¡G¶³²H·»´10142966 µoªí®É¶¡:2018/4/9 ¤U¤È 09:01:14²Ä 622 ½g¦^À³
|
·|¤£·|©Ò¦³¥Í§Þ³£½ü§¹«á¡A¦A¥Ñ¤¤¤j«¬¸¨«áªº«ü¼Ð¥Í§ÞªÑ±µ³Ì«á¤@´Î? |
|
|
·|û¡GG94010145720 µoªí®É¶¡:2018/4/9 ¤U¤È 06:06:06²Ä 621 ½g¦^À³
|
mengs¤j¡A¥xÆW¦¤j»¡ªº¨ä¹ê³£¹ï §ÚÓ¤H¬Ýªk¡A¥D¤O¦o¦³t³d°µ½u¸ò°µ»ùªº³d¥ô¡A§Æ±æ¯d¤U¨ÓªºÄw½X¬Oéw«×¤ñ¸û°ªªº ³o¨Ç¹Lµ{¡AµL¤j¤]³£¦b¥¦ªº½×z¸Ì´£¹L¦n´X¦¸ 4147 ¬O·sÃÄ«ü¼Ð«¬ÓªÑ¡A¤]¤£¥i¯à¤@¸ô©Ô¤@¤U¤l§â¦æ±¡©Ô§¹¡A¨º¬O¦bª£¥»¹Ú¤ñªº¶¥¬q¡A¤~·|¤@ª½ºu¶qºu»ù ¥un¨CÓÂà§éÁÙºû«ù¦hÀY¬[ºc¡AÁÙ¬O»Ýnµ¹¤@¨Ç@¤ß¡A·í®ÉÃÄÃÒ®³¨ì«e«á1-2Ӥ몺ªÑ»ùÅܤƤ£´N¬O«D±`ºë±mªº½d¨Ò¡A ·íµMµu½u¤W¤j®a´N¤£n¹L«×°l»ù³y¦¨°l°ª±þ§Cªºµ~¹Ò¡A«O«ù»ùȧë¸ê¤ßºA¡A¥i¯à¤~·|¤ñ¸û»´ÃP¤@ÂI |
|
|
·|û¡Gmengs10146592 µoªí®É¶¡:2018/4/9 ¤U¤È 05:48:03²Ä 620 ½g¦^À³
|
´X¥G¨C¤Ñ³£¬O¶}°ª¨«§C¡A®M¦b¤W±ªº½L«á¬ÝÄw½X¤]³£¬O´²³æ¡C ³o¨Ç²{¦b³Q®Mªº´N¬O¤UӤ몺޻î¡A¥H¦¹Ãþ±À¤£°±ªºÀ£¨îµÛªÑ»ù¡C ·í¨ä¥L¥Í§ÞªÑ¶X³o¶ÕÀY¦b¤j¼Q®É¡A¯uªº¤£»Ýn©ê³o°¦®z¶ÕªÑ¡A¤¤¸Îªº¦U¤è±§Ú³£¬Ý¦n¡A¦Û¤vºâªº¼Æ¾Ú¤]©Mª©¤W¥H¤Î¥[®³¤jºô¤Í¤À¨Éªº®t¤£¦h¡Aªø½u³£¬Ý¦n¡A´î½X¥u¬O¬°¤F°µ§ó¦³®Ä²vªº§ë¸ê¡Aµ¥½L°÷¤Fºt°÷¤F¡A©Î¬O¤U±þ¨ì¤j¤áÄ@·N¶R¶i«ù¦³¤£n¦b¤@°ï¯B¸ê®É§Ú·|¦^¨Ó¡C ³oÓ¶W«×Þ»îÁÙ·|«ùÄò¦h¤[¨S¤Hª¾¹D¡C¦ôp¤]¤£¥i¯à·|µo¥Í¨C¤Ñº¦°±¤W¤£¤F¨®ªºª¬ªp¡A¨ì®É¦A¤W¨®¤]¤£¿ð¡C §Ú¥u§Æ±æ¨S«H¥õªº§ÖÂI½æ¤@½æ¡A¸õªÅ¤U±þ»°©³¤]¦n¡A¤£n¨C¤Ñ¤ïÀ¸©ì´×¤@ª½¶}°ª¨«§CµL¤îºÉªº½L¤U¥h |
|
|
·|û¡Gmengs10146592 µoªí®É¶¡:2018/4/9 ¤U¤È 05:42:43²Ä 619 ½g¦^À³
|
³o¤£¬OÀ£½Lªü¡A´N¬OÀò§Q¥X²æ¡C³o°¦¥~¸ê¤]¤£¬O¥D¤O¡A¥e¤ñ¤]¤£¤j¡C ÂI¿U¥Í§Þ¤§¤õ«á´N¤@¸ôºÎ¡A¤µ¤Ñ§ó¬O¶^¯}¤ë½u¡AÆ[¹î½L¤¤¶i¥X¤]³£¬O¤p³æ¡A¦ôp³£¬O´²¤á¦bª±¡C §Ú¤W¤W§«ô´N¥X±¼¤C¦¨ªº¤¤¸ÎÂà¶i¨ä¥L¥Í§Þ¤F¡Aµ¥µo°Ê¦A¦^¨Ó¡A²{¦bªº¸Ñ®M½æÀ£±j¤j¨ì¤j¶^§Ú³£¤£·|¤Ó·N¥~ |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/9 ¤U¤È 05:34:54²Ä 618 ½g¦^À³
|
¶V¨ì¶}½æ¤§«e,¥~¸ê¶V¬OÀ£½LÁÙ½æ¶W ¬G·N»s³y¾P°â¶q¤£ªÖ©wªº°²¶H ¥~¸ê¤âªk¤Ó½â¤F,¬~½L§a,¬~¤@¬~¤]¦n |
|
|
·|û¡G¯º¦10143600 µoªí®É¶¡:2018/4/6 ¤W¤È 05:43:27²Ä 617 ½g¦^À³
|
Theratechnologies¦b4/5¤½§GQ1 report®É¡ACEOªí¹Fªº£¸¬q¸Ü¡G ¡¦We have every reason to be excited and proud of where we are today with the recent approval of Trogarzo™. We are seeing strong interest from both physicians and patients. As Trogarzo™ will soon be commercially available, our fully-trained sales force started calling on more than 5,000 physicians who treat the vast majority of people living with multidrug resistant HIV. Moreover, we had our strongest first quarter ever in terms of net sales of EGRIFTAR,¡¨ said Luc Tanguay, President and CEO, Theratechnologies Inc. Selling and Market Development Expenses Selling and market development expenses amounted to $6,693,000 for the first quarter of 2018, reflecting the size increase of our sales force and other investment made after the first quarter of 2017 in preparation of the launch of Trogarzo™. This compares to $3,767,000 for the same three-month period last year. Again, selling and market development expenses were lower in the first quarter of 2018 than in the fourth quarter of 2017. Selling and market development expenses include branded and non-branded campaigns to support EGRIFTAR, the launch of Trogarzo™ in the United States and the development of the European regulatory strategy for Trogarzo™. |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/5 ¤U¤È 03:18:51²Ä 616 ½g¦^À³
|
ÁÂÁ¤ѩR¤j«ü±Ð´£ÂI¡A¤p§Ì·|¦A¥J²Ó¬ãŪÅé·|¡C |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/5 ¤U¤È 02:25:40²Ä 615 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j¡G ·PÁ§AµL¨p¤À¨É¡C«OÀI¤½¥q³o«h°T®§¡A¤p§Ìı±o¹ï©óMDR±wªÌªº¥ÎÃÄ¡A±ø¥ó¦ü¥G§ó¥[ÄY®æ¦Ó«D©ñ¼e¡C¨ä¤¤c¶µ²Ä¤GÂI«ü¥X¡G¤£¦ý¥²¶·¬°¦hºØ§ÜÃĩʱwªÌ¡A¦Ó¥BÁÙn¨Ï¥Î¤T¤j¾÷ÂàªvÀø¤è¦¡¤¤¥ô¦ó¤@ºØ¡A¥B¬ö¿ýÅã¥Ü¹ï¨ä¨ã¦³§ÜÃÄ©Ê¡C³o©M§Ú̲z¸Ñ¤¤¡A¥un¬OMDR±wªÌ«K¥i¨Ï¥ÎTrogarzo¦ü¦³¥X¤J¡C±z¤å¤¤¦ü«ü¥un¥Î¹L¤T¤j¾÷ÂàªvÀø¤è¦¡¤¤¥ô¦ó¤@ºØ§Y¥i¡A½Ð°Ý¬O§_¤p§Ì¿ù»~¸ÑŪ¡AÁÙ±æ¤j¤j«üÂI¡C |
|
|
·|û¡G¯º¦10143600 µoªí®É¶¡:2018/4/4 ¤U¤È 01:43:04²Ä 614 ½g¦^À³
|
ÃÄ©ú¥Íª««ùÄò³Ð·s°ª¡I |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/4/3 ¤U¤È 02:10:31²Ä 613 ½g¦^À³
|
¤¤¸Î¸òÃĵس̪ñ¥u¦b½L¾ã,¨SÔ£º¦ ³oªi¥Í§Þº¦ªº³£¬O¤@¨ÇÃD§÷ªÑ ¦ü¥G§ÚÌ¥xÆWÁÙ¬O¤ñ¸û³ßÅwª£§@¥»¹Ú¤ñ |
|
|
·|û¡G¬ã¨sû10145703 µoªí®É¶¡:2018/4/2 ¤U¤È 10:13:27²Ä 612 ½g¦^À³
|
¥Lªº·N«ä¬O¨C¼W¥[1000¤H¡ATHªÑ»ù·|¼W¥[10¤¸¡H Every 1,000 patients adds $10 to the share price of TH #patients X Net price X 48% / nbr shares X ¡]PE ¡^ratio 1000 X $82600 X 0.48 / 75 000 000 X 20 = $ 10.57 (¹ê»Ú¤W¡A¤W±ªº¼Æ¦rÀ³¸ÓÁÙn±N¬üª÷§éºâ¦¨¥[¹ô¡A©Ò¥HÀ³¸Ó¬O$10.57*1.25=C$13 ¦Ü©ó§A¼gªº¡G The ratio =48%/nbr sharex 20% ratio=net price x9.6% (around 10%) ±Àºâ¥X²b§Q²v10%¡H ¦³ÂI¤£À´ |
|
|
·|û¡G¯º¦10143600 µoªí®É¶¡:2018/4/2 ¤U¤È 10:02:11²Ä 611 ½g¦^À³
|
¬ü°êªºÂåÀø¶O¥Î¡A¤£¬O¥xÆW¤H¯à°÷·Q¹³ªº¡A¤À¨É¤@½g¦b¬ü°ê¦P¾Çªº¶K¤å¡A·P¨ü°ªÃÄ»ùªº±`ºA©Ê ¬ü°êÂåÀø¹ê¦b¬O¶Q±oÀ~¦º¤H¡A¬Ý¯fªº±b³æ¤ñ¯fÁÙ¥i©È¡A¨S¯f³£±oÀ~¥X¯f¨Ó¡C¤ñ¸û°_¨Ó¥xÆWªº°·«O¯u¬OÄ_¡C §Ú¤Ó¤Ó«e¤@°}¤lG¤£µÎªA¡A®a®xÂå¥Í°µ¤F´X¶µÀˬd¡A¤]¶}¤FÃÄ¡AÂå¥Íªº§PÂ_¬O¨S¤°»ò¤j°ÝÃD¡A¬°¤F«OÀI°_¨£¡AÂå¥Í«Øij¥h·ÓGÃè½T©w¡A§Ú̬°¤F¤ß¦w¡A´N·Ó¦oªº«Øij¥h°µ¤F¡C·ÓGÃè¤]«Ü¶¶§Q¡AÂå¥Í½T©w¥¿±`¡A°µ¤F¤Á¤ùÀËÅç¤]¥¿±`¡A¦bÂå°|«Ý¤F®t¤£¦h¤T¤p®É´N§¹¦¨¤F¡C ¤@Ó¬P´Á«á±µ¨ì²Ä¤@±i±b³æ¡A¢C644¬Û·í©ó¥x¹ô¤@¸U¤K¤d¦h¡A·Q·Q¦¬¶OÁÙºâ¦X²z¡A¥J²Ó¤@¬Ý¡A±b³æ¬O¥Iµ¹³Â¾KÂå®vªº¶O¥Î¦Ó¤w¡A¨ä¥Lªº¶O¥Î³£ÁÙ¨Sºâ¡A³oÁÙ¬O¦³«OÀIªº»ù®æ©O¡I¬ü°êªºÂåÀø±b³æ«Ü°Q¹½¡A¨CӬݹLªºÂå¥Í³£¦Û¤v¦¬¶O¡A©Ò¥H¦³®a®xÂå¥Í¡A³Â¾KÂå¥Í¡AG¬ìÂå¥Í³£¦³¦Û¤vªº±b³æ¡A°µ¤â³NªºÂå°|¦³±b³æ¡A¤ÆÅçÁÙ¦³±b³æ¡A¥ú·d³o¨Ç±b³æ´N¤@ÓÀY¨âÓ¤j¡A¦Ó¥B¤â³N«eÂå°|¤]¨S¿ìªk·Ç½T¦ôp¶O¥Î¡A¦]¬°¦¬¶O³æ¦ì¤Ó¦h¡A¦A¥[¤WÂåÀø«OÀI¤½¥qªº³W©w¤S½ÆÂø¨ì¥L̦ۤv³£±`·d¤£²M·¡¡A¤Ï¥¿¤H®a·à¤l¤j¶}¤f§A´N¨Ä¨Ä¥I±b§a¡C ¹L´X¤Ñ³Ì¤j¤@±iÂå°|¥[GÃè¤â³Nªº±b³æ¨Ó¤F¡G$2877¡A³o¬O«OÀI«áªº»ù¿ú¡A¨S«OÀIªº¸Ün$7025¡A§Ú²³æªº´«ºâ¤@¤U¡A§ÚÌ©Ò¦³ªº¶O¥Î®t¤£¦h¦X¥x¹ô¤Q¤@¸U¦h¤¸¡A¨S«OÀIªº¸Ün¥I¨ì®t¤£¦h¤G¤Q¤T¸U¤¸¥x¹ô¡A³oÓ¿ú³£°÷¶R¤@±i°Ó°È¿µ¾÷²¼¦^¥xÆW¡A¸Ó°µªºÀˬd°µ¤@°µ¡A¦b¦Y³Üª±¼Ö¤@Ó§«ô¦A¦^¨Ó¡A¿ú¥i¯àÁٳѤ@¨Ç¡C¦P¼Ëªº¿ú¦b¬ü°ê¶iÂå°|°µGÃè¤T¤p®É´Nªá§¹¤F¡C ©Ò¥H¦b¥xÆWªºªB¤Í¯uªºn¦n¦n¬Ã±¤°·«OÂåÀø |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/2 ¤U¤È 09:36:30²Ä 610 ½g¦^À³
|
¥i§_½Ð±Ð¤Ñ©R¤j³o¼Æ¾Ú¬O±qstockhouseªºþ½g±oª¾ªº¡HÁÂÁ TH¡Cnet profit around at 10% of net sales. ¡X-according to stockhouse |
|
|
·|û¡G¬ã¨sû10145703 µoªí®É¶¡:2018/4/2 ¤U¤È 09:10:38²Ä 609 ½g¦^À³
|
¤Ñ©R¤j¡A ³Ìªñ¦bTHªº°Q½×ª©¬Ý¨ì±z¦h½gªº¤j§@¡A±zªñ´Á§ë¸ê¤FTH? ½Ð±Ð±z¹ïTH¤Î¤¤¸Îªº§ë¸êµ¦²¤¬Ýªk¡H |
|
|
·|û¡G¶³²H·»´10146472 µoªí®É¶¡:2018/4/2 ¤U¤È 03:43:08²Ä 608 ½g¦^À³
|
¦ôªº«O¦u? or ¶Kªñ¥«³õ? www.rjhealthsystems.com/2018/03/07/drug-alert-fda-approval-ibalizumab-uiyk-trogarzotm/ Drug Sales Forecast (in millions): 2018(F) 2019(F) 2020(F) 2021(F) 2022(F) 2023(F) TrogarzoTM $67 $168 $272 $367 $467 $566 |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/2 ¤U¤È 02:40:02²Ä 607 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j¦U¦ì¤j¤j ±qUnitedHealthcare¸Ì±¹ï©ó¥ÎÃĪº»¡©ú¶·²Å¦X¦p¤U For initial therapy, all of the following: A. Both of the following: 1. Diagnosis of HIV-1 infection 2. Physician attestation that the patient has multi-drug resistant HIV-1 infection and B. Physician confirms that the patient has been prescribed an optimized backround antiretroviral regimen ³o¼Ë°£¤FMDR¥H¥~,¨ä¥L¨âÓ±Ú¸sªº¬O§_ÁÙ¥]¬A¦b¸Ì±©O¡H |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/2 ¤U¤È 01:55:52²Ä 606 ½g¦^À³
|
ÁÂÁ¤ѩR¤j¡I¤p§Ì·|¥J²Ó«ôŪ¡C |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/2 ¤U¤È 01:42:08²Ä 605 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j¡G ¤¤¸Î©e¥~³ø§iA¤ÎBªº¥þ¤å¡A¨º¸Ì¥i¥H·j´M¨ì¡C ¸g±`«ôŪ±zªº¤ÀªR¡A¨ü¯q¤£²L¡A§Æ±æ¯à¦A«ü±Ð¡C ¦hÁ°աC §Ì ¸Î§Q¤j ·q°U |
|
|
·|û¡G¸Î§Q¤j10141530 µoªí®É¶¡:2018/4/2 ¤U¤È 01:42:07²Ä 604 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j¡G ¤¤¸Î©e¥~³ø§iA¤ÎBªº¥þ¤å¡A¨º¸Ì¥i¥H·j´M¨ì¡C ¸g±`«ôŪ±zªº¤ÀªR¡A¨ü¯q¤£²L¡A§Æ±æ¯à¦A«ü±Ð¡C ¦hÁ°աC §Ì ¸Î§Q¤j ·q°U |
|
|
·|û¡G§g10000178 µoªí®É¶¡:2018/4/1 ¤U¤È 11:16:47²Ä 603 ½g¦^À³
|
·PÁ¤ѩR¤jªº¤À¨É¡A¤¤¸Î¤§«e³o¥÷¼Æ¾Ú¤@ª½¬O¤£¤Ö®a¤ÀªR®É¤Þ¥Îªº¸ê®Æ¡A ¦ý²Ó¬Ý§A·|µo²{³o¬O¦b 2011 ¦~©Ò±oªº¼Æ¦r¡A·í®Éªº MDR ¤H¼Æ¬O 8000¤H¡A ¦ýªñ´Á¥[®³¤j¤½¥q¦ô¥Xªº MDR ¤H¼Æ¬O 3 ¿ªº 22000¤H¨ì24000¤H¡A¬O¤¤ ¸Î쥻¼Æ¦rªº 3 ¿¡AY¥H¦¹¦¨ªø³t«×¡A¨ºì¥»ªº 30000¤H¹w¨¾¼Æ¦r¤]À³ ¦Pµ¥¼W¥[¤~¬O |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/1 ¤U¤È 11:09:56²Ä 602 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j ¥Ø«eTMB-355¤w¶¶§Q®³¨ìÃÄÃÒ ¨º»ò¤U¤@Ó¦æµ{¸û§ÖªºÃÄ´N¬OTMB-607 ¤£ª¾¹D¦U¦ì¤j¤j¹ï©ó³oÓÃĬO§_¦³§ó¶i¤@¨Bªº°T®§¥i¥H¤À¨É ¨Ò¦p¦¨¥\²v¤§Ãþªº? ÁÂÁ |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/4/1 ¤U¤È 06:09:24²Ä 601 ½g¦^À³
|
¬ü°ê³Ì¤j°Ó·~«OÀI¤½¥q¡§Áp¦X°·±d¶°¹Î¡§ »{¦PTROGARZO ¥iªvÀø¤Î¹w¨¾ HIV MDR. OFF-LABEL USE ±N±q¨p¤H°Ó·~«OÀI¤½¥q¶}©l¡C ¬ü°ê¥Ø¼Ð¥«³õ±N©ñ¤j¨ì55000¤H¡C ½Ð°Ý¤Ñ©R¤j §Ú¨Ã¨S¦³¬Ý¨ì¤º¤å¦³¼g»¡¥«³õ·|©ñ¤j¦Ü55000¤H ½Ð°Ý³o¬O±qþÃä¬Ý¨ìªº©O |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2018/3/31 ¤U¤È 05:17:24²Ä 600 ½g¦^À³
|
ÁÂÁ¤ѩR¤j³o»ò¦h¸ê®Æ¤À¨É, ¨ü¥Î¤£¤Ö¡I °O±o°õ¦æªøÁ¿¹L, ·R´þ¯fªº½¯©µ¦b¬ü°ê¬O¤½¦@½Ã¥Í°ÝÃD 1¤H¤£Âåªv¥i¯à¼vÅT§ó¦h¤H, ³y¦¨§ó¦hªÀ·|¦¨¥», ©Ò¥H³\¦h¬ü°ê¨C¦~¬F©²¼·¥I´X¤Q»õ¬üª÷¹wºâ¸É§U¨S¿úªº¯f¤H¥ÎÃÄ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/3/29 ¤U¤È 12:47:57²Ä 599 ½g¦^À³
|
Trogarzo ªø³o¼Ë ½LÂI2018¦~²Ä¤@©u«×FDA§å㪺·s¤À¤l¹êÅéÃĪ«(NMEs) ¨Ó·½¡GÃÄ´ç ¡@2018-03-29 med.sina.com/article_detail_103_2_43500.html |
|
|
·|û¡G¯º¦10143600 µoªí®É¶¡:2018/3/29 ¤U¤È 12:40:53²Ä 598 ½g¦^À³
|
3¤ë©³¡A±i©Àì±Nn¸©¹¥[®³¤j»X¯S°ú¡A°Ñ¥[·sÃĤW¥«ªº»}®v¤j·|¡F¤¤¸Î¦@¦P³Ð¿ì¤H¡Bº®u¬ì§ÞÅU°Ý¦ó¤j¤@¡A¤]±N¥X®uµoªíºtÁ¿¡C½Ð¤j®a¦h¦hÃöª`¡I |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/3/29 ¤U¤È 12:15:15²Ä 597 ½g¦^À³
|
ÁÂÁ¤ѩR¤jªº¤À¨É ©Ò¥H·N«ä¬O§_¬O¥un¬O¦X²z¦³ÃÒ¾Ú¹ï¯f¤H¦³¦n³Bªºoff-label use. ¨º«OÀI¤]·|µ¹¥I, ¯f±w¤£¶·¦Û¤v¥I¶O¹ï¶Ü? |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2018/3/29 ¤W¤È 09:10:07²Ä 596 ½g¦^À³
|
¤Ñ©R¤j¤j§A¦n, ·PÁ¤F |
|
|
·|û¡G§g10000178 µoªí®É¶¡:2018/3/29 ¤W¤È 06:46:06²Ä 595 ½g¦^À³
|
·PÁ¤ѩR¤jªº¦^À³¡A¤p§Ì¤]»{¬°·sÃĪº»âÀY¦ÏÀ³¸Ó¬O¤¤¸Î¸òÃĵØÃÄ¡A ¤¤¸Îªº³¡¥÷¡A±q¤Ñ©R¤j¤§«e©Ò¸É¥Rªº¸ê®Æ¤¤¡A¥i¥H¬Ýªº¥X¤¤¸Î¥¼¨Ó¦¨ªøªº¼ç¤O¡A ¦ý¦]¬°¤½¥qªº«O¦u¡AÅý¥~¤HÃú¸Ì¬Ýªá¡A§C¦ô¤F¤½¥qªº¦¨ªø¤O¹D¡A§ÚÓ¤H»{¬°³o ¤GÀɳ£¬O¦¨ªø«¬ªº©w¦sªÑ¡A¨ä¤¤ªº¤¤¸Î¡A¤£¥u¬O³Ì«á¤@½u¥ÎÃÄ¡A§ó¬Oªñ10¦~¨Ó ªº·s¾÷Âà¥ÎÃÄ¡A¨Ã«D¥u¯à¥Î¦b³Ì«á½u¤¤¡A¦Ó¬O¥i¥H°t¦X¨ä¥L½u¹ï¾÷Âà¤w¦³§ÜÃĩʪº¯f¤H¨Ï¥Î¡A ¦ý³o³¡¥÷¦]¬°¦³¥i¯à¬O off label use¡A¤½¥q¤£¯à«Å¶Ç¤]¤£·|¥h¦ô³o³¡¥÷¡A ¥u¥H¤WÂd»¡©ú·|®É¥Îªº®Ö¤ß¤H¼Æ MDR ³¡¥÷§@³Ì«O¦uªº¹w¦ô¡A¥BÃÄ»ù¦b·í®É¤]¬O ¤p¤ßªº»¡©ú¡A¦b¦b»¡©ú¤½¥q¬Oĵ·V¤p¤ßªº¤½¥q¡A³o¦b¬ãµo¸ò¤½¥qªv²z¬O¦n¨Æ¡A¦ý¬O ¹ïnµû¦ô¤½¥q¹ê»Ú»ùȮɡA·|¦]¬°¤½¥qªº«O¦u¦ôp¦Ó§C¦ô¡A¦A¥[¤W¤Ñ©R¤j¤§«e´£§Y ªº MDR ¦~¦º¤`²v³¡¥÷¡AY¦³³¡¥÷Âà¤JÅܦ¨¨C¦~·s¼Wªº¤¤¸Î¥ÎÃĤH¼Æ¡A³o¬O§_·| ½Æ¨î·íªìÃe¨©¤ó¯gªº¬G¨Æ¡A±q¤@¶}©l¨S¤H¬Ý¦nªº¯f¯g¡A¨ì²×¨¥ÎÃÄÅܦ¨¼s¤jªº¥ÎÃıڸs¬G¨Æ¡C ¦Ü©ó¤Ñ©R¤jªº¦ôp¡A2019¦~ EPS ¥u¦³10¤¸¡A¬O§_¬O¦]¬°¤w´£¦C²ÖÁ«ªº10¤¸¡A³y¦¨§C¦ôªº±¡§Î? ³Ì«á·PÁ¤ѩR¤jªº¸ê°T»P¤À¨É |
|
|
·|û¡G§g10000178 µoªí®É¶¡:2018/3/27 ¤U¤È 10:42:01²Ä 594 ½g¦^À³
|
·PÁ¤ѩR¤jªº JAKAFI ¨Ò¤l¡A½Ð°Ý¤Ñ©R¤j¬O§_¥i¥HÂহ¤å³¹¨ìÃĵØÃĪº±Mª©¤W¡A ¥t¥~¡A«_¬Nªº½Ð±Ð¤Ñ©R¤j±z¹ïÃĵØÃĪº¬Ýªk¡A¬O§_¦³¸ò¤¤¸Î¤@¼ËºëÅPªºÆ[ÂI¡A ½Ð¤£§[¤À¨É¡A¤p§Ì¬~¦Õ®¥Å¥¡AÁÂÁ |
|
|
·|û¡G¯º¦10143600 µoªí®É¶¡:2018/3/27 ¤U¤È 06:21:41²Ä 593 ½g¦^À³
|
ÃÄ©ú¥Íª«¤µ¤Ñ¯¸¤W·s°ªÂI¡A¥xÆW¤H°O±o¸C²´¬Ý¥@¬É |
|
|
·|û¡G¶³²H·»´10146472 µoªí®É¶¡:2018/3/26 ¤U¤È 01:42:06²Ä 592 ½g¦^À³
|
FYR. www.biotuesdays.com/briefs/2018/3/7/cibc-ups-theratechnologies-pt-to-15-from-1030 CIBC ups Theratechnologies PT to $15 from $10.30 CIBC World Markets raised its price target for Theratechnologies (TSX:TH) to $15 from $10.30 after the FDA approved Trogarzo for the treatment of multi-drug resistant HIV patients. The stock was quoted at $9.35 in afternoon trading on March 7. Analyst Prakash Gowd writes that FDA approval of Trogarzo is a very positive development for Theratechnologies, and the market should react positively to the news, as development risk is now off the table. While commercial risk remains, ¡§we are confident that Theratechnologies has all the sales and marketing infrastructure and commercial strategy in place to make Trogarzo a success,¡¨ he added. The company plans to launch Trogarzo within six weeks and reimbursement will likely take six months to ramp up, Mr. Gowd said. Until then, the company will implement co-pay programs and patient assistance plans to ensure access, and help physicians and patients manage prior authorizations for coverage, he added. Mr. Gowd expects the 2018 launch year to be neutral on EBITDA, but to accelerate in 2019. He is forecasting peak sales of $500-million in the U.S. in 2021, based on 5,500 patients with multi-drug resistant HIV-1 infection failing treatment. |
|
|
·|û¡GºCºC¶]10142302 µoªí®É¶¡:2018/3/26 ¤U¤È 01:21:00²Ä 591 ½g¦^À³
|
«OÀIµ¹¥I¹ï·sÃĪºÀ禬¡Bº¯³z²v¼vÅT«Ü¤j ¥¿ÂI¦b©ó«OÀIµ¹¥I.¤£¬O»ÝnÃÄ´N¥i¥H¥ÎÃÄ.³o¼Ë²³æ |
|
|
·|û¡G¬K©M´º©ú10141799 µoªí®É¶¡:2018/3/26 ¤U¤È 01:15:01²Ä 590 ½g¦^À³
|
·sÃÄ¥«³õ¦³«Ü¦h¨Æ±¡§ë¸ê¤H¬O¤£ª¾¹Dªº ´¼Àºªº·s»D ¯ØŦÀù«á½uÃĤÀ¼íáA´¼ÀºPEP503¨üÃöª` www.moneydj.com/KMDJ/News/NewsViewer.aspx?a=1c9e2351-e36a-4512-91d2-181a8a439e68 ³o½g´N¦³¤@Ó¦a¤èȱoª`·N ¸`¿ý³¡¤À¤º®e ¼Ú¬wªº¾P°â¡A¾Ú¤F¸Ñ¡A¥Ø«e¦w¯à±o¤w¦b¼Ú¬w12Ó°ê®a¾P°â¡A¦ý¨ä¤¤¶È¬ù3°ê¦³¨ú±o«OÀIµ¹¥I¡A¥h¦~¥«³õ¦ôp¥þ¼Úªº¾P¶qÀ³¦³ªñ3¤d¸U¬ü¤¸ ±q³o¬q¬Ý¨Ó¡A«OÀIµ¹¥I¹ï·sÃĪºÀ禬¡Bº¯³z²v¼vÅT«Ü¤j ¥t¥~ÁÙ¦³¤@¬q ªk¤H»{¬°¡AÁö¥h¦~¤U¥b¦~¦]¨ä¥L«á½u¥ÎÃÄÁ{§É¦¬®×¡A¾ÉP¾P°â¦¨ªø¦³¨ÇÁͽw ´¼Àº¥h¦~EPS2.6¤¸ §ë¸ê·sÃÄ¡A¤£ºÞ¸Ñª¼¦¨¥\«á»¡±o¦h¦nÅ¥¡A¥«³õ¦h¤j¡A §ë¸ê¤H¤£°µ¥\½Ò¡A°£¤F¤½¥q¤½¥¬ªº±ÂÅv¨½µ{ª÷¡B¤À¼í¤§¥~ ¹ï«OÀI¤v¥I¡B¯f±w²Õ¦¨¡BÄvª§¹ï¤â©M¨ä¶i«×¨S¦³°µ¥\½Ò¤F¸Ñ À禬¤£¦p¹w´ÁÁÙ¤£ª¾¹Dì¦]¦bþ¸Ì ª©¤W¦³¦U¦ì¤j¤j¼ö¤ß¤À¨É¦UºØ¸ê°T¡A¯uªº¬O¸U¤À·PÁ ·sÃħë¸ê³oÓ»â°ì¡A¦U¤è±¦h¤F¸Ñ¤@ÂI¤£¬OÃa¨Æ |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/3/26 ¤W¤È 11:13:43²Ä 589 ½g¦^À³
|
¦ý¡u§ëÅU¡vªº¬ã¨s³ø§i¡A ¦h¼Æ¡A¬Ý¬Ý´N¦n¡A ¤°»ò®ÉÔ¨ì¥L¹w¦ôªº»ù®æ¡A ¤Ñª¾¹D¡I |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/3/26 ¤W¤È 11:03:30²Ä 588 ½g¦^À³
|
«n°T®§ ¤¤¸Î»P¬ü¥[¼Ú¬w¦a°Ïªº¾P°â¹Ù¦ñTheratechnologies(¥[¡FTSX: TH)«Å¥¬¬ü°ê¹Ãĸp¤w¸g©ó3¤ë6¤é®Öã¤FTrogarzo™ (TMB-355¡Fibalizumab)ÀR¯ß¾¯«¬ªºÃÄÃÒ¡C¤¤¸Îªº¸gÀç¹Î¶¤¦b¤§«áªºªk»¡·|°Q½×¤FÃö©óTrogarzo™ªº¦æ¾Pµ¦²¤¡C µû½×¤Î¤ÀªR TrogarzoTMªºÃÄ»ù¬°¨C¦~11.8¸U¬ü¤¸¡C¤¤¸Îªº¾P°â¹Ù¦ñTheratechnologies«Å¥¬TrogarzoTM²×ºÝ»ù®æ(WAC)¬°¨C¦~11.8¸U¬ü¤¸¡Cµ¹³q¸ôªº§éÅý¬°30%¡A²b¾P°â»ù®æ±N¸¨¦b8.26¸U¬ü¤¸¡CTrogarzoTM±N¦¨¬°²Ä¤@Ó¤£»Ý¨C¤éªA¥ÎªºHIV¥ÎÃÄ¡C¤¤¸Î¦ôpTrogarzoTM±N¥i¥Î©óªvÀø¬ù50%ªºMDR HIV-1¯f¤H(~12,000¤H)¡C «OÀIµ¹¥I¤è®×±N©ó¥|¨ì¤»Ó¤ë¤º«Ø¥ß§¹¦¨¡CTrogarzoTM¦Û3¤ë7¤é¥¿¦¡¨ú±oÃÄÃÒ¤§«á°_ºâ¡A¹wp¦b¤»©P¤º¥i¨Ñ¯f¤H¨Ï¥Î¡CTheratechnologies¤w¸g¥R¤À»P«OÀI·~ªÌ¤¬°Ê¡A³o¨Ç«OÀI·~ªÌªº«O¤á¥]§t¤K¦¨¥H¤WªºHIV¯f¤H¡CTrogarzoTM¨ú±oÃÄÃÒ«á¡ATheratechnologies·|P¤O»P«OÀI·~ªÌ¬ãÀÀ¥I¶O¬Fµ¦¡B¥´¶}³q¸ô¡A¨Ã½T©w®Ö«O»Pµ¹¥Iªº¼Ð·Ç¡C«OÀI¥I¶O¤è®×ªº³]p»P¯Ç«O±N©ó¥|¨ì¤»Ó¤ë¤º¨ì¦ì¡C ¹w¦ô¤¤¸Îªº²Ä¤@µ§¾P°âÅv§Qª÷¦¬¤J±N¸¨¦b4Q18¡CTheratechnologies¤w¸g«Ø¥ß°_¾P°âºôµ¸¡A¨Ï§ó¦hªºÂå®v©MMDR HIV-1¯f±w¯à¨Ï¥ÎTrogarzoTM¡CTheratechnologies¹w¦ô¾P°âÃB±N©ó¥¼¨Ó¨â©uÃk¤É¡CÀHµÛ«OÀIµ¹¥I¤è®×©ó¥|¨ì¤»Ó¤ë¤º¨ì¦ì¡A§Ú̹wp¤¤¸Î±N©ó4Q18±µÀòºµ§¾P°âÅv§Qª÷¡C §ë¸ê«Øij §ÚÌ«·sÀ˵ø¹ï¤¤¸Îªº¹w´ú¡A®Ú¾Úªº¬O3¤ë7¤éªk»¡·|©Ò´¦ÅS¤§§ó¦h¦¨¥»µ²ºc²Ó¸`¡C¬°¤F¤Ï¬M¤½¥qªº¦bTrogarzoTM¤W¥««áªº¦¨ªø¼ç¤O¡A§Ų́ϥΤF§é»ù²{ª÷¬y¼Ò«¬¡A¨Ã¥B±N¥Ø¼Ð»ù×¥¿¦Ü335¤¸¡C |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/3/26 ¤W¤È 10:59:55²Ä 587 ½g¦^À³
|
¦Ï¤j¶K¥X¨Ó¤¸´IÃҨ骺¡B ¨ºÂy¤H¤]§â³Í°ò§ëÅUªº¬ã¨s³ø§i¡A ¶K¥X¨Ó¡A¶È®¥°Ñ°u¡ã B22B24F0-EC67-47EA-A9CE-489A102291C8 F1CF48C8-3F23-48D4-B2EB-9890A0B7505A 3D7C8006-E98A-421D-A736-6184B76B678B ¤¤¸Î(4147.TW/4147 TT): ·R´þ·sÃÄTrogarzo™¨ú±o¬ü°êÃÄÃÒ 3BCAE91C-AC12-4CB4-A958-158699CD3997 B20BB1EA-B73A-4187-A649-ABA6F373415A 5B5B3D53-FA1D-4AF3-ADD6-BD2B8CE3EE73 ¬ã¨sû¡G·¨¤S¿o D759E617-0473-4293-B34B-BD465DF6EB4F 085483BA-9B8F-4A62-9BC4-11DFF28F0C71 A074AA8E-87EE-446F-9A16-B5A3B73688A1 «n°T®§ F4781F41-9AD5-4DA4-BB8A-AE248E5EF5E0 ¤¤¸Î»P¬ü¥[¼Ú¬w¦a°Ïªº¾P°â¹Ù¦ñTheratechnologies(¥[¡FTSX: TH)«Å¥¬¬ü°ê¹Ãĸp¤w¸g©ó3¤ë6¤é®Öã¤FTrogarzo™ (TMB-355¡Fibalizumab)ÀR¯ß¾¯«¬ªºÃÄÃÒ¡C¤¤¸Îªº¸gÀç¹Î¶¤¦b¤§«áªºªk»¡·|°Q½×¤FÃö©óTrogarzo™ªº¦æ¾Pµ¦²¤¡C µû½×¤Î¤ÀªR 2E9476B3-489A-4ED8-B85E-1C37C8C57816 TrogarzoTMªºÃÄ»ù¬°¨C¦~11.8¸U¬ü¤¸¡C¤¤¸Îªº¾P°â¹Ù¦ñTheratechnologies«Å¥¬TrogarzoTM²×ºÝ»ù®æ(WAC)¬°¨C¦~11.8¸U¬ü¤¸¡Cµ¹³q¸ôªº§éÅý¬°30%¡A²b¾P°â»ù®æ±N¸¨¦b8.26¸U¬ü¤¸¡CTrogarzoTM±N¦¨¬°²Ä¤@Ó¤£»Ý¨C¤éªA¥ÎªºHIV¥ÎÃÄ¡C¤¤¸Î¦ôpTrogarzoTM±N¥i¥Î©óªvÀø¬ù50%ªºMDR HIV-1¯f¤H(~12,000¤H)¡C «OÀIµ¹¥I¤è®×±N©ó¥|¨ì¤»Ó¤ë¤º«Ø¥ß§¹¦¨¡CTrogarzoTM¦Û3¤ë7¤é¥¿¦¡¨ú±oÃÄÃÒ¤§«á°_ºâ¡A¹wp¦b¤»©P¤º¥i¨Ñ¯f¤H¨Ï¥Î¡CTheratechnologies¤w¸g¥R¤À»P«OÀI·~ªÌ¤¬°Ê¡A³o¨Ç«OÀI·~ªÌªº«O¤á¥]§t¤K¦¨¥H¤WªºHIV¯f¤H¡CTrogarzoTM¨ú±oÃÄÃÒ«á¡ATheratechnologies·|P¤O»P«OÀI·~ªÌ¬ãÀÀ¥I¶O¬Fµ¦¡B¥´¶}³q¸ô¡A¨Ã½T©w®Ö«O»Pµ¹¥Iªº¼Ð·Ç¡C«OÀI¥I¶O¤è®×ªº³]p»P¯Ç«O±N©ó¥|¨ì¤»Ó¤ë¤º¨ì¦ì¡C ¹w¦ô¤¤¸Îªº²Ä¤@µ§¾P°âÅv§Qª÷¦¬¤J±N¸¨¦b4Q18¡CTheratechnologies¤w¸g«Ø¥ß°_¾P°âºôµ¸¡A¨Ï§ó¦hªºÂå®v©MMDR HIV-1¯f±w¯à¨Ï¥ÎTrogarzoTM¡CTheratechnologies¹w¦ô¾P°âÃB±N©ó¥¼¨Ó¨â©uÃk¤É¡CÀHµÛ«OÀIµ¹¥I¤è®×©ó¥|¨ì¤»Ó¤ë¤º¨ì¦ì¡A§Ú̹wp¤¤¸Î±N©ó4Q18±µÀòºµ§¾P°âÅv§Qª÷¡C §ë¸ê«Øij F4F2C1E9-348E-412C-8205-D2DE2CA2F6ED §ÚÌ«·sÀ˵ø¹ï¤¤¸Îªº¹w´ú¡A®Ú¾Úªº¬O3¤ë7¤éªk»¡·|©Ò´¦ÅS¤§§ó¦h¦¨¥»µ²ºc²Ó¸`¡C¬°¤F¤Ï¬M¤½¥qªº¦bTrogarzoTM¤W¥««áªº¦¨ªø¼ç¤O¡A§Ų́ϥΤF§é»ù²{ª÷¬y¼Ò«¬¡A¨Ã¥B±N¥Ø¼Ð»ù×¥¿¦Ü335¤¸¡C |
|
|
·|û¡G¦Ï«§«§10141876 µoªí®É¶¡:2018/3/26 ¤W¤È 10:26:41²Ä 586 ½g¦^À³
|
¬ü°ê§i±¶¡A«¿U¥xÆW¥Í§Þµo®i«H¤ß ²³©ÒÆf¥Ø¡A¤¤¸ÎTMB-355©ó2018/3/6¨ú±o¬ü°êFDA BLA¤W¥«³\¥i¡A·m±Ï³Ì¥½½u±wªÌ¡G¤¤¸Î¤½§i·R´þ¯f·sÃÄTMB-355¡]°Ó«~¦W¬°Trogarzo¡^©ó¬ü°ê®É¶¡2018/3/6¥¿¦¡Àò±o¬ü°ê¹«~º[ÃĪ«ºÞ²z§½(FDA)¥Íª«»s¾¯ÃÄ«~¤W¥«¬dÅçµn°O(BLA)®Öã¡A¥Î©óªvÀø¥Ø«e¤wµL¸û¨ÎÃĪ«¥i¥Îªº¥½½uHIV¦h«§ÜÃĩʱwªÌ¡CTMB-355¬°HIVªvÀø»â°ì¤¤²Ä¤@Ó®Ö㤧³æ¯]§ÜÅé¡A¤]¬O²Ä¤@¤äHIVªø®Ä«¬·sÃÄ¡C ¥þ·s¾÷ÂàCD4¶i¤J§í¨î¾¯¡Aªø®Ä¤Î§C°Æ§@¥Î±N´£¤É±wªÌ¥ÎÃÄ·NÄ@: Trogarzoªº¤@¤jÀu¶Õ¦b©ó¨ä¬°¨â©Pª`®g¤@¦¸ªºÀR¯ßª`®g¾¯«¬¡A±N¥i§ïµ½±wªÌ¨C¤éªAÃĪº¤£«K¡A¥ç´î¤Ö¦]µL¿í±qÂåÅñ¦Ó¨ÏHIV¯f¬r²£¥Í§ÜÃĩʪº·ÀI¡A¥B®Ú¾ÚÁ{§É¸ÕÅç¼Æ¾Ú¡ATrogarzoªº°Æ§@¥Î¬Û¹ï¥Ø«eHIVÃĪ«¬°§C¡A¥¼¨Ó°£¥Ø«eMDR¦h«§ÜÃĩʱwªÌ¥~¡A¥ç¦³¨ä¥LµLªk§Ô¨ü²{¦³ÃĪ«ªvÀø¦Ó¨Ï¥ÎTrogarzoÃĪ«±wªÌªº¥i¯à¡C ©w»ùÀu©ó¹w´Á¡A«á½u±wªÌ¿ï¾Ü¦³¡A¤½¥q»ùÈ©úÅã´£¤É¡A¹w¦ô¥_¬ü¥«³õ¾P°â°ª®p¥i¹F6»õ¬ü¤¸¡G¦¹¦¸¤½¥q¥ç¤½§iTrogarzoÃÄ»ù¡]whole sales price¡^¬°¨C¤H118,000¬ü¤¸/¦~¡A©úÅãÀu©ó¥«³õ¹w´Á70,000¤ô·Ç¡F¤¸´I»{¬°¥Dn¦]¯À¦b©óTrogarzoÄÝ©ó©t¨àÃÄ¡A¥B¦h«§ÜÃĩʱwªÌ¥ç³B©óµLÃÄ¥iÂ媬ªp¡A¥ç¨Ï¨ä¨ã¦³q»ùÀu¶Õ¡A®Ú¾ÚTheratechnologies²Îp¡A¥Ø«e¬ù¦³25000¦W±wªÌ¨ã¦³¦h«§ÜÃÄ©Ê¡A¨ä¤¤12000¦W±wªÌ«æ»Ý·sªºªvÀøÃĪ«¡A¬G¦b°²³]¾P°â°ª®pº¯³z²v¹F25%~30%¤U¡AY¥H¦©°£³q¸ô«P¾PªºÃÄ»ù8.2¸U¬ü¤¸pºâ¡A¬ü°ê¥«³õ¾P°â°ª®p¥i¹F¨ì6»õ¬ü¤¸/¦~¡C ¥xÆW¥Í§Þµo®i«¤j¨½µ{¸O¡A««Ø¥ÍÂå²£·~«H¤ß¡G ¦bµû»ù¤W¡A¤¤¸ÎTrogarzo¬°¥xÆWÄ~´¼Àº«á¦h¦~¨Ó¤S¤@®a¨ú±oFDAÃÄÃÒ¤½¥q¡A¥B¥þ²y¥Íª«Ãĵo®i¤õ¼ö¡A¤¤¸ÎTrogarzo¥ç¬°¥xÆW²Ä¤@¤ä¥Íª«»s¾¯·sÃÄ¡A¹êÄÝ¥xÆW¥Í§Þ²£·~ªñ´Á³Ì¬°«¤j¨½µ{¡F®i±æ«á¥«¡A¦b¨ã¦³©ú½T¥«³õ¥H¤Î²`¨ã§Þ³Nªº«áÄò²£«~½u¤U¡A¤¸´I¼ÖÆ[¬Ý«Ý¤¤¸Îªø´Áµo®i¡A«¥Ó¶R¶iµûµ¥¡F¥t¦b¬ÛÃö¤½¥qµû»ù¤è±¡A3/6 ¤¤¸Î±ÂÅv¾P°â¹Ù¦ñTheratechnologiesªÑ»ù¤W´27.6%¡A¦ÓCMOÃÄ©ú¥Íª«3/7ªÑ»ù¤W´5.36%¡A¥çÅã¥Ü¥þ²y¹ï©ó¦¹¤äÃĪ«Ãöª`«×¡A¤¸´I¦Ò¶q¦¹¦¸ÃÄ»ùq»ùÀu©ó¹w´Á¡A½Õ¤É¥Ø¼Ð»ù¥Ñ236¤¸¦Ü275¤¸¡C |
|
|
·|û¡G¤g¼·¹«10146506 µoªí®É¶¡:2018/3/26 ¤W¤È 06:19:54²Ä 585 ½g¦^À³
|
½Ð°Ý¤j¤j2018¡A2019¡B2020¡B2021¦~¦U¦~ªº EPS¹w¦ô¤j·§¦h¤Ö©O??? |
|
|
·|û¡G¬K©M´º©ú10141799 µoªí®É¶¡:2018/3/25 ¤U¤È 10:35:22²Ä 584 ½g¦^À³
|
·PÁ¤ѩR¤jªº¤À¨É¡I¡I °ê»ÚÃÄ»ù¬Fµ¦»PºÞ²z¨î«×Ū®Ñ·|·|ij¸ê®Æ ³o½g¸ê®Æ¹ê¦b¬O¤ÓÆg¤F¡I¡I ¦UºØ¯à¼W¥[§ë¸êªÌ¤F¸Ñ¥«³õªº¸ê°T¬O¦h¦h¯qµ½°Ú¡I¡I §Æ±æ±z¤£·|³Q¤Ö³¡¤À¤Hªº¨¥½×¼vÅT¨ì¡C |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/3/25 ¤U¤È 09:47:46²Ä 583 ½g¦^À³
|
¤Ñ©R¤j¡A ±z¯uªº¦n¥Î¤ß«õ±¸¸ê°T¡A ¦ý¤¤¸Î¯uªº¤£¤Ó»Ýn¦A¶O¤ß¤F¡A ¤½¥q¦ÛµM·|´À§ë¸êªÑªF´M¨D³Ì¨Îªº§Q¯q¡A ¯d¤@¨ÇÂaÄgªº¬ü¹Ú¡A¤]¤£¿ùªº¡A ¦³·N¥~¡A¤~¦³Åå³ß¡A ±i°õ¦æªø3¤ëªì¤~説¹L¡A ³ÌÃø¹LªºÃö¡A¤w¸g¸g¾ú¹L¤F¡]¥xÆWÀqÀqµL»Dªº ¬ãµo«¬¤p¤½¥q§Ñ·Q¨ú¬ü°ê¤jÃÄÃÒ¡^¡A TMB355¥u¬O¸Îªº¶}©l¡]¥¼¨Ó3-5¦~¡^¡A ¦Ó¥¦ªºôôTMB365ªº¬ãµo¡A ¤~¬O5¦~«áªº¤jÀ¸¡I |
|
|
·|û¡GÂyªÌ10142287 µoªí®É¶¡:2018/3/25 ¤U¤È 09:30:36²Ä 582 ½g¦^À³
|
¦b¤µ¦~3¤ë7¤é¤¤¸Î¶}§¹ªk説·|«á¡A ¥»¤g¨é°Ó¡u³Í°ò§ëÅU¡v¤Î¥D¿ì¨é°Ó ªº¡u¤¸´I§ëÅU¡v¡A ¦³§Y®É¦b3¤ë9¤é¦U¥X¤F¤¤¸Îªº¬ã¨s³ø§i¡A ¦U¦³µu¡B¤¤¡Aªø´ÁªºÀò§Q½×zÆ[ÂI¡A ȱoÃöª`¡A ±q2018¡A2019¡B2020¡B2021¦~¦U¦~ªº EPS¹w¦ô¡A¤]¤jP¥X¨Ó¤F¡A «Øij«ù¦³¤¤¸Îªº§ë¸ê¤H¥h¬Ý¬Ý¡A ©Î³\´Nª¾¹D¡A¬°¤°»ò¦³¨Ç¤H«ùÄò ÀqÀq¶R¥¦¤F¡C |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/3/25 ¤U¤È 07:47:01²Ä 581 ½g¦^À³
|
¨C¤H¦~¾P°â²b§Q30% A.°ê¤º¦³¨Ç³ø¯È¦ô 118000¬ü¤¸x70%x52%x30%=12885¬ü¤¸/¦~¤@¤H B.¥~¸ê¥i¯à¦ô±À´ú118000¬ü¤¸x70%x30%=24780¬ü¤¸¡þ¦~¤@¤H ------------------------- ¾Ú¤½¥qªº»¡ªk¤ò§Q8¦¨, ²b§Q3¦¨. ³o¼Ë¥u¦³B²Å¦X. ¥~¸ê²{¦b¥i¥H¥Î5§é»ù¶R¤¤¸ÎÀ³¸Ó¬O²n¦b¤ß¸Ì¤fÃø¶} |
|
|
·|û¡G·®p¨®10144846 µoªí®É¶¡:2018/3/25 ¤U¤È 06:39:49²Ä 580 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j ©Ò¥H¥~¸ê¤@ª½¶R °ê¤º¤@ª½½æ ¥Nªí¤°»ò·N«ä ¤£¬O«ÜÀ´¡C¬O¹ïÀ禬ªº»~¸Ñ¡CÁÙ¬O¡H¦º ½Ð±Ð¤@¤U¡CÁÂÁ |
|
|
·|û¡G¯º¦10143600 µoªí®É¶¡:2018/3/25 ¤W¤È 07:10:36²Ä 579 ½g¦^À³
|
¡u²×©óÃP¤F¤@¤j¤f®ð¡A¡v¤¤¸Î·sÃÄ¡]ì¦t©÷¥Í§Þ¡^°õ¦æªø±i©Àì¡A³z¹L¶V¬v¹q¸Ü¡A¶Ç¹F³ß®®¡C¥L±a¹Î¶¤·i°«¤F¤Q¦~¡A¶}µoªº·R´þ¯f·sÃÄ¡uTMB-355¡v¡A²×®³¨ì¬ü°êFDAÃÄÃÒ¡C ¬O¥þ²yªñ¤Q¦~¨Ó·R´þ¯fÃĪ«ªº³Ì¤j¬ð¯}¡A§ó¬O¥xÆW²Ä¤@ÓÀò±o¬ü°êFDA®Ö㪺³J¥Õ½è·sÃÄ¡C¡u§ÚÌÃÒ©ú¤F¡A²£«~¦n¡B¹Î¶¤¦³«H¤ß¡BªÑªF°÷°í«ù¡A¥xÆW¦³¯à¤O°µ¨ì¡A¡v³oªÑ«H©À¡AÅý´¿¬O¬ü°ê¦×¬r±ìµß±À¤âªº±i©ÀìµL©Ò¬ÈÄß¡Aªð¥x¦¨¬°·R´þ¯f·sÃĪº¶Ê¥ÍªÌ¡A®¼¹L¦t©÷®×ªº¬Fªv·¼É¡B¸êª÷Ãø²£¡C ¨ú±oÃÄÃÒ¡A¬O¤¤¸Î¥´¥@¬É¬×ªº¤J³õ¨é¡C ®ø®§¤½¥¬«á¤£¨ì¤Q¤Ñ¡A±i©À즤w°¨¤£°±¿á¡X¡X¥ý¦b¥xÆWÁ|¿ìªk»¡·|¡A¦A»°u¬ü°ê©M¦U¦{¬F©²¡B«OÀI¤½¥qºW±Û¡A±q¼s§i¨ì©w»ù¡A³£±o¸g¨ó°Ó¡B¼f®Ö¡F3¤ë©³¡A¥L±Nn¸©¹¥[®³¤j»X¯S°ú¡A°Ñ¥[·sÃĤW¥«ªº»}®v¤j·|¡F¤¤¸Î¦@¦P³Ð¿ì¤H¡Bº®u¬ì§ÞÅU°Ý¦ó¤j¤@¡A¤]±N¥X®uµoªíºtÁ¿¡C |
|
|
·|û¡G¸²µåô10146373 µoªí®É¶¡:2018/3/24 ¤U¤È 09:18:18²Ä 578 ½g¦^À³
|
reference.medscape.com/drug/trogarzo-ibalizumab-1000196 |
|
|
·|û¡G¸²µåô10146373 µoªí®É¶¡:2018/3/24 ¤U¤È 04:52:56²Ä 577 ½g¦^À³
|
³Ìªñ³o´X¶gªº°ê»Ú§½¶Õ©M·ÀI¤j®a¤FµM©ó¯Ý Âб_¤§¤UµL§¹§Z¡A µu´Á¦b¨S¦³©úÅã§Q¦h¨ë¿E¤U¡A ¤¤¸ÎÃø§K·|¤]¨ü¨ì°ê»Ú½LÀ£§í¡A §Y«K¨S¦³¦p¹q¤lªÑ©úÅã¦^ÀÉ¡A ¤]·|¦³¤@¬q¾ã²z´Á¡C |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/3/23 ¤W¤È 08:38:51²Ä 576 ½g¦^À³
|
TMB-355¾P°â«á°ª®p®É,EPS¤£·|¥u¦³10¤¸ ¯Â¯q¤j·§·|¨ì70»õ,EPS¬ù36¤¸ ¦U¦ì«ùªÑ¤¤¸Îªº¤j¤j,µ¥µÛÀò§Q§Y¥i! |
|
|
·|û¡G¸²µåô10146373 µoªí®É¶¡:2018/3/23 ¤W¤È 06:04:07²Ä 575 ½g¦^À³
|
¸²µå¤ý½æ¯q¥Íµß¤@¦~¥i¥HÁÈ10¤¸ ¤¤¸Î©é¦º©é¬¡¦pªG¤]¥uÁÈ10¤¸ ·|¤£·|¤Ó©e©}¤F |
|
|
·|û¡G¸²µåô10146373 µoªí®É¶¡:2018/3/23 ¤W¤È 05:57:45²Ä 574 ½g¦^À³
|
³o´X¤Ñ¤¤¸Îªº®z¶Õ¬O¥²µMªº ¦~ÃÄ»ù11.8¸U¤Ó§C¤F ¦Ü¤Ö±M·~¤H¤h³o¼Ë»{¬° ¥i¯à¤¤¸Î¨S¦b¬ü°ê³]¼t GILEADªºC¨xÃÄ»ù¤@ÓÀøµ{¤TÓ¤ë100¸U¬üª÷¤W¤U §Æ±æ¦Ù¦×«¬¥i¥H©Ô°ª¦Ü30¸U¥H¤W ½a¤H¬O¨S¥Í¯fªºÅv§Qªº ¤p´²¤á°£¤FÀ¹¦n¦w¥þ´U ¤]nÀ¹¦n«OÀI®M¡I |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/3/22 ¤U¤È 04:46:51²Ä 573 ½g¦^À³
|
µ¥¥|¤ë¤¤¦¯¶}½æ,¤@¤Áµª®×¤ô¸¨¥Û¥X |
|
|
·|û¡GµLµß®ñ10021927 µoªí®É¶¡:2018/3/22 ¤W¤È 11:40:21²Ä 572 ½g¦^À³
|
¥i§_½Ð¤j¤j¤ÀªR¤@¤UTMB-355©MUB-421ªºÀu¶Õ©M¦H¶Õ?¨Ã²q´ú¤@¤U¥¼¨Óªºµo®i? |
|
|
·|û¡Grabbit10136567 µoªí®É¶¡:2018/3/22 ¤W¤È 10:49:11²Ä 571 ½g¦^À³
|
Hi Ibalizumab (TMB-355) ªº§ÜÃĩʨӦ۩ó¤À¤lµ²ºc¤Wªº¯Ê³´ §Ú»{¬°¤å¦r¤W³o¼Ë»¡¤£¤j²M·¡¡A¯S¥H¸É¥R¡AY¦³¿ù»~½Ð«ü¥¿ ³¡¤À«~¨tªºHIV-1(~10%)¯Ê¤ÖV5¦hÁÞ LM52 ¦³n¸Ñ¨M³o³¡¤À ¨ú¦Ü¤¤¸Î©xºô |
|
|
·|û¡G°]°È¦Û¥Ñ¤H10132540 µoªí®É¶¡:2018/3/22 ¤W¤È 10:38:19²Ä 570 ½g¦^À³
|
Ibalizumab (TMB-355) ªº§ÜÃĩʨӦ۩ó¤À¤lµ²ºc¤Wªº¯Ê³´¡A¹ï¬Y¨Ç Hiv ¯f¬rµLªkªý¾×¡C ¥Ø«e¬ù 8~10% ¯f¤H¦s¦b§ÜÃĩʪº°ÝÃD(°õ¦æªø¤]»¡¹L¡A¤@ºØÃĤ£¥i¯à 100% ªº¯f¤H³£¯à¦³®Ä) ©Ò¥H¡A355 ªº§ÜÃĩʨӦ۩ó³oÃþ¯f¬rªº¶Ç¬V³t«×¡A«DÃĥΤ[¤F²£¥Íªº§ÜÃÄ©Ê¡C Y¯f¤H³£¨S¦³³Q³oÃþ Hiv ¯f¬r¶Ç¬Vªº¸Ü¡A²z½×¤W¨Ó»¡²×¨³£¤£·|¦³§ÜÃÄ©Ê¡C Å餺¯f¬r·|¤£·|¬ðÅܦӲ£¥Í§ÜÃÄ©Ê©O¡H 355 ªºÃĪ«¯S½è¤£®e©ö¦³³o¼Ëªºª¬ªpµo¥Í¡C ¦p¦P Cliff ©Ò»¡¡A¤j®a¥i¥H¥h½½¤§«eªº°Q½×¡A¦³ªº«Ü²`¤J¥B±M·~¡C |
|
|
·|û¡GµLµß®ñ10021927 µoªí®É¶¡:2018/3/22 ¤W¤È 10:04:39²Ä 569 ½g¦^À³
|
¡uTMB-355ÃĪ«¼Ðªº¬°±J¥D²ÓM¡A¸û¤£®e©ö¦³¥Ø«e§Ü·R´þÃĪ«´¶¹Mªº§ÜÃÄ©Ê°ÝÃD¡C¡v ¤§«e´¿¦³¤j¤j´£¤Î¡u¬ù3,4¦~¶}©l²£¥Í§ÜÃÄ©Ê¡v,§Ú¬O¼ÖÆ[¹w´Á¦Ü¤Ö¤Q¦~¤º³£¤£·|¦³§ÜÃÄ©Ê°ÝÃD¡C ¤]´N¬O¨Ï¥Î¦³®Äªº¯f¤H³£·|Ä~Äò²Ö¿n¬°ªø´Á¨Ï¥Îªº©w¤H,¥|½u¤H¼Æ·|¥Ñì¥ý5%©¹¤W«ùÄò¼W¥[¤W¥h, ©¡®É¬Æ¦Ü¦³¥i¯à¥|½u¯f±w¤ñ¤G¤T½u¤H¼Æ¦h¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2018/3/22 ¤W¤È 09:56:04²Ä 568 ½g¦^À³
|
GSK744´N¬OGSK1265744¡A¸¯Äõ¯À¥v§J¬ü¥eÃļt¦ÑÃÄ¡A©ö»P¦å²G¤¤³J¥Õ½èµ²¦X¦ÓµLªkªø®Ä¡A©ó¬O©`¦Ì¤Æ«á¡AÅܦ¨GSK744LA¡A¥´¤@°w¥i«ùÄò¤TÓ¤ë¡C(LA¡Glong acting) ¤£¬O¦ó³Õ¤h©Ò¬ãµo¡C ³oÓ¦ÑijÃD¥i¥Hª¦Âª©±¡G¡u2014 Q4 ¶i«×°lÂÜ»P°Q½×¡vpage 4¡G²Ä75½g¦^À³ ~ ²Ä120½g¦^À³ ¤×¨ä¬O²Ä120½g¦^À³¡A¦³·í¦~¤é²±¤ÀªR®vªº³ø§i¥i°Ñ¦Ò¡C ²{¦b¦^·Q2014¦~11¤ë©³Ó¤H¶K¤å«e¡A´¿¥´¤F¤@³q¹q¸Ü¦V°]°Èªø¸ß°Ý¶i«×¡Aµ²ªG¶i«×¤ñ¤j®a¹w´ÁªººC¨Ç¡A¤Ï¥¿´N¬OÁÙn¦Aµ¥¡A©Ò¥H¤£´±¶K¤å¡Aª½¨ìBRN¤j2014/11/27¥ý¶K¥X¥L»P°]°Èªø³q¹q¸Üªºµ²ªG«á¡K¡K¡FªGµM¥«³õ¤£»â±¡¡AªÑ»ù¤@¸ô¤S¶^¤F±Nªñ¤@¦~¡Aª½¨ì2015/9¶}©l¯u¥¿¤j´T¤Wº¦¡A¦b¨º¤@ªi½æ¥Xªº¤H²{¦b¤£ª¾°µ¦ó·P·Q¡H ¥t¥~§ä¤F¤@¨Ç¸ê®Æ¡AY¦³¿ù»~½ÐªÈ¥¿¡C ¬ãµo·R´þ¬Ì]ªº¸ô¤W¤w¸g¦³¤TÓ¬Ì]pµe¥¢±Ñ¡]¹w¨¾²v§C©ó50¢H¡^¡C ²Ä¤TÓ¬O2009¦~¤@¶µ¥N¸¹¡uRV144¡vªº®õ°ê¬Ì]¹êÅç¡A·í¦~ªº¹êÅç¬O¥Ñ¬ü°êx¤è·R´þ¯f¬ã¨spµe»P®õ°ê½Ã¥Í³¡¦X§@¶i¦æ¡A¹ï1,6042¤H¶i¦æ¬I¥´¡A¦b¸g¹L3¦~¥bªºÆ[¹î«á¡Aµo²{³o´Ú·R´þ¬Ì]ªº¹w¨¾²v¤w¸g¹F¨ì¬ù31¢H¡C¡]www.sciencedirect.com/topics/immunology-and-microbiology/rv-144¡^ ²Ä¥|Ó¬Ì]pµe©ÓŧRV144¦Ó¨Ó¡A±q2016/11¶}©l¡A¥N¸¹¡uHVTN 702¡v¡A¦b«n«D¥H5400¦W18¨ì35·³¡B¦³¥¿±`©Ê¥Í¬¡ªº¨k¤k¬°¹êÅç¹ï¶H¡AÆ[¹î´Á¹F4¦~¡C¡]tw.appledaily.com/new/realtime/20161130/1000641/¡^ ²Ä¤Ó´N¬O¼b¥Í¤½¥q2017¦~³ø¾Éªº¡A±N¶i¤J 2b ¶¥¬q¡A½d³ò±N·|ÂX¤j¨ì´X¤d¤H¤§µ¥¯Å¡A¹wp¾ãÓ¹Lµ{¤j·§»Ýn¤T¦~®É¶¡¡C¡C¡]www.inside.com.tw/2017/08/11/johnson-and-johnson-jnj-developed-an-hiv-vaccine-that-may-protect-against-multiple-strains-at-once ¡^ |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/3/21 ¤U¤È 05:43:21²Ä 567 ½g¦^À³
|
¦A½Ð°Ý¤Ñ©R¤j GSK 744LA³oÓÃĤ]¬O¦ó¤j¤@³Õ¤hµo©úªº, ¸¹ºÙ¤TӤ르¤@¦¸ ½Ð°Ý±z¬O§_¹ï³oÓÃĦ³¬ã¨s? ¬O§_·|¬O¤¤¸ÎªºÄvª§¹ï¤â? ±q·s»D¬Ý¦ü¥G¤w¸g·Ç³Æ¶i¤J¤T´Á(©Î¬O¤w¸g¶i¤J?) |
|
|
·|û¡G¦Ï«§«§10141876 µoªí®É¶¡:2018/3/21 ¤U¤È 05:39:38²Ä 566 ½g¦^À³
|
¤¤¸Î¡G¨Ì³Ì·s¬ã½Õ¬ü°ê·R´þ¯f¦h«§ÜÃĩʱڸs¤H¼Æ¬ù2~2.5¸U¤H¡B°ª©ó¤½¥q¥ý«e¦ôÈ 2016/11/02 07:09 Moneydj²z°]ºô ÃÒ¥æ©Ò«¤j°T®§¤½§i (4147)¤¤¸Î¥»¤½¥q·R´þ¯f·sÃÄTMB-355¥Dn¥ÎÃĥؼЦh«§ÜÃĩʯf±w±Ú¸s¤W׳̷s¬ü°ê¥«³õ¹w¦ô¼Æ 1.¨Æ¹êµo¥Í¤é:105/11/01 2.¤½¥q¦WºÙ:¤¤¸Î·sÃÄ 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥q·R´þ¯f·sÃÄTMB-355¾P°â¹Ù¦ñ¥[®³¤jTheratechnologies Inc.©ó2016¦~11¤ë1¤éÁ|ªk¤H»¡©ú·|¡A°w¹ïTMB-355(ibalizumab)°Q½×¦³¨â¤j³¡¤À¡A¨ä¤¤IDWeek 2016·P¬V©Ê¯e¯f¬ã°Q·|³ø§iTMB-301Á{§É¸ÕÅç¥Dn«ü¼Ð(primary endpoint)ªºµ²ªG¡A¥»¤½¥q¤w©ó2016¦~10¤ë30¤é«¤j°T®§µoªí¦b®×¡C¥t¥~¤@Ó³¡¤À«YTheratechnologies¤º³¡¹Î¹ï¤Î±Mºë©óÂå¥Í¤Î¤ä¥IºÝ¤§¥«³õ¬ã¨sªº¥~³¡¿W¥ßÅU°Ý©Ò§@ªº³Ì·s¥«³õ¬ã¨s³ø§i¡C¥»¤½¥q°ò©ó¸ê°Tªº¤Î®É©Ê¤Î¹ïµ¥©Ê¡A¬G¦P¨Bµoªí¬ÛÃö°T®§µ¹¥»¤½¥q§ë¸ê¤j²³ª¾±x¡C ¨Ì¾Ú¦¹¤@¥«³õ¤ÀªR³ø§iªº¥Dnµ²½×¡A¦b¬ü°ê¦a°Ï©w¸q¬°·R´þ¯f¦h«§ÜÃĩʤ§±Ú¸s(¦b§Ü·R´þ¯f¬rÃĪ«ªº¤¤jÃþ«¬¤¤¡A¦Ü¤Ö¹ï¨ä¤¤¤TºØ¤w¦³§ÜÃÄ©Ê¡^¤H¼Æ¬ù¦³20,000~25,000¤H¡A³oӼƦr©úÅã°ª©ó¥»¤½¥q¤§«e¦ô¦C8,000¦Ü10,000¤H¼Æ¦r¡C(µù¡G¤¤¸Î·sÃÄ©ó104¦~11¤ë¤WÂd«e»¡·|²³ø»¡©ú¡A¥¼¨ÓTMB-355¦b¬ü°ê¤W¥««á¥i¯à¥i¨Ï¥Î¤§±Ú¸s¬ù¬°38,000¤H¡A¥]¬A¤T¤j¥Ø¼Ð±Ú¸s¡G¦h«§ÜÃĩʳ̫á½u¯f±wMDR¡B¹ï즳ÃĪ«@¨ü©Ê¤£¨}ªº¯f±wARV-intolerant¡B»PªAÃĶ¶¾A©Ê¤£¨ÎNon-adherantªº¯f±w¡A¨ä¤¤TMB-355Á{§É¸ÕÅç¥Ø¼Ð¥B¬°³Ì®Ö¤ß¥ÎÃıڸs¹ï¶H¬°¦h«§ÜÃĩʯf±w¡A¤H¼Æ¬ù¦b8,000¦Ü10,000¤H¡^¹L¥h35¦~¨Ó·R´þ¯fªº±±¨îªvÀø¤w¦³«Ü¤jªº¶i®i¡A±©°w¹ï¦h«§ÜÃĩʱwªÌ¤´µM«D±`Ãø¥HªvÀø¡A§Ú̷̳s¬ã¨sÅã¥Ü¬ù¦³50%~56%ªº¦h«§ÜÃĩʯf±w¦b¸g¾ú48¶gªº§Ü¯f¬rnÃĪ«ªvÀø «á¤w¸gµLªk¦³®Ä±±¨î¯f¬r¶q¦Ó»ÝnÂå¥Í§ïÅܽվã¥ÎÃÄ¡C ®Ú¾ÚTheratechnologies»P¬ü°êÃÄ«~¤ä¥IºÝªº¬ã¨s¡AµL½×¨p¤H©Î¤½¥ßªº«OÀIÅé¨tp¹º§¡»{¦P°w¹ï³o¨Ç·R´þ¯f¦h«§ÜÃĩʯf±w¤§¥¼º¡¨¬»Ý¨D(unmet medical need)¡A¨Ã°w¹ï³o¨Ç«Ü§xÃøªvÀøªº«á½u¯f±w¡A¸ÓÃĪ«¥i¥HÃÒ©ú¦³«D±`¦nªº¦w¥þ©Ê¤Î¦³®Ä©Êªí¹F¥¿±ºA«×¡CTheratechnologies ¤§¥«³õ¬ã¨s³ø§i¸ê°T«Y¨Ì¾Ú²{¦³¥«³õ¤w¸g¤½¶}µoªí¤§¸ê°T¡A¥H¤Î¸Ó¤½¥q©e°U¥~³¡¿W¥ßÅU°Ýºî¦X¤ÀªR¤§µ²ªG¡C¨ä¤¤¥~³¡¤½¶}¸ê°T¨Ó·½¦³the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), the NCHHSTP Atlas (the Center for Disease Control and Prevention¡¦s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention), the Stanford University HIV Drug Resistance Database and the Swiss HIV Cohort Studyµ¥³æ¦ì¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
|
·|û¡G¦n¹B10137114 µoªí®É¶¡:2018/3/21 ¤U¤È 02:07:04²Ä 565 ½g¦^À³
|
½Ð°Ý¦³¤j¤j¦³3/7ªk»¡·|ªº¿ýµÀɮ׶ܡAÁٽФ£§[´£¨Ñ¡C ÁÂÁ |
|
|
·|û¡G¶³²H·»´10146472 µoªí®É¶¡:2018/3/21 ¤U¤È 01:07:55²Ä 564 ½g¦^À³
|
«D±`·PÁ¤ѩR¤j¤jªº¸Ñ»¡!!! |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/3/21 ¤U¤È 12:43:07²Ä 563 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j, ¦U¦ì¤j¤j ¤£ª¾¬O§_¦³¤Hª¾¹D 1. TMB-607¤µ¦~¬O§_·|¦³¤@´Áµ²ªG? 2. ©Ó¤W, Y¤@´Áµ²ªG¤£¿ù, ¤½¥q¬O§_¦Ò¼{ª½±µ¶i¤T´Á? 3. MDR/ARV intolerant/Non-adherantªº±Ú¸s, °£¤FMDR¥H¥~, ¨ä¥L¨âºØ¯f±w¬O§_«OÀI¤£µ¹¥I, »Ýn¦Û¤v¥X¿ú? ¦]¬°label¨Ã¨S©w¸qªº«Ü²M·¡, ¤£ª¾¸Ó¦p¦ó¸ÑŪ |
|
|
·|û¡G¶³²H·»´10146472 µoªí®É¶¡:2018/3/21 ¤W¤È 11:25:20²Ä 562 ½g¦^À³
|
½Ð±Ð¦U¦ì¤j¤j¤U¦C°ÝÃD. 1. TMB-355¥Ø«eªºÄvª§¹ï¤â°£¤FFuzeon, Selzentry (Maraviroc), ÁÙ¦³¨ä¥Lªº¶Ü? 2. «á½uY¨Ï¥ÎTMB-355, ¯f¤HÁÙ»ÝnÄ~ÄòªA¥Î1/2/3½uªºÃĶÜ? ÁÙ¬O¥u»Ý¥ÎTMB-355¤@ºØ? 3. ©Ó2, YÁÙ»Ýn, ¨ºTMB-355ªº§C°Æ§@¥Î, ¥[¤À´N¤£¤j¤F¶Ü? ¦]¬°Á`ÅéÁÙ¬O¦³°Æ§@¥Î? 4. ¤½§i´£¨ì¥¼¨Ó°w¾¯¥i¯à¬O2, 3 ½u, ¬Æ¦Ü1½u, ¬O«üTMB-607/365..., TMB355 ¤£ºÞÀR¯ß©Î¦Ù¦×ª`®g³£¥u¯à©T©w¦b³Ì«á½u¤F¶Ü? 5. ±i°õ¦æªøªí¥Ü, ®³¨ì50%¥«³õ, ´Nº¡·N, ¬O«üMDR 20000~25000 ¤Hªº50%, ÁÙ¬O10000~12000ªº50%? 6. ¬Ý¤@¤U¹L¥hªºÂ²³ø, 2017/9 «e¥Dn³£¦³´£³o¤T¶ô¯f¤H MDR/ARV intolerant/Non-adherant, ¤§«á¤j³¡¤À¥ufocus ¦bMDR, ¬O¥t¤G¶ô¥«³õ¤£¬O«ÂI¶Ü? ¥H¤W°ÝÃD, ´÷±æ¦³¤j¤jÌ¥i¥H¸Ñ´b, ·PÁÂ. |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/3/21 ¤W¤È 10:26:28²Ä 561 ½g¦^À³
|
ÃÄ©ú¥Íª«ªÑ»ù¤S¤jº¦ªñ8% ¥Nªí¤w¸g±µ¨ì¤¤¸Îªº¤j³æ¥Í²£ ¤Z¨ÆÁ`¦³¤H¦¤@¨Bª¾¹D |
|
|
·|û¡G¬ã¨sû10145703 µoªí®É¶¡:2018/3/20 ¤U¤È 10:44:25²Ä 560 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j¡A¥H¤U¸ê®Æ¬Oºô¸ô¬d¨ì¡H¬O§_¦³³sµ²¡H·PÁ±zÂ×´I²`¤Jªº¸ê®Æ FUZEON ¥_¬ü¦a°Ï(¬ü°ê&¥[®³¤j)¦~¾P°â¶q(KITS)¾ã²z 2003 (3¤ë©³FDA ®Öã¤W¥«) 19,400 KITS (¨C¤H¨C¤ë¤@Kit /60 ²~) 2004 58,900 KITS 2005 72,000 KITS 2006 79,700 KITS(¾P°â°ª®p) 2007 72,700 KITS 2008 36,000 KITS 2009 20,000 KITS 2010 16,100 KITS *¼Ú¬w¤Î¨ä¥L°ê®a¥¼²Îp¡C *¸ê®Æ¨Ó·½ºô¸ô³ø¾É *¦±ß¯f¤H¦U¥´°w¤@¦¸¡C |
|
|
·|û¡Gdoghead10146360 µoªí®É¶¡:2018/3/20 ¤U¤È 09:06:48²Ä 559 ½g¦^À³
|
°ê®a«ùªÑÀ³¸Ó¬O«ÜÃø°Õ~! |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/3/20 ¤U¤È 04:59:10²Ä 558 ½g¦^À³
|
·|¤£·|§ï¤ÑTMB-355½æ±o¦n,Gilead·|¨Ó¨ÖÁʤ¤¸Î!? ¯ÂÄÝÓ¤H²q·Q! |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/3/20 ¤U¤È 01:28:15²Ä 557 ½g¦^À³
|
»P¤¤¸Î¬ÛÃö¦X§@ªºth.toªÑ»ùªñ´Á³Ð·s°ª,ÃÄ©ú¥Íª«³Ð·s°ª! ¦Ó¤¤¸Î¦b¨ú±oÃÄÃÒ«á,ªÑ»ù±q170´Xº¦¨ì257,µu´Áº¦¤F40´X%,´N¦^ÀÉ! §Ú¯uı±o¥xÆW¤Hªº®æ§½¸ò²´¥ú¤Ó¤p¤F,¤j®an¥[ªo! ¦^ÀɧC±µ¤¤¸ÎªÑ²¼¬OÃø±oªº¾÷·|! |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/3/20 ¤W¤È 11:19:53²Ä 556 ½g¦^À³
|
§Úè¬Ý¤F¤@¤U ªº½TÃÄ©ú¥Íª«¤jº¦ªñ11%,¬Q¤Ñth.toªÑ»ù¤]¦¬¬õ! ¤¤¸În¥[¥[ªo! ¥xÆW¤§¥ú! |
|
|
·|û¡G¯º¦10143600 µoªí®É¶¡:2018/3/20 ¤W¤È 11:12:42²Ä 555 ½g¦^À³
|
ÃÄ©ú¥Íª«¤µ¤Ñ¤jº¦6%³Ð·s°ª¡A¥xÆW¤H°O±o¸C²´¬Ý¥@¬É |
|
|
·|û¡G¦¿¤j¤á10140161 µoªí®É¶¡:2018/3/20 ¤W¤È 11:03:58²Ä 554 ½g¦^À³
|
µû¦ô¤]¬On«ù¥¦Ó½×¡An°µ¤â¾÷¬ÛÃö´N»¡¤â¾÷¦³´X¥ü¥«³õ¡A±M¬DÄ«ªG»¡¤@¦~Àç·~ÃB¦h¤j¡A«ç»ò¤£»¡»¡¨ä¥LÁ«·l¨S¦¨¥\ªº?? |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/3/20 ¤W¤È 10:53:59²Ä 553 ½g¦^À³
|
¦¿¤j¤á¤j¤j~ °µ¥Í·N¤£¬O§â§O¤H¼Æ¾Ú®³¨Ó¤ñ¤@¤ñ¦Û¤v´N·|¸ò§O¤H¤@¼Ë! §ÚÁöµM¤£¹³¤Ñ©R¤j³o»ò±M·~,¥i¬O¤£®³¼Æ¾Ú¤ñ,«ç»òµû¦ô¥«³õ!? ¦p¦P§Aı±o¤¤¸ÎTMB-355¥«³õ¨S³o»ò¤j,¤]¬O¦³§Aªº¨Ì¾Ú! ¥u¬O¬Ýªk¤£¦P¬OÓ¤H¦Û¥Ñ,¤j®a°Q½×¤Á½RµL¶Ë¤j¶®! |
|
|
·|û¡G¦¿¤j¤á10140161 µoªí®É¶¡:2018/3/20 ¤W¤È 10:34:03²Ä 552 ½g¦^À³
|
©t¨àÃĤ£¥Nªí¥¦¬O¿W¥e¥«³õ§a?n¬O³o»ò¯«Ã±µ¹¥[®³¤j¤½¥q? |
|
|
·|û¡G¦¿¤j¤á10140161 µoªí®É¶¡:2018/3/20 ¤W¤È 10:06:19²Ä 551 ½g¦^À³
|
°µ¥Í·N¤£¬O§â§O¤H¼Æ¾Ú®³¨Ó¤ñ¤@¤ñ¦Û¤v´N·|¸ò§O¤H¤@¼Ë¡An¬O³o»ò²³æHTC¦´NÁȽ¤F¡C |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/3/20 ¤W¤È 09:01:54²Ä 550 ½g¦^À³
|
ÁÂÁ¦U¦ì¤j¤jªººëÅP¸ÑªR! |
|
|
·|û¡GµLµß®ñ10021927 µoªí®É¶¡:2018/3/19 ¤U¤È 11:21:53²Ä 549 ½g¦^À³
|
¥Ñ¤T½u¨«¹L¨Ó¥|½uªº(¦]¬°²£¥Í§ÜÃÄ©Ê),¤@¥b¯d¤U¨Ó(¦]¬°TMB¦ÓÄ~Äò¦s¬¡)¡C ¤é¿n¤ë²Ö,¨ì³Ì«á¥|½uªº¤H¼Æ·|Ãz¼W,¤Ï¦Ó¶W¹L¤T½u¬Æ¦Ü¤G½u¤H¼Æ! ¦³¤FTMB355,¥|½u¤ñ²v·|¥Ñ5%¤@ª½¼W¥[¤W¥h¡C¥ú¾a³oÓ´N¥i¥H¦¨ªø¼Æ¤Q¦~¤F¡C ¦A¥[¤W¦b¦U°ê«ùÄò¨úÃÒ,¨Ï¥Î¤H¼Æ¤S¦A¦¨ªø¡C Âù«¦¨ªøÃzµo¤O¯S±j!¥«³õµ´¹ï¤£¬O²{¦b¸³¨Æªø»¡ªº³o¼Ë¦Ó¤w,¦Ó¬O¤£Â_ÂX¤j! |
|
|
·|û¡G¬K©M´º©ú10141799 µoªí®É¶¡:2018/3/19 ¤U¤È 10:18:04²Ä 548 ½g¦^À³
|
«Ü¦h¯e¯fªº¥«³õ¬O¸òÃÄ¥»¨ªº»ùȫܦ³¬ÛÃö ÃĦn¡A¥«³õ¬O·|¼W¥[¡B°µ¤j ·R´þ¯f¬OÂû§À°sÀøªk nºâÄvª§©Ê¤]¬O¦P¤@¾÷Â઺ÃĦbÄvª§ ¹³C¨x¯f¬rÃĪ«Sovaldi¤W¥««e C«¬¨xª¢¥«³õ¦n¹³¤~40»õ¬ü¤¸¥ª¥k 2013¦~Sovaldi¤W¥« 2014¦~Sovaldi´N´ÀGilead³Ð³y¦Ê»õÀ禬 ·í®ÉC«¬¨xª¢¥«³õ¬ù40»õ¬ü¤¸¥ª¥k¡A½Ö·Q¨ì³oÁûÃÄ·|³o»òÁÈ? ªvÀøC¨xÅSÀÆ¥ú ·sÃÄSovaldi±N¤W¥« ³o½g·s»DÁÙ¥u»{¬°Sovaldi2014¦~Á`¾P¶q·|¬O16»õ¬ü¤¸¦Ó¤w ·R´þ¯f¬OÂû§À°sÀøªk TMB-355¬O¬ð¯}©ÊÀøªk¤S¬O³Ì«á¤@½uªº©t¨àÃÄ §ËÀ´¤F´N·|¤F¸ÑTMB-355ªº»ùÈ ·R´þ¯f¬OÂû§À°sÀøªk TMB-355¬O¬ð¯}©ÊÀøªk¤S¬O³Ì«á¤@½uªº©t¨àÃÄ §ËÀ´¤F´N·|¤F¸ÑTMB-355ªº»ùÈ |
|
|
·|û¡G¥xÆW¦10140942 µoªí®É¶¡:2018/3/19 ¤U¤È 07:24:46²Ä 547 ½g¦^À³
|
±i©Àì«ü¥X¡A¥þ²y·R´þ¯fªº·sÃÄì¼t¥«³õÃB¶W¹L200»õ¬ü¤¸¡A²³æ¤À¦¨¤T¤j¶ô¡A¤@½u¥ÎÃĬù¦û¤»¦¨¡A¤G¡B¤T½u¥ÎÃĦû¤ñ¬ù35%¡A³Ì«á¤@½u¥ÎÃĤñ«¬ù5%¡C TMB-355ÄÝ©ó³Ì«á¤@½u¥ÎÃÄ(5%)...5%¤S¤£¬O¥þ®³! ½Ð°Ý¦U¦ì¤j¤j~³o¼Ë¤pªº¥«³õ,¤¤¸Î¯àÁȦh¤Ö? |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/3/19 ¤W¤È 05:37:12²Ä 546 ½g¦^À³
|
±M®aÆ[ÂI¡þ¬üÂåÀø·~¨ÖÁʱa¨Óªº¾÷·|»P«Â¯Ù 2018-03-19 00:01¸gÀÙ¤é³ø ªLµØx udn.com/news/story/7485/3038593?from=udn_ch2cate6644sub7485_pulldownmenu ¦]¦¹¿ï¾Ü¶}µo¥«³õ¤W¥¼º¡¨¬ªºÂåÀø»Ý¨D¡]Unmet medical need¡^¡Bµ}¤Ö¾AÀ³¯g¡]Orphan drug¡^©Î¨ã¦³¬ð¯}©ÊÀøªk¡]Breakthrough¡^ªºÃÄ«~¡A±N§ó¦³§Q©ó¥¼¨Ó»P«OÀI¤ÎPBMij»ùªÅ¶¡¡A¤~¯à¦b¬ãµo§ë¤J¶O¥Î»P·ÀI§¡·¥°ªªº·sÃĬãµo²£·~¡A¥ß©ó¤£±Ñ¤§¦a¡C ¤¤¸Î TMB-355 ¸U¨Æ¬Ò³Æ¡A´N«Ý°_·°ª¸ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a¡I |
|
|
·|û¡G¸²µåô10146373 µoªí®É¶¡:2018/3/18 ¤W¤È 07:14:48²Ä 545 ½g¦^À³
|
§Úı±o²{¦b³Ì«nªº¬OÀ¹¦n¦w¥þ´U |
|
|
·|û¡G¸²µåô10146373 µoªí®É¶¡:2018/3/17 ¤W¤È 08:37:26²Ä 544 ½g¦^À³
|
¤¤¸Î 106¦~3¤ë¦Ü107¦~2¤ëÀ禬³£¬O80.2¸U §Úı±o¹ïµu½u¼vÅT¤ñ¸û¤jªº À³¸Ó¬O¤µ¦~34¤ëªºÀ禬 ½Ð±Ð¦³¿ìªk¦ôºâ¶Ü?? |
|
|
·|û¡G¤ß»·¦a¦Û°¾10141241 µoªí®É¶¡:2018/3/16 ¤U¤È 05:31:17²Ä 543 ½g¦^À³
|
¤Ñ©R¤j °õ¦æªø¥h¦~ªÑªF·|¦³»¡¹L¥Í²£ªº°ÝÃD, ±q¥Lªº¸Ü¤¤§Úªº²z¸Ñ¬O2000L¥Í²£¤@¦¸¤j·§¥i¨Ñ100Ó¤H¨Ï¥Î¤@¦~ ¦p¦¹¥i¥Hpºâ¥X²£¯à |
|
|
|